U.S. patent application number 09/845420 was filed with the patent office on 2001-11-08 for pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction.
Invention is credited to Albert, Stephen Derek, Bunnage, Mark Edward, Mathias, John Paul, Wood, Anthony.
Application Number | 20010039271 09/845420 |
Document ID | / |
Family ID | 26313490 |
Filed Date | 2001-11-08 |
United States Patent
Application |
20010039271 |
Kind Code |
A1 |
Bunnage, Mark Edward ; et
al. |
November 8, 2001 |
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of
sexual dysfunction
Abstract
Compounds of the formulae (IA) and (IB): 1 wherein R.sup.1 is
C.sub.1 to C.sub.3 alkyl optionally substituted with phenyl, Het or
a N-linked heterocyclic group selected from piperidinyl and
morpholinyl; wherein said phenyl group is optionally substituted by
one or more substitutents selected from C.sub.1 to C.sub.4 alkoxy;
halo; CN; CF.sub.3; OCF.sub.3 or C.sub.1 to C.sub.4 alkyl wherein
said C.sub.1 to C.sub.4 alkyl group is optionally substituted by
C.sub.1 to C.sub.4 haloalkyl or haloalkoxy either of which is
substituted by one or more halo atoms; R.sup.2 is C.sub.1 to
C.sub.6 alkyl and R.sup.13 is OR.sup.3 or NR.sup.5R.sup.6, or
pharmaceutically or veterinarily acceptable salts thereof, or
pharmaceutically or veterinarily acceptable solvates of either
entity are potent and selective inhibitors of type 5 cyclic
guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and
have utility in the treatment of, inter alia, male erectile
dysfunction (MED) and female sexual dysfunction (FSD).
Inventors: |
Bunnage, Mark Edward;
(Sandwich, GB) ; Mathias, John Paul; (Sandwich,
GB) ; Albert, Stephen Derek; (Sandwich, GB) ;
Wood, Anthony; (Sandwich, GB) |
Correspondence
Address: |
Gregg C. Benson
Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton
CT
06340
US
|
Family ID: |
26313490 |
Appl. No.: |
09/845420 |
Filed: |
April 30, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09845420 |
Apr 30, 2001 |
|
|
|
09402242 |
Sep 29, 1999 |
|
|
|
6251904 |
|
|
|
|
09402242 |
Sep 29, 1999 |
|
|
|
PCT/IB99/00519 |
Mar 25, 1999 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
514/234.2; 514/262.1; 544/118; 544/262 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
1/06 20180101; A61P 17/06 20180101; A61P 17/00 20180101; A61P 11/02
20180101; A61P 37/00 20180101; A61P 15/06 20180101; A61P 37/06
20180101; C07D 401/12 20130101; A61K 31/519 20130101; A61P 9/04
20180101; A61P 25/00 20180101; A61P 9/00 20180101; A61P 35/04
20180101; A61P 11/00 20180101; A61P 13/08 20180101; A61P 25/28
20180101; A61P 25/02 20180101; C07D 213/80 20130101; C07D 487/04
20130101; A61P 17/14 20180101; A61P 27/06 20180101; A61P 1/00
20180101; A61P 15/00 20180101; A61P 13/00 20180101; A61P 9/12
20180101; A61P 35/00 20180101; C07D 405/12 20130101; A61P 11/06
20180101; A61P 13/10 20180101; A61P 43/00 20180101; A61P 15/10
20180101 |
Class at
Publication: |
514/210.21 ;
514/258; 544/262; 514/234.2; 544/118 |
International
Class: |
A61K 031/519; A61K
031/5377 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 20, 1998 |
GB |
9808315.7 |
Jun 30, 1998 |
GB |
9814187.2 |
Claims
1. A compound of the formula (IA) or (IB): 143or a pharmaceutically
or veterinarily acceptable salt thereof, or a pharmaceutically or
veterinarily acceptable solvate of either entity, wherein R is
C.sub.1 to C.sub.3 alkyl optionally substituted with phenyl, Het or
a N-linked heterocyclic group selected from piperidinyl and
morpholinyl; wherein said phenyl group is optionally substituted by
one or more substitutents selected from C.sub.1 to C.sub.4 alkoxy;
halo; CN; CF.sub.3; OCF.sub.3 or C.sub.1 to C.sub.4 alkyl wherein
said C.sub.1 to C.sub.4 alkyl group is optionally substituted by
C.sub.1 to C.sub.4 haloalkyl or haloalkoxy either of which is
substituted by one or more halo atoms; R.sup.2 is C.sub.1 to
C.sub.6 alkyl; R.sup.13 is OR.sup.3 or NR.sup.5R.sup.6; R.sup.3 is
C.sub.1 to C.sub.6 alkyl optionally substituted with one or two
substituents selected from C.sub.3 to C.sub.5 cycloalkyl, OH,
C.sub.1 to C.sub.4 alkoxy, benzyloxy, NR.sup.5R.sup.6, phenyl,
furanyl and pyridinyl; C.sub.3 to C.sub.6 cycloalkyl; 1-(C.sub.1 to
C.sub.4 alkyl) piperidinyl; tetrahydrofuranyl or tetrahydropyranyl;
and wherein said C.sub.1 to C.sub.6 alkyl or said C.sub.1 to
C.sub.4 alkoxy groups are optionally terminated by haloalkyl;
R.sup.4 is SO.sub.2NR.sup.7R.sup.8; R.sup.5 and R.sup.6 are each
independently selected from H and C.sub.1 to C.sub.4 alkyl
optionally substituted with C.sub.3 to C.sub.5 cycloalkyl or
C.sub.1 to C.sub.4 alkoxy, or, together with the nitrogen atom to
which they are attached, form an azetidinyl, pyrrolidinyl,
piperidinyl or morpholinyl group; R.sup.7 and R.sup.8, together
with the nitrogen atom to which they are attached, form a
4-R.sup.10-piperazinyl group optionally substituted with one or two
C.sub.1 to C.sub.4 alkyl groups and optionally in the form of its
4-N-oxide; R.sup.10 is H; C.sub.1 to C.sub.4 alkyl optionally
substituted with one or two substituents selected from OH,
NR.sup.5R.sup.6, CONR.sup.5R.sup.6, phenyl optionally substituted
with C.sub.1 to C.sub.4 alkoxy, benzodioxolyl and benzodioxanyl;
C.sub.3 to C.sub.6 alkenyl; pyridinyl or pyrimidinyl; and Het is a
C-linked 6-membered heterocyclic group containing one or two
nitrogen atoms, optionally in the form of its mono-N-oxide, or a
C-linked 5-membered heterocyclic group containing two or three
nitrogen atoms, wherein either of said heterocyclic groups is
optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to
C.sub.4 alkoxy or NHR.sup.15 wherein R.sup.15 is H, C.sub.1 to
C.sub.4 alkyl or C.sub.1 to C.sub.4 alkanoyl and halo is Br, Cl, F
or I.
2. A compound according to claim 1 wherein R.sup.1 is C.sub.1 to
C.sub.2 alkyl optionally substituted with Het:
2-(morpholin-4-yl)ethyl or benzyl; R.sup.2 is C.sub.2 to C.sub.4
alkyl; R.sup.13 is OR.sup.3 or NR.sup.5R.sup.6; R.sup.3 is C.sub.1
to C.sub.4 alkyl optionally substituted with one or two
substituents selected from cyclopropyl, cyclobutyl, OH, methoxy,
ethoxy, benzyloxy, NR.sup.5R.sup.6, phenyl, furan-3-yl,
pyridin-2-yl and pyridin-3-yl; cyclobutyl; 1-methylpiperidin-4-yl;
tetrahydrofuran-3-yl or tetrahydropyran-4-yl: R.sup.5 and R.sup.6
are each independently selected from H and C.sub.1 to C.sub.2 alkyl
optionally substituted with cyclopropyl or methoxy, or, together
with the nitrogen atom to which they are attached, form a
azetidinyl, pyrrolidinyl or morpholinyl group; R.sup.7 and R.sup.8,
together with the nitrogen atom to which they are attached, form a
4-R.sup.10-piperazinyl group optionally substituted with one or two
methyl groups and optionally in the form of its 4-N-oxide; R.sup.10
is H, C.sub.1 to C.sub.3 alkyl optionally substituted with one or
two substituents selected from OH, NR.sup.5R.sup.6,
CONR.sup.5R.sup.6, phenyl optionally substituted with methoxy,
benzodioxol-5-yl and benzodioxan-2-yl; allyl; pyridin-2-yl;
pyridin-4-yl or pyrimidin-2-yl; and Het is selected from
pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl;
6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and
1-methylimidazol-2-yl.
3. A compound according to claim 2 wherein R.sup.1 is C.sub.1 to
C.sub.2 alkyl optionally substituted with Het;
2-(morpholin-4-yl)ethyl or benzyl; R.sup.2 is C.sub.2 to C.sub.4
alkyl; R.sup.13 is OR.sup.3; R.sup.3 is C.sub.1 to C.sub.4 alkyl
optionally monosubstituted with cyclopropyl, cyclobutyl, OH,
methoxy, ethoxy, phenyl, furan-3-yl or pyridin-2-yl: cyclobutyl;
tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R.sup.7 and R.sup.8,
together with the nitrogen atom to which they are attached, form a
4-R.sup.10-piperazinyl group optionally in the form of its
4-N-oxide; R.sup.10 is C.sub.1 to C.sub.3 alkyl optionally
monosubstituted with OH; and Het is selected from pyridin-2-yl;
1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl;
pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.
4. A compound according to any of claims 1 to 3 selected from:
3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-
-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4.3-d]pyrimidin-7-on-
e;
3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridi-
n-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4.3-d]pyrimidin-7-o-
ne;
3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyetho-
xy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4.3-d]pyri-
midin-7-one;
5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyr-
idin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d-
]pyrimidin-7-one;
5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy-
)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4-
,3-d]pyrimidin-7-one;
(+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2--
(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazol-
o[4,3-d]pyrimidin-7-one;
3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(-
2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-(6-methylpyridin-2-yl)methyl-2-
,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
5-[2-ethoxy-5-(4-ethylpipera-
zin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(6-methoxypyridin-2-yl)methyl-2,-
6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
5-[2-i-butoxy-5-(4-ethylpiper-
azin-1-ylsulphonyl)pyridin-3-yl]-2,3-diethyl-2,6-dihydro-7H-pyrazolo[4,3-d-
]pyrimidin-7-one; and
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridi-
n-3-yl]-3-ethyl-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]py-
rimidin-7-one.
5. A pharmaceutical composition comprising a compound of formula
(IA) or (IB), or a pharmaceutically acceptable salt thereof, or a
pharmaceutically acceptable solvate of either entity, together with
a pharmaceutically acceptable diluent or carrier.
6. A veterinary formulation comprising a compound of formula (IA)
or (IB), or a veterinarily acceptable salt thereof, or a
veterinarily acceptable solvate of either entity, together with a
veterinarily acceptable diluent or carrier.
7. A compound of formula (IA) or (IB), or a pharmaceutically
acceptable salt thereof, or a pharmaceutically acceptable solvate
of either entity, or a pharmaceutical composition containing any of
the foregoing, for use as a human medicament.
8. A compound of formula (IA) or (IB), or a veterinarily acceptable
salt thereof, or a veterinarily acceptable solvate of either
entity, or a veterinary formulation containing any of the
foregoing, for use as an animal medicament.
9. The use of a compound of formula (IA) or (IB), or a
pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate of either entity, for the manufacture of a human
medicament for the curative or prophylactic treatment of a medical
condition for which a cGMP PDE5 inhibitor is indicated.
10. The use of a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a veterinarily acceptable
solvate of either entity, for the manufacture of an animal
medicament for the curative or prophylactic treatment of a medical
condition for which a cGMP PDE5 inhibitor is indicated.
11. The use of a compound of formula (IA) or (IB), or a
pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate containing either entity, for the manufacture of
a human medicament for the curative or prophylactic treatment of
male erectile dysfunction (MED), female sexual dysfunction (FSD),
premature labour, dysmenorrhoea, benign prostatic hyperplasia
(BPH), bladder outlet obstruction, incontinence, stable, unstable
and variant (Prinzmetal) angina, hypertension, pulmonary
hypertension, congestive heart failure, atherosclerosis, stroke,
peripheral vascular disease, conditions of reduced blood vessel
patency, chronic asthma, bronchitis, allergic asthma, allergic
rhinitis, glaucoma or diseases characterised by disorders of gut
motility.
12. The use of a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a veterinarily acceptable
solvate containing either entity, for the manufacture of an animal
medicament for the curative or prophylactic treatment of male
erectile dysfunction (MED), female sexual dysfunction (FSD),
premature labour, dysmenorrhoea, benign prostatic hyperplasia
(BPH), bladder outlet obstruction, incontinence, stable, unstable
and variant (Prinzmetal) angina, hypertension, pulmonary
hypertension, congestive heart failure, atherosclerosis, stroke,
peripheral vascular disease, conditions of reduced blood vessel
patency, chronic asthma, bronchitis, allergic asthma, allergic
rhinitis, glaucoma or diseases characterised by disorders of gut
motility;
13. A method of treating or preventing a medical condition for
which a cGMP PDE5 inhibitor is indicated, in a mammal (including a
human being), which comprises administering to said mammal a
therapeutically effective amount of a compound of formula (IA) or
(IB), or a pharmaceutically or veterinarily acceptable salt
thereof, or a pharmaceutically or veterinarily acceptable solvate
of either entity, or a pharmaceutical composition or veterinary
formulation containing any of the foregoing.
14. A method of treating or preventing male erectile dysfunction
(MED), female sexual dysfunction (FSD), premature labour,
dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet
obstruction, incontinence, stable, unstable and variant
(Prinzmetal) angina, hypertension, pulmonary hypertension,
congestive heart failure, atherosclerosis, stroke, peripheral
vascular disease, conditions of reduced blood vessel patency,
chronic asthma, bronchitis, allergic asthma, allergic rhinitis,
glaucoma or diseases characterised by disorders of gut motility in
a mammal (including a human being). which comprises administering
to said mammal a therapeutically effective amount of a compound of
formula (IA) or (IB), or a pharmaceutically or veterinarily
acceptable salt thereof, or a pharmaceutically or veterinarily
acceptable solvate of either entity, or a pharmaceutical
composition or veterinary formulation containing any of the
foregoing.
15. A compound of formula (IIA) or (IIB): 144wherein Y is halo, and
R.sup.1, R.sup.2 and R.sup.13 are as defined in claim 1.
16. A compound according to claim 16 wherein Y is chloro.
17. A compound of formula (IVA) or (IVB): 145wherein R.sup.1,
R.sup.2 and R.sup.13 are as defined in claim 1.
18. A compound of formula (VA) or (VB): 146wherein R.sup.1, R.sup.2
and R.sup.13 are as previously defined in claim 1.
19. A compound of the formula (IXA) or (IXB): 147wherein R.sup.1,
R.sup.2, R.sup.4 and R.sup.13 are as previously defined in claim
1.
20. A process for the preparation of a compound of formula (IA) or
(IB): 148wherein R.sup.1 is C.sub.1 to C.sub.3 alkyl optionally
substituted with phenyl, Het or a N-linked heterocyclic group
selected from piperidinyl and morpholinyl; wherein said phenyl
group is optionally substituted by one or more substitutents
selected from C.sub.1 to C.sub.4 alkoxy; halo: CN; CF.sub.3;
OCF.sub.3 or C.sub.1 to C.sub.4 alkyl wherein said C.sub.1 to
C.sub.4 alkyl group is optionally substituted by C.sub.1 to C.sub.4
haloalkyl or haloalkoxy either of which is substituted by one or
more halo atoms; R.sup.2 is C.sub.1 to C.sub.6 alkyl; R.sup.13 is
OR.sup.3 or NR.sup.5R.sup.6; R.sup.3 is C.sub.1 to C.sub.6 alkyl
optionally substituted with one or two substituents selected from
C.sub.3 to C.sub.5 cycloalkyl, OH, C.sub.1 to C.sub.4 alkoxy,
benzyloxy, NR.sup.5R.sup.6, phenyl, furanyl and pyridinyl; C.sub.3
to C.sub.6 cycloalkyl; 1-(C.sub.1 to C.sub.4 alkyl) piperidinyl;
tetrahydrofuranyl or tetrahydropyranyl; and wherein said C.sub.1 to
C.sub.6 alkyl or said C.sub.1 to C.sub.4 alkoxy groups are
optionally terminated by haloalkyl; R.sup.4 is
SO.sub.2NR.sup.7R.sup.8; R.sup.5 and R.sup.6 are each independently
selected from H and C.sub.1 to C.sub.4 alkyl optionally substituted
with C.sub.3 to C.sub.5 cycloalkyl or C.sub.1 to C.sub.4 alkoxy,
or, together with the nitrogen atom to which they are attached,
form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl group;
R.sup.7 and R.sup.8, together with the nitrogen atom to which they
are attached, form a 4-R.sup.10-piperazinyl group optionally
substituted with one or two C.sub.1 to C.sub.4 alkyl groups and
optionally in the form of its 4-N-oxide; R.sup.10 is H; C.sub.1 to
C.sub.4 alkyl optionally substituted with one or two substituents
selected from OH, NR.sup.5R.sup.6, CONR.sup.5R.sup.6, phenyl
optionally substituted with C.sub.1 to C.sub.4 alkoxy,
benzodioxolyl and benzodioxanyl; C.sub.3 to C.sub.6 alkenyl;
pyridinyl or pyrimidinyl; and Het is a C-linked 6-membered
heterocyclic group containing one or two nitrogen atoms, optionally
in the form of its mono-N-oxide, or a C-linked 5-membered membered
heterocyclic group containing two or three nitrogen atoms, wherein
either of said heterocyclic groups is optionally substituted with
C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy or NHR.sup.15
wherein R.sup.15 is H, C.sub.1 to C.sub.4 alkyl or C.sub.1 to
C.sub.4 alkanoyl and halo is Br, Cl, F or I. which process
comprises reacting a compound of formula (IIA) or (IIB),
respectively: 149wherein Y is halo, and R.sup.1, R.sup.2 and
R.sup.13 are as previously defined in this claim, with a compound
of formula (III): R.sup.7R.sup.8NH (III)wherein R.sup.7 and R.sup.8
are as previously defined in this claim, optionally followed by
formation of a pharmaceutically or veterinarily acceptable salt of
the required product or a pharmaceutically or veterinarily
acceptable solvate of either entity.
21. A process for the preparation of a compound of formula (IA) or
(IB) as defined in claim 20, or a pharmaceutically or veteririarily
acceptable salt thereof, or a pharmaceutically or veterinarily
acceptable solvate of either entity, which comprises cyclisation of
a compound of formula (VA) or (VB) respectively: 150wherein
R.sup.1, R.sup.2 and R.sup.13 are as previously defined for
formulae (IA) and (IB) in claim 20 to form a compound of formula
(IVA) or (IVB): 151which can be converted to a compound of formula
(IIA) or (IIB), by reaction with a compound of formula (III)
R.sup.7R.sup.8NH wherein R.sup.7 and R.sup.8 are as defined in
claim 20, said compound of formula (IIA) or (IIB) may in turn be
converted by the process according to claim 20 to form a compound
of formula (IA) or (IB) which is optionally followed by formation
of a pharmaceutically or veterinarily acceptable salt of the
required product or a pharmaceutically or veterinarily acceptable
solvate of either entity.
22. A process for the preparation of a compound of formufa (IA) or
(IB) as defined in claim 20, or a pharmaceutically or veterinarily
acceptable salt thereof, or a pharmaceutically or veterinarily
acceptable solvate of either entity which comprises cyclisation of
a compound of formula (IXA) or (IXB) respectively: 152wherein
R.sup.1, R.sup.2, R.sup.4 and R.sup.13 are as defined in claim 20.
Description
[0001] This invention relates to a series of
pyrazolo[4,3-d]pyrimidin-7-on- es, which inhibit cyclic guanosine
3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably,
the compounds of the invention are potent and selective inhibitors
of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase
(cGMP PDE5) and have utility therefore in a variety of therapeutic
areas.
[0002] In particular, the compounds are of value in the treatment
of male erectile dysfunction (MED) and female sexual dysfunction
(FSD) but, clearly, will be useful also for treating other medical
conditions for which a potent and selective cGMP PDE5 inhibitor is
indicated. Such conditions include premature labour, dysmenorrhoea,
benign prostatic hyperplasia (BPH), bladder outlet obstruction,
incontinence, stable, unstable and variant (Prinzmetal) angina,
hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, conditions of reduced blood vessel patency, e.g.
post-percutaneous transluminal coronary angioplasty (post-PTCA),
peripheral vascular disease, stroke, bronchitis, allergic asthma,
chronic asthma, allergic rhinitis, glaucoma and diseases
characterised by disorders of gut motility, e.g. irritable bowel
syndrome (IBS).
[0003] Other conditions which may be mentioned include
pre-eclampsia, Kawasaki's syndrome, nitrate tolerance, multiple
sclerosis, peripheral diabetic neuropathy, stroke, Alzheimer's
disease, acute respiratory failure, psoriasis, skin necrosis,
cancer, metastasis, baldness, nutcracker oesophagus, anal fissure
and hypoxic vasoconstriction.
[0004] Particularly preferred conditions include MED and FSD.
[0005] Thus the invention provides compounds of formulae (IA) and
(IB): 2
[0006] or a pharmaceutically or veterinarily acceptable salt
thereof, or a pharmaceutically or veterinarily acceptable solvate
of either entity,
[0007] wherein
[0008] R.sup.1 is C.sub.1 to C.sub.3 alkyl optionally substituted
with phenyl, Het or a N-linked heterocyclic group selected from
piperidinyl and morpholinyl; wherein said phenyl group is
optionally substituted by one or more substituents selected from
C.sub.1 to C.sub.4 alkoxy; halo; CN; CF.sub.3, OCF.sub.3 or C.sub.1
to C.sub.4 alkyl wherein said C.sub.1 to C.sub.4 alkyl group is
optionally substituted by C.sub.1 to C.sub.4 haloalkyl or C.sub.1
to C.sub.4 haloalkoxy either of which is substituted by one or more
halo atoms;
[0009] R.sup.2 is C.sub.1 to C.sub.6 alkyl;
[0010] R.sup.13 is OR.sup.3 or NR.sup.5R.sup.6;
[0011] R.sup.3 is C.sub.1 to C.sub.6 alkyl optionally substituted
with one or two substituents selected from C.sub.3 to C.sub.5
cycloalkyl, OH, C.sub.1 to C.sub.4 alkoxy, benzyloxy,
NR.sup.5R.sup.6, phenyl, furanyl and pyridinyl; C.sub.3 to C.sub.6
cycloalkyl; 1-(C.sub.1 to C.sub.4 alkyl)piperidinyl;
tetrahydrofuranyl or tetrahydropyranyl; and wherein the C.sub.1 to
C.sub.6 alkyl and C.sub.1 to C.sub.4 alkoxy groups may optionally
be terminated by a haloalkyl group such as CF.sub.3;
[0012] R.sup.4 is SO.sub.2NR.sup.7R.sup.8;
[0013] R.sup.5 and R.sup.6 are each independently selected from H
and C.sub.1 to C.sub.4 alkyl optionally substituted with C.sub.3 to
C.sub.5 cycloalkyl or C.sub.1 to C.sub.4 alkoxy, or, together with
the nitrogen atom to which they are attached, form an azetidinyl,
pyrrolidinyl, piperidinyl or morpholinyl group;
[0014] R.sup.7 and R.sup.8, together with the nitrogen atom to
which they are attached, form a 4-R.sup.10-piperazinyl group
optionally substituted with one or two C.sub.1 to C.sub.4 alkyl
groups and optionally in the form of its 4-N-oxide;
[0015] R.sup.10 is H; C.sub.1 to C.sub.4 alkyl optionally
substituted with one or two substituents selected from OH,
NR.sup.5R.sup.6, CONR.sup.5R.sup.6, phenyl optionally substituted
with C.sub.1 to C.sub.4 alkoxy, benzodioxolyl and benzodioxanyl;
C.sub.3 to C.sub.6 alkenyl; pyridinyl or pyrimidinyl;
[0016] and
[0017] Het is a C-linked 6-membered heterocyclic group containing
one or two nitrogen atoms, optionally in the form of its
mono-N-oxide, or a C-linked 5-membered heterocyclic group
containing two or three nitrogen atoms, wherein either of said
heterocyclic groups is optionally substituted with C.sub.1 to
C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy or NHR.sup.15 wherein
R.sup.15 is H, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4
alkanoyl.
[0018] In the above definition, unless otherwise indicated, alkyl,
alkoxy and alkenyl groups having three or more carbon atoms, and
alkanoyl groups having four or more carbon atoms, may be straight
chain or branched chain. The term halo atom includes, Cl, Br, F,
and I. Haloalkyl and haloalkoxy are preferably CF.sub.3 and
OCF.sub.3 respectively.
[0019] The compounds of formulae (IA) and (IB) may contain one or
more chiral centres and therefore can exist as stereoisomers, i.e.
as enantiomers or diastereoisomers, as well as mixtures thereof.
The invention includes both the individual stereoisomers of the
compounds of formulae (IA) and (IB) and any mixture thereof.
Separation of diastereoisomers may be achieved by conventional
techniques, e.g. by fractional crystallisation or chromatography
(including HPLC) of a diastereoisomeric mixture of a compound of
formula (IA) or (IB) or a suitable salt or derivative thereof. An
individual enantiomer of a compound of formula (IA) or (IB) may be
prepared from a corresponding optically pure intermediate or by
resolution, either by HPLC of the racemate using a suitable chiral
support or, where appropriate, by fractional crystallisation of the
diastereoisomeric salts formed by reaction of the racemate with a
suitable optically active acid or base.
[0020] The compounds of formulae (IA) and (IB) may also exist in
tautomeric forms and the invention includes both mixtures thereof
and the individual tautomers.
[0021] Also included in the invention are radiolabelled derivatives
of compounds of formulae (IA) and (IB) which are suitable for
biological studies.
[0022] The pharmaceutically or veterinarily acceptable salts of the
compounds of formulae (IA) and (IB) which contain a basic centre
are, for example, non-toxic acid addition salts formed with
inorganic acids such as hydrochloric, hydrobromic, sulphuric and
phosphoric acid, with carboxylic acids or with organo-sulphonic
acids. Compounds of formulae (IA) and (IB) can also provide
pharmaceutically or veterinarily acceptable metal salts, in
particular non-toxic alkali metal salts, with bases. Examples
include the sodium and potassium salts.
[0023] A preferred group of compounds of formulae (IA) and (IB) is
that wherein R.sup.1 is C.sub.1 to C.sub.2 alkyl optionally
substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R.sup.2 is
C.sub.2 to C.sub.4 alkyl; R.sup.13 is OR.sup.3 or NR.sup.5R.sup.6;
R.sup.3 is C.sub.1 to C.sub.4 alkyl optionally substituted with one
or two substituents selected from cyclopropyl, cyclobutyl, OH,
methoxy, ethoxy, benzyloxy, NR.sup.5R.sup.6, phenyl, furan-3-yl,
pyridin-2-yl and pyridin-3-yl; cyclobutyl; 1-methylpiperidin-4-yl;
tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R.sup.5 and R.sup.6
are each independently selected from H and C.sub.1 to C.sub.2 alkyl
optionally substituted with cyclopropyl or methoxy, or, together
with the nitrogen atom to which they are attached, form a
azetidinyl, pyrrolidinyl or morpholinyl group; R.sup.7 and R.sup.8,
together with the nitrogen atom to which they are attached, form a
4-R.sup.10-piperazinyl group optionally substituted with one or two
methyl groups and optionally in the form of its 4-N-oxide; R.sup.10
is H, C.sub.1 to C.sub.3 alkyl optionally substituted with one or
two substituents selected from OH, NR.sup.5R.sup.6,
CONR.sup.5R.sup.6, phenyl optionally substituted with methoxy,
benzodioxol-5-yl and benzodioxan-2-yl; allyl; pyridin-2-yl;
pyridin-4-yl or pyrimidin-2-yl; and Het is selected from
pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl;
6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and
1-methylimidazol-2-yl.
[0024] A more preferred group of compounds of formulae (IA) and
(IB) is that wherein R.sup.1 is C.sub.1 to C.sub.2 alkyl optionally
substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R.sup.2 is
C.sub.2 to C.sub.4 alkyl; R.sup.13 is OR.sup.3; R.sup.3 is C.sub.1
to C.sub.4 alkyl optionally monosubstituted with cyclopropyl,
cyclobutyl, OH, methoxy, ethoxy, phenyl, furan-3-yl or
pyridin-2-yl; cyclobutyl; tetrahydrofuran-3-yl or
tetrahydropyran-4-yl; R.sup.7 and R.sup.8, together with the
nitrogen atom to which they are attached, form a
4-R.sup.10-piperazinyl group optionally in the form of its
4-N-oxide; R.sup.10 is C.sub.1 to C.sub.3 alkyl optionally
monosubstituted with OH; and Het is selected from pyridin-2-yl;
1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl;
pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.
[0025] Particularly preferred individual compounds of the invention
include
3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl-
)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo
[4,3-d]pyrimidin-7-one;
3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(-
2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazo-
lo[4,3-d]pyrimidin-7-one;
3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulph-
onyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro--
7H-pyrazolo[4,3-d]pyrimidin-7-one;
[0026]
5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-
-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrim-
idin-7-one;
5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyrid-
in-3-yl]-3-n-propyl-2-(pyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]- pyrimidin-7-one;
(+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-me-
thoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-
-d]pyrimidin-7-one;
[0027]
3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-met-
hylethoxy)pyridin-3-yl]-2-(6-methylpyridin-2-yl)methyl-2,6-dihydro-7H-pyra-
zolo [4,3-d]pyrimidin-7-one;
[0028]
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-
-2-(6-methoxypyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-- 7-one;
5-[2-i-butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2,3-d-
iethyl-2,6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one; and
[0029]
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-
-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.
[0030] According to a further aspect of the present invention there
are provided compounds of the formula (IA) and (IB) as defined
hereinbefore but wherein R.sup.1 is not unsubstituted C.sub.1
alkyl; the optional substituent on the C.sub.1 alkyl group of
R.sup.1 is not a substituted phenyl group or a N-linked
heterocyclic group; the optional substituent on the C.sub.2 or
C.sub.3 alkyl group of R.sup.1 is not phenyl or Het; or wherein
R.sup.13 is not NR.sup.5R.sup.6; or wherein the alkyl group of
R.sup.3 is not C.sub.5 or C.sub.6; or wherein the optional
substituent on R.sup.3 is not C.sub.3 to C.sub.5 cycloalkyl; or
wherein neither the alkyl or the optional alkoxy substituents on
R.sup.3 are terminated by a haloalkyl group; or wherein the C.sub.1
to C.sub.4 alkyl groups of R.sup.5 and R.sup.6 are not substituted
by C.sub.3 to C.sub.5 cycloalkyl or C.sub.1 to C.sub.4 alkoxy; or
wherein the C.sub.1 to C.sub.4 alkyl groups of R.sup.5 and R.sup.6
do not, together with the nitrogen group to which they are attached
form an azetidinyl group; or wherein Het is not a C.sub.1 to
C.sub.4 alkoxy or an HNR.sup.15 group.
[0031] In a further aspect, the present invention provides
processes for the preparation of compounds of formulae (IA) and
(IB), their pharmaceutically and veterinarily acceptable salts, and
pharmaceutically and veterinarily acceptable solvates of either
entity, as illustrated below.
[0032] It will be appreciated by persons skilled in the art that,
within certain of the processes described, the order of the
synthetic steps employed may be varied and will depend inter alia
on factors such as the nature of other functional groups present in
a particular substrate, the availability of key intermediates and
the protecting group strategy (if any) to be adopted. Clearly, such
factors will also influence the choice of reagent for use in the
said synthetic steps.
[0033] Illustrative of a protecting group strategy is the route to
the 2.sup.1-(2-hydroxyethoxy) analogue (Example 33), the precursor
to which (Example 32) contains benzyl as the alcohol-protecting
group.
[0034] It will also be appreciated that various standard
substituent or functional group interconversions and
transformations within certain compounds of formulae (IA) and (IB)
will provide other compounds of formulae (IA) and (IB). Examples
include alkoxide exchange at the 2-position of the 5-(pyridin-3-yl)
substituent (see conversions of Example 1 to Examples 4B. 9, 11,
13, 23, 24, 32 and 64, Example 2 to Example 14, Example 20 to
Example 21, Example 26 to Examples 29, 65, 66, 67 and 68, Example
35 to Example 36, Example 38 to Examples 39 and 40, and Example 45
to Example 46), amine exchange at the 2-position of the
5-(pyridin-3-yl) substituent (see conversions of Example 78 to
Examples 148 and 154) and piperazine and/or pyridine N-oxidation
(see conversions of Example 1 to Example 70, Example 28 to Example
71, and Example 4 to Examples 72 and 73).
[0035] The following processes are illustrative of the general
synthetic procedures which may be adopted in order to obtain the
compounds of the invention.
[0036] 1. A compound of formula (IA) or (IB) may be prepared from a
compound of formula (IIA) or (IIB) respectively: 3
[0037] wherein Y is halo, preferably chloro, and R.sup.1, R.sup.2
and R.sup.13 are as previously defined for formulae (IA) and (IB),
by reaction with a compound of formula (III):
R.sup.7R.sup.8NH (III)
[0038] wherein R.sup.7 and R.sup.8 are as previously defined for
formulae (IA) and (IB).
[0039] The reaction is generally conducted at from about 0.degree.
C. to about room temperature, preferably in the presence of an
appropriate solvent such as a C.sub.1 to C.sub.3 alkanol or
dichloromethane, using an excess of (III) or other suitable base
such as triethylamine to scavenge the acid by-product (HY).
[0040] Conveniently, this reaction lends itself to "high-speed
analogue synthesis" (HSAS), as illustrated by Examples 203 to 212
in which a particular compound of formula (IIB) is coupled with a
range of readily accessible amines of formula (III).
[0041] A compound of formula (IIA) or (IIB) may be prepared from a
compound of formula (IVA) or (IVB) respectively: 4
[0042] wherein R.sup.1, R.sup.2 and R.sup.13 are as previously
defined for formulae (IIA) and (IIB), by the application of known
methods for converting amino to a SO.sub.2Y group wherein Y is also
as previously defined for formulae (IIA) and (IIB). For example,
when Y is chloro, by the action of about a two-fold excess of
sodium nitrite in a mixture of concentrated hydrochloric acid and
glacial acetic acid at from about -25.degree. C. to about 0.degree.
C., followed by treatment with excess liquid sulphur dioxide and a
solution of about a three-fold excess of cupric chloride in aqueous
acetic acid at from about -15.degree. C. to about room temperature.
When R.sup.13 contains a primary or secondary amino group,
protection of the said amino group with an acid stable group such
as acetyl or benzyl will generally be advantageous.
[0043] A compound of formula (IVA) or (IVB) may be prepared by
cyclisation of a compound of formula (VA) or (VB) respectively:
5
[0044] wherein R.sup.1, R.sup.2 and R.sup.13 are as previously
defined for formulae (IVA) and (IVB). Preferably, the cyclisation
is base-mediated, using an alkali metal salt of a sterically
hindered alcohol or amine. For example, the required cyclisation
may be effected using about a 1.5 to 5, preferably a 3- to 5-fold
excess of potassium t-butoxide or potassium
bis(trimethylsilyl)amide, optionally in the presence of molecular
sieves, in a suitable solvent at the reflux temperature of the
reaction mixture, or, optionally in a sealed vessel at about
100.degree. C. When R.sup.13 is OR.sup.3 and an alcohol is selected
as solvent, the appropriate alcohol of formula R.sup.3OH should be
employed in order to obviate potential problems associated with
alkoxide exchange at the 2-position of the pyridine ring.
[0045] A compound of formula (VA) or (VB) may be prepared by
reduction of a compound of formula (VIA) or (VIB) respectively:
6
[0046] wherein R.sup.1, R.sup.2 and R.sup.13 are as previously
defined for formulae (VA) and (VB), by conventional catalytic or
catalytic transfer hydrogenation procedures. Typically, the
hydrogenation is achieved using a Raney nickel catalyst or a
palladium catalyst such as 10% Pd on charcoal, in a suitable
solvent such as ethanol at a hydrogen pressure of from about 345
kPa (50 psi) to about 414 kPa (60 psi) at from about room
temperature to about 60.degree. C. preferably from about 40.degree.
C. to about 50.degree. C.
[0047] A compound of formula (VIA) or (VIB) may be prepared by
reaction of a compound of formula (VIIA) or (VIIB) respectively:
7
[0048] wherein R.sup.1 and R.sup.2 are as previously defined for
formulae (VIA) and (VIB). with a compound of formula (VIII): 8
[0049] wherein R.sup.13 is also as previously defined for formulae
(VIA) and (VIB). Again, as for (IVA) and (IVB), a conventional
amine protecting group strategy is preferred for (VIII) when
R.sup.13 contains a primary or secondary amino group.
[0050] The coupling reaction may be achieved using conventional
amide bond-forming techniques, e.g. via the acyl chloride
derivative of (VIII) in the presence of up to about a five-fold
excess of a tertiary amine such as triethylamine or pyridine to act
as scavenger for the acid by-product (HY), optionally in the
presence of a catalyst such as 4-dimethylaminopyridine, in a
suitable solvent such as dichloromethane, at from about 0.degree.
C. to about room temperature. For convenience pyridine may also be
used as the solvent.
[0051] In particular, any one of a host of amino acid coupling
variations may be is used. For example, the acid of formula (VIII)
or a suitable salt (e.g. sodium salt) thereof may be activated
using a carbodiimide such as 1,3-dicyclohexylcarbodiimide or
1-ethyl-3-(3-dimethylaminoprop-1-- yl)carbodiimide optionally in
the presence of 1-hydroxybenzotriazole hydrate and/or a catalyst
such as 4-dimethylaminopyridine, or by using a
halotrisaminophosphonium salt such as
bromotris(pyrrolidino)phosphonium hexafluorophosphate or by using a
suitable pyridinium salt such as 2-chloro-1-methylpyridinium
iodide. Either type of coupling is conducted in a suitable solvent
such as dichloromethane or tetrahydrofuran, optionally in the
presence of a tertiary amine such as N-methylmorpholine or
N-ethyldiisopropylamine (for example when either the compound of
formula (VIIA) or (VIIB), or the activating reagent, is presented
in the form of an acid addition salt), at from about 0.degree. C.
to about room temperature. Preferably, from 1 to 2 molecular
equivalents of the activating reagent and from 1 to 3 molecular
equivalents of any tertiary amine present are employed.
[0052] In a further variation, the carboxylic acid function of
(VIII) may first of all be activated using up to about a 5% excess
of a reagent such as N,N-carbonyldiimidazole in a suitable solvent,
e.g. ethyl acetate or butan-2-one, at from about room temperature
to about 80.degree. C., followed by reaction of the intermediate
imidazolide with either (VIIA) or (VIIB) at from about 20.degree.
C. to about 90.degree. C.
[0053] 2. An alternative, generally applicable, synthetic route to
compounds of formulae (IA) and (IB) involves the incorporation of
the R.sup.4 substituent at an earlier stage of the synthesis.
[0054] Thus a compound of formula (IA) or (IB) may be prepared by
cyclisation of a compound of formula (IXA) or (IXB) respectively:
9
[0055] wherein R.sup.1, R.sup.2, R.sup.13 and R.sup.4 are as
previously defined for formulae (IA) and (IB), by analogy with the
previously described cyclisation of the compounds of formulae (VA)
and (VB).
[0056] Alternative reaction conditions are to conduct the reaction
with about 1.2 to 4 molecular equivalents of sterically hindered
base in a sealed vessel at from about 100.degree. C. to about
120.degree. C. or, rather than an alcohol of formula R.sup.3OH, to
use a sterically hindered alcohol, e.g. 3-methylpentan-3-ol, as
solvent with about 1.5 to 4.5 molecular equivalents of sterically
hindered base, such as potassium t-butoxide or KHMDS, and
optionally in a sealed vessel at from about 120.degree. C. to about
150.degree. C.
[0057] A compound of formula (IXA) or (IXB) may be prepared by
reaction of a compound of formula (VIIA) or (VIIB) respectively,
wherein R.sup.1 and R.sup.2 are as previously defined for formulae
(IXA) and (IXB) with a compound of formula (X): 10
[0058] wherein R.sup.13 and R.sup.4 are also as previously defined
for formulae (IXA) and (IXB), by analogy with the reactions of
(VIIA) or (VIIB) with the nicotinic acid derivatives of formula
(VIII) already described. Compounds having the general formula (X)
may be prepared directly from compounds having the general formula
(VIII) by reduction and subsequent conversion to R.sup.4 as
detailed previously herein.
[0059] 3. As mentioned earlier, certain compounds of formulae (IA)
and (IB) can be interconverted by inducing alkoxide exchange or
displacement at the 2-position of the 5-(pyridin-3-yl)
substituent.
[0060] (i) When R.sup.13 is OR.sup.3, this may be achieved, by
treating the appropriate alcohol with an alkali metal salt of a
sterically hindered alcohol or amine in order to generate the
required alkoxide anion which then reacts with the substrate.
Typically, in a two-step procedure, a mixture of from about 5 to
about 8 molecular equivalents of potassium bis(trimethylsilyl)amide
and the required alcohol as solvent is heated at from about
80.degree. C. to about 100.degree. C. for about 0.5 to 1 hour,
followed by addition of the compound of formula (IA) or (IB) and
heating of the reaction mixture at from about 100.degree. C. to
about 120.degree. C. Alternatively, in a one-step procedure, the
substrate may be treated directly, in the required alcohol as
solvent, with from about 1.2 to about 6, preferably from about 4 to
about 6 molecular equivalents of, for example, potassium
bis(trimethylsilyl)amide or potassium t-butoxide at from about
80.degree. C. to about 130.degree. C. A further variation employs
the required alcohol as solvent, saturated with ammonia, at about
100.degree. C. in a sealed vessel.
[0061] (ii) When R.sup.13 is NR.sup.5R.sup.6, the substrate may be
treated with an excess of R.sup.5R.sup.6NH, or a suitable acid
addition salt thereof, in the presence of an excess of a sterically
hindered amine in a suitable solvent. Typically, R.sup.5R.sup.6NH
is used as the free base with about a 3-fold excess (over the
substrate) of potassium bis(trimethylsilyl)amide (KHMDS) in
dimethylformamide (DMF) as solvent at about 100.degree. C.
Alternatively, an excess of R.sup.5R.sup.6NH may be used as the
solvent and the reaction conducted in the presence of about a 50%
excess of copper(II) sulphate at up to the reflux temperature of
the reaction medium. Where the desired amino substituent on the
compound of the formula (IA) or (IB) is --NR.sup.5R.sup.6 and one
of either R.sup.5 or R.sup.6 is H, then the exchange reaction may
be carried out by refluxing with the appropriate amine, and
copper(II)sulphate penta- or hepta-hydrate or KHDMS in DMF.
Typically, to exchange the OR.sup.3 group for alternative amines of
the formula NHR.sup.5R.sup.6, such as compounds wherein R.sup.5 or
R.sup.6 are selected from aliphatic or cyclic amines, optionally
including oxygen, then the reaction is preferably carried out by
treating with the appropriate amine and about 3 equivalents of
potassium bis(trimethylsilyl)amide in DMF for about 18 hours at
100.degree. C.
[0062] 4. Clearly, for certain compounds of formulae (IA) and (IB)
wherein R.sup.13 is OR.sup.3, by exploiting the cyclisation and
alkoxide exchange methodology described hereinbefore, it may be
particularly advantageous to generate a compound of formula (IA) or
(IB) from a compound of formula (IXA) or (IXB) respectively,
wherein the 2-alkoxy group of the 5-(pyridin-3-yl) substituent in
the former is different from that in the latter, directly in a
"one-pot reaction".
[0063] When the alcohol which is to provide the new 2-alkoxy group
is too scarce or expensive to be employed as the reaction solvent,
then it will be expedient to use a suitable alternative such as
1,4-dioxan.
[0064] 5. A further, generally applicable, synthetic route to
compounds of formula (IA) and (IB) involves incorporation of the
R.sup.1 substituent in the final step of the synthesis.
[0065] Thus a compound of formula (IA) or (IB) may be prepared by
alkylation of a compound of formula (IA) or (IB) wherein R.sup.1 is
hydrogen and R.sup.2, R.sup.13 and R.sup.4 are as previously
defined for formulae (IA) and (IB), using one or more of a plethora
of well-known methods, such as:
[0066] (i) reaction with a compound of formula R.sup.1 X, wherein
R.sup.1 is as previously defined for formulae (IA) and (IB), and X
is a suitable leaving group, e.g. halo (preferably chloro, bromo or
iodo), C.sub.1-C.sub.4 alkanesulphonyloxy,
trifluoromethanesulphonyloxy or arylsulphonyloxy (such as
benzenesulphonyloxy or p-toluenesulphonyloxy), in the presence of
an appropriate base, optionally in the presence of sodium iodide or
potassium iodide, at from about -70.degree. C. to about 100.degree.
C. Preferably the alkylation is conducted at from about room
temperature to about 80.degree. C. Suitable base-solvent
combinations may be selected from
[0067] (a) sodium, potassium or caesium carbonate, sodium or
potassium bicarbonate, or a tertiary amine such as triethylamine or
pyridine, together with a C.sub.1 to C.sub.4 alkanol,
1,2-dimethoxyethane. tetrahydrofuran, 1,4-dioxan, acetonitrile,
pyridine, dimethylformamide or N,N-dimethylacetamide;
[0068] (a) sodium or potassium hydroxide, or a sodium or potassium
C.sub.1 to C.sub.4 alkoxide, together with a C.sub.1 to C.sub.4
alkanol, water or mixtures thereof;
[0069] (b) lithium, sodium or potassium hydride, lithium, sodium or
potassium bis(trimethylsilyl)amide, lithium diisopropylamide or
butyllithium, together with toluene, ether, 1,2-dimethoxyethane,
tetrahydrofuran or 1,4-dioxan; or
[0070] (d) under phase transfer catalysis conditions, a
tetraalkylammonium halide or hydroxide, together with a mixture of
an aqueous solution of sodium or potassium hydroxide and
dichloromethane, 1,2-dichloroethane or chloroform:
[0071] (i) reaction with a compound of formula R.sup.1OH, wherein
R.sup.1 is as previously defined for formulae (IA) and (IB), using
classical Mitsunobu methodology. Typical reaction conditions
involve treating the substrate with the alkanol in the presence of
a triarylphosphine and a di(C.sub.1 to C.sub.4)alkyl
azodicarboxylate, in a suitable solvent such as tetrahydrofuran or
1,4-dioxan, at from about -5.degree. C. to about room
temperature.
[0072] Typically, about a 10% excess of sodium hydride is added to
a solution of the substrate in a suitable solvent, e.g. anhydrous
tetrahydrofuran, and the resulting anion treated with about a 10%
excess of the required R.sup.1X.
[0073] A compound of formula (IA) or (IB) wherein R.sup.1 is
hydrogen and R.sup.2, R.sup.13 and R.sup.4 are as previously
defined for formulae (IA) and (IB) may be obtained from a compound
of formula (IXA) or (IXB) respectively wherein R.sup.1 is hydrogen
and R.sup.2, R.sup.13 and R.sup.4 are as previously defined for
formulae (IXA) and (IXB), under the same conditions as those used
for the conversion of a compound of formula (IXA) or (IXB) to a
compound of formula (IA) or (IB) respectively when R.sup.1 is other
than hydrogen, followed by acidification of the reaction mixture to
a pH of about 6.
[0074] The amines of formula (III), the
4-aminopyrazole-5-carboxamides of formulae (VIIA) and (VIIB), the
carboxylic acids of formulae (VIII) and (X), the nitrites of
formula (XIII) and the esters of formula (XVI), when neither
commercially available nor subsequently described, can be obtained
either by analogy with the processes described in the Preparations
section or by conventional synthetic procedures, in accordance with
standard textbooks on organic chemistry or literature precedent,
from readily accessible starting materials using appropriate
reagents and reaction conditions.
[0075] Moreover, persons skilled in the art will be aware of
variations of, and alternatives to, those processes described
hereinafter in the Examples and Preparations sections which allow
the compounds defined by formulae (IA) and (IB) to be obtained.
[0076] The pharmaceutically acceptable acid addition salts of the
compounds of formulae (IA) and (IB) which contain a basic centre
may also be prepared in a conventional manner. For example a
solution of the free base is treated with the appropriate acid,
either neat or in a suitable solvent, and the resulting salt
isolated either by filtration of by evaporation under vacuum of the
reaction solvent.
[0077] Pharmaceutically acceptable base addition salts can be
obtained in an analogous manner by treating a solution of a
compound of formula (IA) or (IB) with the appropriate base. Both
types of salt may be formed or interconverted using ion-exchange
resin techniques.
[0078] The biological activities of the compounds of the present
invention were determined by the following test methods.
Phosphodiesterase (PDE) Inhibitory Activity
[0079] In vitro PDE inhibitory activities against cyclic guanosine
3',5'-monophosphate (cGMP) and cyclic adenosine 3',5'-monophosphate
(cAMP) phosphodiesterases were determined by measurement of their
IC.sub.50 values (the concentration of compound required for 50%
inhibition of enzyme activity).
[0080] The required PDE enzymes were isolated from a variety of
sources, including human corpus cavernosum, human and rabbit
platelets, human cardiac ventricle, human skeletal muscle and
bovine retina, essentially by the method of W. J. Thompson and M.
M. Appleman (Biochem., 1971, 10, 311). In particular, the
cGMP-specific PDE (PDE5) and the cGMP-inhibited cAMP PDE (PDE3)
were obtained from human corpus cavernosum tissue, human platelets
or rabbit platelets; the cGMP-stimulated PDE (PDE2) was obtained
from human corpus cavernosum; the calcium/calmodulin
(Ca/CAM)-dependent PDE (PDE1) from human cardiac ventricle; the
cAMP-specific PDE (PDE4) from human skeletal muscle; and the
photoreceptor PDE (PDE6) from bovine retina.
[0081] Assays were performed using a modification of the "batch"
method of W. J. Thompson et al. (Biochem., 1979, 18, 5228). Results
from these tests show that the compounds of the present invention
are potent and selective inhibitors of cGMP-specific PDE5.
Functional Activity
[0082] This was assessed in vitro by determining the capacity of a
compound of the invention to enhance sodium nitroprusside-induced
relaxation of pre-contracted rabbit corpus cavernosum tissue
strips, as described by S. A. Ballard et al. (Brit. J. Pharmacol.,
1996, 118 (suppl.), abstract 153P).
In Vivo Activitv
[0083] Compounds were screened in anaesthetised dogs to determine
their capacity, after i.v. administration, to enhance the pressure
rises in the corpora cavernosa of the penis induced by
intracavernosal-injection of sodium nitroprusside, using a method
based on that described by Trigo-Rocha et al. (Neurourol. and
Urodyn., 1994, 13, 71).
[0084] In human therapy, the compounds of formulae (IA) and (IB),
their pharmaceutically acceptable salts, and pharmaceutically
acceptable solvates of either entity, can be administered alone,
but will generally be administered in admixture with a
pharmaceutical carrier selected with regard to the intended route
of administration and standard pharmaceutical practice. Preferably,
they are administered orally in the form of tablets containing such
excipients as starch or lactose, or in capsules or ovules either
alone or in admixture with excipients, or in the form of elixirs,
solutions or suspensions containing flavouring or colouring agents.
They can also be injected parenterally, for example
intracavernosally, intravenously, intramuscularly or
subcutaneously. For parenteral administration, they are best used
in the form of a sterile aqueous solution which may contain other
substances, for example enough salts or monosaccharides to make the
solution isotonic with blood. For buccal or sublingual
administration they may be administered in the form of tablets or
lozenges which can be formulated in a conventional manner. The
compounds may also be administered intranasally or formulated for
dermal application.
[0085] For oral, parenteral, buccal and sublingual administration
to patients, the daily dosage level of the compounds of formulae
(IA) and (IB) and their pharmaceutically acceptable salts and
solvates may be from 10 to 500 mg (in single or divided doses).
Thus, for example, tablets or capsules may contain from 5 to 250 mg
of active compound for administration singly, or two or more at a
time, as appropriate. The physician in any event will determine the
actual dosage which will be most suitable for an individual patient
and it will vary with the age, weight and response of the
particular patient. The above dosages are exemplary of the average
case; there can, of course, be individual instances where higher or
lower dosage ranges are merited and such are within the scope of
this invention. The skilled person will also appreciate that, in
the treatment of certain conditions (including MED and FSD),
compounds of the invention may be taken as a single dose on an "as
required" basis (i.e. as needed or desired).
[0086] Generally, in humans, oral administration of the compounds
of the invention is the preferred route, being, the most convenient
and, for example in MED, avoiding the well-known disadvantages
associated with intracavernosal (i.c.) administration. A preferred
oral dosing regimen in MED for a typical man is from 25 to 250 mg
of compound when required. In circumstances where the recipient
suffers from a swallowing disorder or from impairment of drug
absorption after oral administration, the drug may be administered
parenterally, sublingually or buccally.
[0087] For veterinary use, a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a veterinarily acceptable
solvate of either entity, is administered as a suitably acceptable
formulation in accordance with normal veterinary practice and the
veterinary surgeon will determine the dosing regimen and route of
administration which will be most appropriate for a particular
animal.
[0088] Thus the invention provides a pharmaceutical composition
comprising a compound of formula (IA) or (IB), or a
pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate of either entity, together with a
pharmaceutically acceptable diluent or carrier.
[0089] It further provides a veterinary formulation comprising a
compound of formula (IA) or (IB), or a veterinarily acceptable salt
thereof, or a veterinarily acceptable solvate of either entity,
together with a veterinarily acceptable diluent or carrier.
[0090] The invention also provides a compound of formula (IA) or
(IB), or a pharmaceutically acceptable salt thereof, or a
pharmaceutically acceptable solvate of either entity, or a
pharmaceutical composition containing any of the foregoing, for use
as a human medicament.
[0091] In addition, it provides a compound of formula (IA) or (IB),
or a veterinarily acceptable salt thereof, or a veterinarily
acceptable solvate of either entity, or a veterinary formulation
containing any of the foregoing, for use as an animal
medicament.
[0092] In yet another aspect, the invention provides the use of a
compound of formula (IA) or (IB), or a pharmaceutically acceptable
salt thereof, or a pharmaceutically acceptable solvate of either
entity, for the manufacture of a human medicament for the curative
or prophylactic treatment of a medical condition for which a cGMP
PDE5 inhibitor is indicated. There is further provided the use of a
compound of formula (IA) or (IB) or a suitable salt or solvate
thereof, in the manufacture of a medicament for the treatment of a
medical condition in which inhibition of a cGMP PDE5 is
desirable.
[0093] It also provides the use of a compound of formula (IA) or
(IB), or a veterinarily acceptable salt thereof, or a veterinarily
acceptable solvate of either entity, for the manufacture of an
animal medicament for the curative or prophylactic treatment of a
medical condition for which a cGMP PDE5 inhibitor is indicated.
[0094] Moreover, the invention provides the use of a compound of
formula (IA) or (IB), or a pharmaceutically acceptable salt
thereof, or a pharmaceutically acceptable solvate containing either
entity, for the manufacture of a human medicament for the curative
or prophylactic treatment of male erectile dysfunction (MED),
female sexual dysfunction (FSD), premature labour, dysmenorrhoea,
benign prostatic hyperplasia (BPH), bladder outlet obstruction.
incontinence, stable, unstable and variant (Prinzmetal) angina,
hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, stroke, peripheral vascular disease, conditions of
reduced blood vessel patency, (e.g. post transluminal coronary
angioplasty (post-PTCA)), chronic asthma, bronchitis, allergic
asthma, allergic rhinitis, glaucoma or diseases characterised by
disorders of gut motility (e.g. irritable bowel syndrome (IBS)).
Other conditions which may be mentioned include pre-eclampsia,
Kawasaki's syndrome, nitrate tolerance, multiple sclerosis,
peripheral diabetic neuropathy, stroke, Alzheimer's disease, acute
respiratory failure, psoriasis, skin necrosis, cancer, metastasis,
baldness, nutcracker oesophagus, anal fissure and hypoxic
vasoconstriction. Particularly preferred conditions include MED and
FSD.
[0095] It also provides the use of a compound of formula (IA) or
(IB), or a veterinarily acceptable salt thereof, or a veterinarily
acceptable solvate containing either entity, for the manufacture of
an animal medicament for the curative or prophylactic treatment of
male erectile dysfunction (MED), female sexual dysfunction (FSD),
premature labour, dysmenorrhoea, benign prostatic hyperplasia
(BPH), bladder outlet obstruction, incontinence, stable, unstable
and variant (Prinzmetal) angina, hypertension, pulmonary
hypertension, congestive heart failure, atherosclerosis, stroke,
peripheral vascular disease, conditions of reduced blood vessel
patency (e.g. post-PTCA), chronic asthma, bronchitis, allergic
asthma, allergic rhinitis, glaucoma or diseases characterised by
disorders of gut motility (e.g. IBS). Other conditions which may be
mentioned include pre-eclampsia, Kawasaki's syndrome, nitrate
tolerance, multiple sclerosis, peripheral diabetic neuropathy,
stroke, Alzheimer's disease, acute respiratory failure, psoriasis,
skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus,
anal fissure and hypoxic vasoconstriction. Particularly preferred
conditions include MED and FSD.
[0096] Additionally, the invention provides a method of treating or
preventing a medical condition for which a cGMP PDE5 inhibitor is
indicated, in a mammal (including a human being), which comprises
administering to said mammal a therapeutically effective amount of
a compound of formula (IA) or (IB), or a pharmaceutically or
veterinarily acceptable salt thereof, or a pharmaceutically or
veterinarily acceptable solvate of either entity, or a
pharmaceutical composition or veterinary formulation containing any
of the foregoing.
[0097] Still further, the invention provides a method of treating
or preventing male erectile dysfunction (MED), female sexual
dysfunction (FSD), premature labour, dysmenorrhoea, benign
prostatic hyperplasia (BPH), bladder outlet obstruction,
incontinence, stable, unstable and variant (Prinzmetal) angina,
hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, stroke, peripheral vascular disease, conditions of
reduced blood vessel patency (e.g. post PTCA), chronic asthma,
bronchitis, allergic asthma, allergic rhinitis, glaucoma or
diseases characterised by disorders of gut motility in a mammal
(including a human being), which comprises administering to said
mammal a therapeutically effective amount of a compound of formula
(IA) or (IB), or a pharmaceutically or veterinarily acceptable salt
thereof, or a pharmaceutically or veterinarily acceptable solvate
of either entity, or a pharmaceutical composition or veterinary
formulation containing any of the foregoing.
[0098] The invention also includes any novel intermediates
described herein, for example those of formulae (IIA), (IIB),
(IVA), (IVB), (IXA), (IXB), (VA) and (VB).
[0099] The syntheses of the compounds of the invention and of the
intermediates for use therein are illustrated by the following
Examples and Preparations.
[0100] .sup.1H Nuclear magnetic resonance (NMR) spectra were
recorded using either a Varian Unity 300 or a Varian Inova 400
spectrometer and were in all cases consistent with the proposed
structures. Characteristic chemical shifts (.delta.) are given in
parts-per-million downfield from tetramethylsilane using
conventional abbreviations for designation of major peaks: e.g. s,
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br,
broad.
[0101] Mass spectra (m/z) were recorded using a Fisons Instruments
Trio mass spectrometer in the thermospray ionisation mode.
[0102] Room temperature means 20 to 25.degree. C.
EXAMPLE 1
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyr-
idin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0103] Alternative A
[0104] 60% Sodium hydride dispersion in mineral oil (14.3 mg, 0.36
mmol) was added to a stirred suspension of the title compound of
Preparation 44 (150 mg, 0.325 mmol) in anhydrous tetrahydrofuran (5
ml) under nitrogen. After 1 hour, a solution of
2-(chloromethyl)pyridine (45.5 mg, 0.36 mmol) in tetrahydrofuran (1
ml) was added and the reaction mixture heated at 40.degree. C. for
16 hours, then allowed to cool. The resulting mixture was
evaporated under reduced pressure and the residue partitioned
between dichloromethane (15 ml) and water (5 ml). The organic phase
was separated, combined with a dichloromethane extract (20 ml) of
the aqueous phase, dried (MgSO.sub.4) and evaporated under reduced
pressure. The residual yellow foam was purified by column
chromatography on silica gel, using dichloromethane: methanol
(97:3) as eluant, followed by HPLC using a 5 .mu.m Spherisorb
silica column with water: acetonitrile: diethylamine (50:50:0.1) as
eluant at a rate of 1 ml/min, to give the title compound (30 mg,
17%) as a white foam. .delta.(CDCl.sub.3): 1.03 (3H,t), 1.30
(3H,t), 1.57 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 3.05 (2H,q), 3.12
(4H,m), 4.75 (2H,q), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.64
(1H,m), 8.56 (1H,d), 8.64 (1H,s), 9.04 (1H,s), 10.65 (1H,s). LRMS:
m/z 553 (M+1).sup.+.
[0105] Alternative B
[0106] A mixture of the title compound of Preparation 45B (17.4 g,
30.5 mmol) and potassium bis(trimethylsilyl)amide (7.28 g, 36.5
mmol) in ethanol (155 ml) was heated at 120.degree. C. in a sealed
vessel for 10 hours, allowed to cool and evaporated under reduced
pressure. The residue was suspended in water (200 ml), the
suspension extracted with dichloromethane (2.times.300 ml) and the
combined extracts dried (MgSO.sub.4) and evaporated under reduced
pressure. The crude product was purified by column chromatography
on silica gel, using dichloromethane: methanol (97:3) as eluant, to
give a pale yellow foam (11.2 g, 66%) which was crystallised from
diisopropyl ether-methanol to yield the title compound as a
crystalline solid. Found: C, 55.58; H, 5.90; N, 19.58.
C.sub.26H.sub.32N.sub.8O.sub.4S; 0.50 H.sub.2O requires C, 55.60;
H, 5.92; N, 19.95%.
EXAMPLE 2
5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2--
(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0107] 1-Methylpiperazine (0.2 ml, 1.8 mmol) was added dropwise to
a stirred suspension of the title compound of Preparation 63 (450
mg, 0.92 mmol) in ethanol (40 ml) and the reaction mixture stirred
at room temperature for 18 hours, then evaporated under reduced
pressure. The residue was partitioned between saturated aqueous
sodium bicarbonate solution (30 ml) and ethyl acetate (90 ml), then
the organic phase separated, washed with brine (2.times.20 ml),
dried (Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residual oil was purified by column chromatography on silica gel,
using an elution gradient of dichloromethane: methanol (100:0 to
96:4), followed by crystallisation from hexane-ethyl acetate to
provide the title compound (340 mg, 67%) as a white solid. Found:
C, 55.90; H, 5.85; N, 20.04. C.sub.26H.sub.32N.sub.8O.sub.4S; 0.50
H.sub.2O requires C, 55.60; H, 5.92; N, 19.95%.
.delta.(CDCl.sub.3): 0.94 (3H,t), 1.58 (3H,t), 1.74 (2H,m), 2.27
(3H,s), 2.40 (4H,m), 2.99 (2H,t), 3.14 (4H,m), 4.69 (2H,q), 5.68
(2H,s), 7.09 (1H,d), 7.23 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.63
(1H,s), 9.03 (1H,s), 10.64 (1H,s). LRMS: m/z 552 (M).sup.+.
EXAMPLE 3
3-Ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin--
3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0108] Triethylamine (83 .mu.l, 0.59 mmol) and 1-methylpiperazine
(36 mg, 0.356 mmol) were added to a stirred, ice-cooled suspension
of the title compound of Preparation 64 (150 mg, 0.30 mmol) in
dichloromethane (10 ml) and the reaction mixture stirred for 2
hours at room temperature. The resulting mixture was washed with
water (5 ml), dried (MgSO.sub.4) and evaporated under reduced
pressure to give a beige solid, which was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (98:2 to 95:5), followed by trituration
with ether, to furnish the title compound (145 mg, 85%) as a white
solid. Found: C, 54.53; H, 5.69; N, 19.38.
C.sub.26H.sub.32N.sub.8O- .sub.5S; requires C, 54.92; H, 5.67;
N,19.71%. .delta.(CDCl.sub.3): 1.30 (3H,t), 2.28 (3H,s), 2.50
(4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.57 (3H,s), 3.86 (2H,t), 4.78
(2H,t), 5.68 (2H,s), 7.09 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58
(1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.81 (1H,s). LRMS: m/z 569
(M+1).sup.+.
EXAMPLE 4
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0109] Alternative A
[0110] Potassium t-butoxide (56 mg, 0.50 mmol) was added to a
stirred solution of the title compound of Preparation 45A (200 mg,
0.35 mmol) in 2-methoxyethanol (10 ml) and the reaction mixture
stirred under reflux for 2 hours, then allowed to cool. Saturated
aqueous ammonium chloride solution (1 ml) was added, followed by
water (5 ml), and the mixture extracted with ethyl acetate
(2.times.10 ml). The combined extracts were dried (MgSO.sub.4) and
evaporated under reduced pressure, then the residue purified by
column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 95:5), to afford the title
compound (11 mg, 5%) as a solid. .delta.(CDCl.sub.3): 1.03 (3H,t),
1.30 (3H,t), 2.41 (2H,q), 2.54 (4H,m), 3.04 (2H,q), 3.14 (4H,m),
3.56 (3H,s), 3.87 (2H,t), 4.78 (2H,t), 5.69 (2H,s), 7.10 (1H,d),
7.21 (1H,m), 7.61 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.95 (1H,s),
10.82 (1H,s). LRMS: m/z 583 (M+1).sup.+.
[0111] Alternative B
[0112] A mixture of potassium bis(trimethylsilyl)amide (16.58 g, 83
mol) and 2-methoxyethanol (250 ml) was stirred at 90.degree. C. for
30 minutes, then allowed to cool. The title compound of Example 1
(9.21 g, 16.7 mmol) was then added and the reaction mixture stirred
at 110.degree. C. for 6 hours. The resulting mixture, when cool,
was evaporated under reduced pressure, the residue dissolved in
water (300 ml) and the solution neutralised to pH 7 with 2M
hydrochloric acid and then extracted with ethyl acetate
(3.times.200 ml). The combined extracts were washed with brine
(3.times.200 ml), dried (Na.sub.2SO.sub.4) and evaporated under
reduced pressure. The residual yellow solid was purified by column
chromatography on silica gel, using dichloromethane: methanol
(98:2) as eluant, followed by trituration with ether,
crystallisation from ethyl acetate and recrystallisation from
acetone, to afford a solvate (with acetone) of the title compound
(7.7 g, 79%) as colourless crystals, m.p. 171.5-173.degree. C.
Found: C, 55.59; H, 5.94; N, 18.78.
C.sub.27H.sub.34N.sub.8O.sub.5S; 0.125 C.sub.3H.sub.6O requires C,
55.72; H, 5.94; N, 19.00%.
[0113] The product was suspended in water (200 ml), sufficient 2M
hydrochloric acid added to achieve dissolution and then the
solution washed with ether (3.times.50 ml) and neutralised with
saturated aqueous sodium bicarbonate solution. The resulting
precipitate was collected, washed with water and dried at
80.degree. C. to afford a hemihydrate of the title compound (5.99
g, 61.6%) as a white solid, m.p. 139-140.degree. C. Found: C,
54.74; H, 5.92; N, 18.86. C.sub.27H.sub.34N.sub.8O.sub.5S; 0.50
H.sub.2O requires C, 54.81; H, 5.96; N, 18.94%.
EXAMPLE 5
3-Ethyl-5-{2-(2-methoxyethoxy)-5-[4-(prop-1-yl)piperazin-1-ylsulphonyl]-py-
ridin-3-yl}-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-
-7-one
[0114] Obtained as a yellow foam (88%) from the title compound of
Preparation 64 and 1-(prop-1-yl)piperazine dihydrobromide, using
the procedure of Example 3. Found: C, 56.12; H, 6.06; N, 18.62.
C.sub.28H.sub.36N.sub.8O.sub.5S requires C, 56.36; H, 6.08; N,
18.78%. .delta.(CDCl.sub.3): 0.86 (3H,t), 1.30 (3H,t), 1.43 (2H,m),
2.30 (2H,t), 2.53 (4H,m), 3.04 (2H,q), 3.12 (4H,m), 3.57 (3H,s),
3.88 (2H,t), 4.78 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.23 (1H,m),
7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.81 (1H,s).
LRMS: m/z 597 (M+1).sup.+.
EXAMPLE 6
3-Ethyl-5-{2-(2-methoxyethoxy)-5-[4-(prop-2-yl)piperazin-1-ylsulphonyl]-py-
ridin-3-yl}-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimdin--
7-one
[0115] Obtained as a white powder (78%) from the title compound of
Preparation 64 and 1-(prop-2-yl)piperazine, using the procedure of
Example 3. Found: C, 55.95; H, 6.06; N, 18.46.
C.sub.28H.sub.36N.sub.8O.s- ub.5S requires C, 56.36; H, 6.08; N,
18.78%. .delta.(CDCl.sub.3): 1.00 (6H,2xd), 1.30 (3H,t), 2.61
(4H,m), 2.68 (1H,m), 3.02 (2H,q), 3.12 (4H,m), 3.57 (3H,s), 3.86
(2H,t). 4.79 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62
(1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.71 (1H,s). LRMS:
m/z 597 (M+1).sup.+.
EXAMPLE 7
5-{5-[4-(2-Aminoethyl)piperazin-1-ylsulphonyl]-2-(2-methoxyethoxy)pyridin--
3-yl}-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimid-
in-7-one
[0116] A solution of the title compound of Preparation 64 (100 mg,
0.198 mmol) in dichloromethane (10 ml) was added dropwise over 1
hour to a stirred solution of 1-(2-aminoethyl)piperazine (102 mg,
0.79 mmol) in dichloromethane (10 ml) and the reaction mixture
stirred for a further 1 hour at room temperature. The resulting
mixture was washed with water (10 ml), dried (MgSO.sub.4) and
evaporated under reduced pressure to give a beige solid, which was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol:0.88 ammonia (90:10:0 to
90:10:1), to yield the title compound (104 mg, 88%) as a white
foam. .delta.(CDCl.sub.3): 1.29 (3H,t), 2.43 (2H,t), 2.54 (4H,m),
2.74 (2H,t), 3.04 (2H,q), 3.12 (4H,m), 3.56 (3H,s), 3.88 (2H,t),
4.79 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m),
8.56 (1H,d), 8.62 (1H,s), 8.99 (1H,s). LRMS: m/z 598
(M+1).sup.+.
EXAMPLE 8
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-
-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
[0117] Potassium t-butoxide (104 mg, 0.97 mmol) was added to a
stirred suspension of the title compound of Preparation 53 (380 mg,
0.618 mmol) in 3-methylpentan-3-ol (30 ml) and the reaction mixture
heated under reflux for 1 hour, then allowed to cool. The resulting
mixture was evaporated under reduced pressure and the residual
yellow gum partitioned between dichloromethane (20 ml) and
saturated aqueous sodium bicarbonate solution (10 ml). The phases
were separated, the aqueous phase extracted with dichloromethane
(2.times.10 ml) and the combined extracts dried (MgSO.sub.4) and
evaporated under reduced pressure. The crude product was purified
by column chromatography on silica gel, using an elution gradient
of dichloromethane: methanol (98:2 to 95:5) to provide the title
compound (75 mg, 13%) as a white foam. .delta.(CDCl.sub.3): 0.93
(3H,t), 1.04 (3H,t), 1.73 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 2.97
(2H,t), 3.13 (4H,m), 3.56 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.68
(2H,s), 7.08 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.54 (1H,d), 8.62
(1H,s), 8.97 (1H,s), 10.80 (1H,s). LRMS: m/z 597 (M+1).sup.+.
EXAMPLE 9
5-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-et-
hyl-2-(pyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0118] A stirred mixture of potassium bis(trimethylsilyl)amide (434
mg, 2.2 mmol) and 2-ethoxyethanol (2 ml) was heated at 90.degree.
C. for 30 minutes, then allowed to cool. A solution of the title
compound of Example 1 (153 mg, 0.27 mmol) in 2-ethoxyethanol (2 ml)
was added and the reaction mixture stirred at 110.degree. C. for 18
hours, then allowed to cool. The resulting mixture was evaporated
under reduced pressure and the residual brown oil purified by
column chromatography on silica gel, using dichloromethane:
methanol (95:5) as eluant, to furnish the title compound (110 mg,
68%) as a yellow foam. .delta.(CDCl.sub.3): 1.04 (3H,t), 1.31
(6H,m), 2.41 (2H,q), 2.54 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.72
(2H,q), 3.90 (2H,t), 4.78 (2H,t), 5.67 (2H,s), 7.10 (1H,d), 7.22
(1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 8.99 (1H,s), 10.78
(1H,s). LRMS: m/z 597 (M+1).sup.+.
EXAMPLE 10
5-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n--
propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on-
e
[0119] A mixture of potassium t-butoxide (110 mg, 0.98 mmol), the
title compound of Preparation 54 (400 mg, 0.63 mmol) and
3-methylpentan-3-ol (5 ml) was stirred at 150.degree. C. for 3
hours, then allowed to cool. The resulting mixture was evaporated
under reduced pressure and the residue partitioned between water (5
ml) and ethyl acetate (5 ml). The phases were separated, the
aqueous phase extracted with ethyl acetate (2.times.10 ml) and the
combined organic solutions dried (MgSO.sub.4) and evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel, using an elution gradient of
dichloromethane:methanol:0.88 aqueous ammonia (99:1:0.5 to
98:2:0.5), to afford the title compound (74 mg, 12%) as a white
foam. Found: C, 56.92; H, 6.33; N, 17.80.
C.sub.29H.sub.36N.sub.8O.sub.5S requires C, 57.21; H, 5.96; N,
18.41%. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.03 (3H,t), 1.30 (3H,t),
1.72 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 3.14 (4H,m), 3.72 (2H,q),
3.90 (2H,t), 4.78 (2H,t), 5.67 (2H,s), 7.09 (1H,d), 7.22 (1H,m),
7.62 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 8.98 (1H,s), 10.77
(1H,s).
EXAMPLE 11
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)-pyri-
din-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
-one
[0120] A mixture of the title compound of Example 1 (200 mg, 0.36
mmol), potassium bis(trimethylsilyl)amide (361 mg, 1.81 mmol) and
3-methoxypropan-1-ol (1.5 ml) was stirred at 90.degree. C. for 18
hours, then allowed to cool. The resulting mixture was evaporated
under reduced pressure and the residue purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (97:3 to 95:5), to give the title
compound (81 mg, 38%) as a foam. Found: C, 55.36; H, 6.11; N,
18.18. C.sub.28H.sub.36N.sub.8O.sub.5S; 0.50 H.sub.2O requires C,
55.52; H, 6.16; N, 18.50%. .delta.(CDCl.sub.3): 1.01 (3H,t), 1.29
(3H,t), 2.19 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 3.02 (2H,q), 3.12
(4H,m), 3.39 (3H,s), 3.65 (2H,t), 4.76 (2H,t), 5.68 (2H,s), 7.09
(1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.93
(1H,s), 10.84 (1H,s). LRMS: m/z 597 (M+1).sup.+.
EXAMPLE 12
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridin-3-yl]-
-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-Pyrazolo[4,3-d]pyrimidin-
-7-one
[0121] Obtained as a foam (26%) from the title compound
of-Preparation 55, using the procedure of Example 10. Found:
C,56.92; H, 6.47; N, 17.78. C.sub.29H.sub.36N.sub.8O.sub.5S
requires C, 57.04; H, 6.27; N, 18.35%. .delta.(CDCl.sub.3): 0.93
(3H,t), 1.02 (3H,t), 1.72 (2H,m), 2.20 (2H,m), 2.40 (2H,q), 2.54
(4H,m), 2.97 (2H,t), 3.12 (4H,m), 3.40 (3H,s), 3.65 (2H,t), 4.77
(2H,t), 5.67 (2H,s), 7.08 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.58
(1H,d), 8.62 (1H,s), 8.94 (1H,s), 10.83 (1H,s). LRMS: m/z 611
(M+1).sup.+.
EXAMPLE 13
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxyprop-2(S)-oxy)py-
ridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-
-7-one
[0122] Obtained as a foam (33%) from the title compound of Example
1 and 1-methoxypropan-2(S)-ol (J.Chem.Soc., Perkin Trans. I, 1996,
1467), using the procedure of Example 9, but with
ether:methanol:0.88 aqueous ammonia (97:3:1) as chromatographic
eluant. Found: C, 55.91; H, 6.17; N, 18.10.
C,.sub.28H.sub.36N.sub.8O.sub.5S; 0.50 H.sub.2O requires C, 55.52;
H, 6.16; N, 18.50%. .delta.(CDCl.sub.3): 1.04 (3H,t), 1.30 (3H,t),
1.52 (3H,d), 2.42 (2H,q), 2.56 (4H,m), 3.04 (2H,q), 3.14 (4H,m),
3.55 (3H,s), 3.66 (1H,dd), 3.74 (1H,dd), 5.60 (1H,m), 5.68 (2H,s),
7.08 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.61 (1H,s),
8.89 (1H,s), 10.85 (1H,s). LRMS: m/z 597 (M+1).sup.+.
EXAMPLE 14
5-[2-(2-Methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3--
n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7--
one
[0123] A mixture of potassium bis(trimethylsilyl)amide (460 mg, 2.3
mmol) and 2-methoxyethanol (40 ml) was stirred at 90.degree. C. for
30 minutes, then allowed to cool. The title compound of Example 2
(270 mg, 0.46 mmol) was added and the reaction mixture stirred at
110.degree. C. for 5 hours, allowed to cool and evaporated under
reduced pressure. The residue was suspended in water (20 ml), the
pH adjusted to 7 with hydrochloric acid and the resulting solution
extracted with ethyl acetate (3.times.30 ml). The combined extracts
were washed with brine (3.times.20 ml), dried (Na.sub.2SO.sub.4)
and evaporated under reduced pressure. The residual oil was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 96:4), followed by
crystallisation from hexane-ethyl acetate, to yield the title
compound (200 mg, 75%) as a white solid. Found: C, 54.83; H, 5.83;
N, 18.90. C.sub.27H.sub.34N.sub.8O.sub.5S; 0.50 H.sub.2O requires
C, 54.81; H, 5.96; N, 18.94%. .delta.(CDCl.sub.3): 0.94 (3H,t),
1.74 (2H,m), 2.28 (3H,s), 2.50 (4H,m), 2.98 (2H,t), 3.15 (4H,m),
3.57 (3H,s), 3.87 (2H,t), 4.80 (2H,t), 5.68 (2H,s), 7.08 (1H,d),
7.22 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.64 (1H,s), 8.96 (1H,s),
10.80 (1H,s). LRMS: m/z 583 (M+1).sup.+.
EXAMPLE 15
5-[2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-
-yl]-3-n-propyl-2-(pyridin-2-yl)
methyl-2,6-dihydro-7H-pvrazolo[4,3-d]-pyr- imidin-7one
[0124] A mixture of the title compound of Preparation 72 (70 mg,
0.10 mmol), potassium t-butoxide (23 mg, 0.20 mmol) and
3-methylpentan-3-ol (3ml) was stirred under reflux for 4 hours,
then allowed to cool and evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel, using
dichloromethane: methanol (98:2) as eluant, to provide the title
compound (6 mg, 9%) as an off-white solid. .delta.(CDCl.sub.3):
0.93 (3H,t), 1.03 (3H,t), 1.72 (2H,m), 2.42 (2H,q), 2.55 (4H,m),
2.98 (2H,t), 3.16 (4H,m), 3.50 (6H,s), 3.77 (2H,m), 3.86 (2H,m),
5.68 (3H,m), 7.08 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.57 (1H,d),
8.61 (1H,s), 8.84 (1H,s), 10.87 (1H,s). LRMS: m/z 641
(M+1).sup.+.
EXAMPLE 16
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0125] Obtained as a white solid (50%) from the title compound of
Preparation 65, using the procedure of Example 10. Found: C, 55.45;
H, 5.91; N, 18.94. C.sub.27H.sub.34N.sub.8O.sub.5S requires C,
55.66; H, 5.88; N, 19.23%. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.40
(3H,t), 2.42 (2H,q), 2.56 (4H,m), 3.00 (2H,q), 3.16 (4H,m), 3.55
(3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.95 (2H,s), 7.01 (1H,d), 7.17
(1H,m), 7.60 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 11.04
(1H,s). LRMS: m/z 583 (M+1).sup.+.
EXAMPLE 17
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-ylox-
y)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2
6-dihydro-7H-pyrazolo[4,3-d]pyrim- idin-7-one
[0126] Obtained as a solid (29%) from the title compound of
Preparation 56, using the procedure of Example 10. Found: C, 55.85:
H, 5.98; N, 17.86. C.sub.28H.sub.34N.sub.8O.sub.5S; 0.20 H.sub.2O;
0.10 CH.sub.2Cl.sub.2 requires C, 55.24; H, 5.73; N, 18.41%.
.delta.(CDCl.sub.3): 1.02 (3H,t), 1.28 (3H,t), 2.40 (4H,m), 2.55
(4H.m), 3.02 (2H,q), 3.13 (4H,m), 4.00 (2H,m) 4.16 (2H,m), 5.68
(2H,s), 5.86 (1H.m), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.56
(1H,d), 8.63 (1H,s), 8.98 (1H,s). 10.42 (1H,s). LRMS: m/z 594
(M).sup.+. [.alpha.].sub.D.sup.25-13.8.degree. (c=0.10,
CH.sub.3OH).
EXAMPLE 18
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-ylox-
y)pyridin-3-yl]-2-(pyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyri- midin-7-one
[0127] Obtained as a solid (24%) from the title compound of
Preparation 75, using the procedure of Example 10. Found: C, 55.32;
H, 5.82; N, 17.70. C.sub.28H.sub.34N.sub.8O.sub.5S; H.sub.2O
requires C, 54.88; H, 5.92; N, 18.29%. .delta.(CDCl.sub.3): 1.02
(3H,t), 1.28 (3H,t), 2.40 (4H,m), 2.55 (4H,m), 3.02 (2H.q), 3.13
(4H,m), 4.00 (2H,m), 4.16 (2H,m), 5.68 (2H,s), 5.86 (1H,m), 7.10
(1H.d), 7.22 (1H,m), 7.63 (1H,m), 8.56 (1H,d), 8.63 (1H,s), 8.98
(1H,s), 10.42 (1H,s). LRMS: m/z 595 (M+1).sup.+.
[.alpha.].sub.D.sup.25+14.0.degree. (c=0.14, CH.sub.3OH).
EXAMPLE 19
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridin-3-
-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrim-
idin-7-one
[0128] Obtained as a white solid (30%) from the title compound of.
Preparation 76, using the procedure of Example 10.
.delta.(CDCl.sub.3): 0.94 (3H,t), 1.03 (3H,t), 1.73 (2H,m), 2.01
(2H,m), 2.22 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.12
(4H,m), 3.66 (2H,m), 4.06 (2H,m), 5.60 (1H,m), 5.69 (2H,s), 7.10
(1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 9.01
(1H,s), 10.55 (1H,s). LRMS: m/z 623 (M+1).sup.+.
EXAMPLE 20
3-Ethyl-5-[5-(4-methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl-2-(-
pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0129] Potassium t-butoxide (540 mg, 4.8 mmol) was added to a
stirred solution of the title compound of Preparation 52 (683 mg,
1.2 mmol) in n-propanoJ (10 ml) and the reaction mixture stirred
under reflux for 18 hours, then allowed to cool. The resulting
mixture was evaporated under reduced pressure and the residual oil
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 95:5) to furnish
the title compound (290 mg, 44%) as a foam. Found: C, 56.32; H,
6.04; N, 19.36. C.sub.26H.sub.32N.sub.8O.sub.4S requires C, 56.50;
H, 5.83; N, 20.27%. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.30 (3H,t),
1.98 (2H,m), 2.38 (3H,s), 2.50 (4H,m), 3.04 (2H,q), 3.13 (4H,m),
4.64 (2H,t), 5.69 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.30 (1H,m),
8.58 (1H,d), 8.63 (1H,s), 9.04 (1H,s), 10.66 (1H,s). LRMS: m/z 553
(M+1).sup.+.
EXAMPLE 21
3-Ethyl-5-[5-(4-methylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-
-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0130] Potassium t-butoxide (290 mg, 2.60 mmol) was added to a
stirred solution of the title compound of Example 20 (239 mg, 0.43
mmol) in propan-2-ol (7 ml) under nitrogen and the reaction mixture
heated under reflux for 48 hours, then allowed to cool. The
resulting mixture was evaporated under reduced pressure and the
residue partitioned between water (20 ml) and ethyl acetate (20
ml).
[0131] The phases were separated, the aqueous phase extracted with
ethyl acetate and the combined organic solutions dried (MgSO.sub.4)
and evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 95:5), to afford the title
compound (84 mg,35%) as a foam. .delta.(CDCl.sub.3): 1.28 (3H,t),
1.56 (6H,2xd), 2.28 (3H,s), 2.50 (4H,m), 3.04 (2H,q), 3.14 (4H,m),
5.68 (3H,m), 7.09 (1H,d), 7.22 (1H,m), 7.62(1H,m), 8.57 (1H,d),
8.62 (1H,s), 9.02 (1H,s), 10.68 (1H,s). LRMS: m/z 553
(M+1).sup.+.
EXAMPLE 22
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]--
2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0132] A mixture of the title compound of Preparation 45A (200 mg,
0.35 mmol), 60% sodium hydride dispersion in mineral oil (400 mg,
10 mmol) and propan-2-ol (20 ml) was stirred under reflux for 18
hours, then allowed to cool. Saturated aqueous ammonium chloride
solution (20 ml) was added, the resulting mixture extracted with
ethyl acetate (3.times.50 ml), then the combined extracts washed
with aqueous sodium bicarbonate solution (150 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 95:5), to give the
title compound (11 mg, 6%) as a foam. .delta.(CDCl.sub.3): 1.04
(3H,t), 1.30 (3H,t), 1.56 (6H,2xd), 2.1 (2H,q), 2.55 (4H,m), 3.04
(2H,q), 3.13 (4H.m), 5.68 (3H,m), 7.10 (1H,d), 7.22 (1H,m), 7.62
(1H,m), 8.57 (1H,d), 8.62 (1H.s), 9.02 (1H,s), 10.68 (1H,s). LRMS:
m/z 567 (M+1).sup.+.
EXAMPLE 23
5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(p-
yridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0133] A mixture of the title compound of Example 1 (200 mg, 0.36
mmol), potassium bis(trimethylsilyl)amide (360 mg, 1.81 mmol) and
n-butanol (5 ml) was stirred at 100.degree. C. for 18 hours, then
allowed to cool. The resulting mixture was evaporated under reduced
pressure and the residue partitioned between water (5 ml) and
dichloromethane (5 ml). The phases were separated and the aqueous
layer extracted with dichloromethane (2.times.10 ml), then the
combined organic solutions dried (MgSO.sub.4) and evaporated under
reduced pressure. The residual yellow solid was purified by column
chromatography on silica gel, using dichloromethane: methanol
(97.5:2.5) as eluant, to yield the title compound (145 mg, 69%) as
a white solid. Found: C, 57.43; H, 6.29; N, 18.82.
C.sub.28H.sub.36N.sub.8O.sub.4S; 0.20 H.sub.2O requires C, 57.56;
H, 6.28; N, 19.18%. .delta.(CDCl.sub.3): 1.03 (6H,2xt), 1.30
(3H,t), 1.55 (2H,m), 1.94 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 3.03
(2H,q), 3.13 (4H,m), 4.67 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22
(1H,m), 7.62 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 9.01 (1H,s), 10.64
(1H,s). LRMS: m/z 581 (M+1).sup.+.
EXAMPLE 24
5-[2-i-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(p-
yridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0134] Obtained as a white solid (67%) from the title compound of
Example 1 and i-butanol, using the procedure of Example 23. Found:
C, 57.25; H, 6.24; N, 18.84. C.sub.28H.sub.36N.sub.8O.sub.4S; 0.20
H.sub.2O requires C, 57.56; H, 6.28; N, 19.18%.
.delta.(CDCl.sub.3): 1.03 (3H,t), 1.12 (6H,d), 1.30 (3H,t), 2.30
(1H,m), 2.40 (2H,q), 2.55 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 4.45
(2H,d), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.58
(1H,d), 8.62 (1H,s), 9.02 (1H,s), 10.63 (1H,s). LRMS: m/z 581
(M+1).sup.+.
EXAMPLE 25
5-[2-Cyclobutoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-
-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0135] A stirred mixture of the title compound of Preparation 45A
(200 mg, 0.35 mmol), cyclobutanol (144 mg, 2 mmol), potassium
t-butoxide (80 mg, 0.70 mmol) and 1,4-dioxan (5 ml) was heated
under reflux for 24 hours, then allowed to cool. The resulting
mixture,was poured into stirred aqueous sodium bicarbonate solution
(20 ml) and this mixture extracted with ethyl acetate (3.times.20
ml). The combined extracts were dried (MgSO.sub.4) and evaporated
under reduced pressure, then the residue purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 96:4), to provide the title
compound (9 mg, 4%) as a solid. .delta.(CDCl.sub.3): 1.03 (3H,t),
1.29 (3H,t), 1.78 (2H,m), 1.98 (2H,m), 2.35 (2H,m), 2.55 (6H,m),
3.04 (2H,q), 3.12 (4H,m), 5.48 (1H,m), 5.68 (2H,s), 7.10 (1H,d),
7.23 (1H,m), 7.63 (1H,m), 8.56 (1H,d), 8.60 (1H,s), 9.01 (1H,s),
10.67 (1H,s). LRMS: m/z 579 (M+1).sup.+.
EXAMPLE 26
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(-
pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0136] Potassium t-butoxide (2.38 g, 21.2 mmol) was added to a
solution of the title compound of Preparation 77 (3.1 g, 5.3 mmol)
in absolute ethanol (95 ml) and the reaction mixture heated at
100.degree. C. in a sealed vessel for 40 hours, then allowed to
cool. The resulting mixture was evaporated under reduced pressure,
the residue dissolved in water (20 ml) and the aqueous solution
acidified to pH 5 with 2M hydrochloric acid. The aqueous suspension
thus obtained was extracted with dichloromethane (3.times.30 ml)
and the combined extracts dried (MgSO.sub.4) and evaporated under
reduced pressure. The residual brown foam was purified by column
chromatography on silica gel using an elution gradient of
dichloromethane: methanol (99:1 to 97:3), to furnish the title
compound (1.39 g, 46%) as a foam. .delta.(CDCl.sub.3): 0.93 (3H,t),
1.02 (3H,t), 1.58 (3H,t), 1.74 (2H,m), 2.40 (2H,q), 2.54 (4H,m),
2.98 (2H,t), 3.13 (4H,m), 4.75 (2H,q), 5.68 (2H,s), 7.09 (1H,d),
7.23 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.02 (1H,s),
10.64 (1H,s).
EXAMPLE 27
5-{5-[4-(3-Dimethylaminoprop-1-yl)piperazin-1-ylsulphonyl]-2-ethoxypyridin-
-3-yl}-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyr-
imidin-7-one trihydrochloride
[0137] A solution of freshly distilled
1-(3-dimethylaminoprop-1-yl)piperaz- ine (J.Chem.Soc. (C), 1971,
132; 160 mg, 0.93 mmol) in ethanol (2 ml) was added to a stirred
solution of the title compound of Preparation 63 (230 mg, 0.467
mmol) in ethanol (10 ml) and the reaction mixture stirred at room
temperature for 18 hours, then evaporated under reduced pressure.
The residue was suspended in aqueous sodium bicarbonate solution
(30 ml), the suspension extracted with ethyl acetate (3.times.30
ml) and the combined extracts washed with brine (2.times.30 ml),
dried (Na.sub.2SO.sub.4), and evaporated under reduced pressure.
The residual oil was purified by column chromatography on silica
gel, using an elution gradient of dichloromethane: methanol (100:0
to 90:10), then the product dissolved in the minimum volume of
ethyl acetate. Saturated ethereal hydrogen chloride solution was
added and the resulting white precipitate collected, triturated
with ether and dried under suction to afford the title compound
(140 mg, 37%) as a white solid. Found: C, 44.45: H, 6.34; N, 15.38.
C.sub.30H.sub.41N.sub.9O.sub.4S; 3HCl; 4H.sub.2O requires C, 44.75;
H, 6.51; N, 15.66%. .delta.(DMSOd.sub.6): 0.86 (3H,t), 1.34 (3H,t),
1.64 (2H,m), 2.12 (2H,m), 2.72 (6H,2xs), 2.95 (2H,t), 3.00 (2H,m),
3.12 (2H,t), 3.18 (2H,m), 3.56 (2H,m), 3.84 (2H,m), 4.50 (2H,q),
5.75 (2H,s), 7.27 (1H,d), 7.42 (1H,m), 7.90 (1H,m), 8.28 (1H,s),
8.57 (1H,d), 8.73 (1H,s), 10.63 (1H,s), 11.47 (1H,s), 11.96 (1H,s).
LRMS: m/z 624 (M+1).sup.+.
EXAMPLE 28
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-3-n-propyl--
2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0138] Obtained as a colourless solid (40%) from the title compound
of Preparation 80, using the procedure of Example 20. Found: C,
57.16; H, 6.15; N, 18.85. C.sub.28H.sub.36N.sub.8O.sub.4S; 0.50
H.sub.2O requires C, 57.03; H, 6.32; N, 19.00%.
.delta.(CDCl.sub.3): 0.94 (3H,t), 1.02 (3H,t), 1.13,(3H,t), 1.74
(2H,m), 1.98 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.98 (2H,t), 3.12
(4H,m), 4.62 (2H,t), 5.66 (2H,s), 7.09 (1H,d), 7.21 (1H,m), 7.62
(1H,m), 8.57 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 10.63 (1H,s). LRMS:
m/z 582 (M+2).sup.+.
EXAMPLE 29
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-3-n-prop-
yl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0139] Obtained as a solid (48%) from the title compound of Example
26 and propan-2-ol, using the procedure of Example 21.
.delta.(CDCl.sub.3): 0.94 (3H,t), 1.03 (3H,t), 1.57 (6H,d), 1.74
(2H,m), 2.41 (2H,q), 2.56 (4H,m), 2.98 (2H,t), 3.12 (4H,m), 5.68
(3H,m), 7.08 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.63
(1H,s), 9.02 (1H,s), 10.67 (1H,s). LRMS: m/z 581 (M+1).sup.+.
EXAMPLE 30
5-{2-Ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-n-
-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
[0140] Obtained as a white solid (49%) from the title compound of
Preparation 63 and 1-(2-hydroxyethyl)piperazine, using the
procedure of Example 2. Found: C, 55.48; H, 5.93; N, 18.85.
C.sub.27H.sub.34N.sub.8O.s- ub.5S; 0.10 C.sub.4H.sub.8O.sub.2
requires C, 55.64; H, 5.93: N, 18.94%. .delta.(CDCl.sub.3): 0.95
(3H,t), 1.59 (3H,t), 1.75 (2H,m), 2.28 (1H,s), 2.58 (2H,m), 2.65
(4H,m), 3.00 (2H,t), 3.16 (4H,m), 3.60 (2H,t), 4.76 (2H,q), 5.68
(2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.64
(1H,s), 9.04 (1H,s), 10.66 (1H,s). LRMS: m/z 583 (M+1).sup.+.
EXAMPLE 31
5-{2-Ethoxy-5-[4-(3-hydroxyprop-1-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-
-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-
-7-one
[0141] Obtained as a white solid (52%) from the title compound of
Preparation 63 and 1-(3-hydroxyprop-1-yl)piperazine, using the
procedure of Example 2. Found: C, 56.27; H, 6.13; N, 18.38.
C.sub.28H.sub.36N.sub.8- O.sub.5S requires C, 56.36; H, 6.08; N,
18.78%. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.60 (3H,t), 1.72 (4H,m),
2.63 (6H,m), 2.98 (2H,t), 3.12 (4H,m), 3.72 (2H,t), 4.15 (1H,s),
4.77 (2H,q), 5.69 (2H,s), 7.08 (1H,d), 7.23 (1H,m), 7.63 (1H,m),
8.58 (1H,d), 8.61 (1H,s), 9.01 (1H,s), 10.67 (1H,s). LRMS: m/z 596
(M).sup.+.
EXAMPLE 32
5-[2-(2-Benzyloxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-
-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on-
e
[0142] Obtained as a yellow oil (57%) from the title compound of
Example 1 and 2-benzyloxyethanol, using the procedure of Example
11. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.32 (3H,t), 2.40 (2H,q),
2.54 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 3.94 (2H,t), 4.76 (2H,s),
4.80 (2H,t), 5.69 (2H,s), 7.11 (1H,d), 7.20-7.37 (4H,m), 7.41
(2H,m), 7.64 (1H,m), 8.60 (2H,m), 8.98 (1H,s), 10.80 (1H,s). LRMS:
m/z 659 (M+1).sup.+.
EXAMPLE 33
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-hydroxyethoxy)pyridin-3-
-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0143] Ammonium formate (62 mg, 0.99 mmol) was added to a mixture
of the title compound of Example 32 (130 mg, 0.197 mmol), 10%
palladium on charcoal (15 mg) and acetone (9 ml) and the reaction
mixture stirred under reflux for 14 hours, then allowed to cool.
The resulting mixture was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using an
elution gradient of dichloromethane: methanol (100:0 to 90:10), to
give the title compound (18 mg, 16%) as a solid.
.delta.(CD.sub.3OD): 1.06 (3H,t), 1.28 (3H,t), 2.44 (2H,q), 2.58
(4H,m), 3.06 (2H,q), 3.14 (4H,m), 3.97 (2H,t), 4.68 (2H,t), 5.75
(2H,s), 7.20 (1H,d), 7.36 (1H,m), 7.80 (1H,m), 8.54 (2H,m), 8.68
(1H,s). LRMS: m/z 569 (M+1).sup.+.
EXAMPLE 34
5-[2-(2-Benzyloxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-
-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
-one
[0144] A stirred mixture of the title compound of Preparation 84
(500 mg, 0.72 mmol), potassium bis(trimethylsilyl)amide (347 mg,
3.09 mmol) and 3-methylpentan-3-ol (8 ml) was heated under reflux
for 36 hours, then allowed to cool. The resulting mixture was
evaporated under reduced pressure and the residue partitioned
between water (1 ml) and dichloromethane (10 ml). The phases were
separated, the aqueous phase extracted with dichloromethane
(2.times.10 ml) and the combined organic solutions dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was purified by two column chromatography operations on
silica gel, using firstly dichloromethane: methanol:0.88 aqueous
ammonia (90:10:1) and then a gradient of ethyl acetate: methanol
(100:0 to 80:20) as eluants, to yield the title compound as an oil.
.delta.(CDCl.sub.3): 0.92 (3H,t), 1.02 (3H,t), 1.73 (2H,m), 2.40
(2H,q), 2.54 (4H,m), 2.99 (2H,t), 3.10 (4H,m), 3.84 (2H,t), 4.58
(2H,s), 4.78 (2H,t), 5.68 (2H,s), 7.09 (1H,d), 7.18-7.42 (6H,m),
7.62 (1H,m), 8.55 (1H,d), 8.61 (1H,s), 8.97 (1H,s), 10.81 (1H,s).
LRMS: m/z 673 (M+1).sup.+.
EXAMPLE 35
2-Benzyl-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-eth-
yl-2 6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0145] Obtained as a white foam (27%) from the title compound of
Preparation 87, using the procedure of Example 10.
.delta.(CDCl.sub.3): 0.90 (3H,t): 1.03 (3H,t), 1.28 (3H,t), 2.40
(2H,q), 2.54 (4H,m), 2.94 (2H,q), 3.12 (4H,m), 4.75 (2H,q), 5.58
(2H,s), 7.22 (2H,m), 7.31 (3H,m), 862 (1H,s), 9.01 (1H.s), 10.65
(1H,s). LRMS: m/z 552 (M+1).sup.+.
EXAMPLE 36
2-Benzyl-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)
pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4.3-d]pyrimidin-7-one
[0146] Obtained as a cream foam (80%) from the title compound of
Example 35 and 2-methoxyethanol, using the procedure of Example 9.
Found: C, 57.05; H, 6.19; N, 16.15.
C.sub.28H.sub.35N.sub.7O.sub.5S; 0.10 CH.sub.2Cl.sub.2 requires C,
57.19; H, 6.01; N, 16.61%. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.27
(3H,t), 2.40 (2H,q), 2.55 (4H,m), 2.94 (2H,q), 3.13 (4H,m), 3.57
(3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.56 (2H,s), 7.22 (2H,m), 7.32
(3H,m), 8.61 (1H,s), 8.96 (1H,s), 10.80 (1H,s).
EXAMPLE 37
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-(1-methylimidazol-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d[pyrimid-
in-7-one
[0147] Obtained as a foam (33%) from the title compound of
Preparation 90, using the procedure of Example 10.
.delta.(CDCl.sub.3): 1.05 (3H,t). 1.34 (3H,t), 2.41 (2H,q), 2.54
(4H,m), 3.13 (4H,m), 3.19 (2H,q), 3.57 (3H,s), 3.79 (3H,s), 3.86
(2H,t), 4.78 (2H,t), 5.65 (2H,s), 6.84 (1H,s), 7.00 (1H,s), 8.62
(1H,s), 8.94 (1H,s), 10.83 (1H,s). LRMS: m/z 586 (M+1).sup.+.
EXAMPLE 38
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(1-methylimi-
dazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0148] A mixture of the title compounds of Preparation 28 (232 mg,
0.58 mmol) and Preparation 92 (152 mg, 0.58 mmol), triethylamine
(403 .mu.l, 2.9 mmol) and dichloromethane (8 ml) was stirred at
room temperature for 18 hours. Brine (20 ml) was added and the
resulting mixture extracted with dichloromethane (2.times.20 ml),
then the combined extracts were dried (MgSO.sub.4) and evaporated
under reduced pressure.
[0149] A stirred solution of this intermediate and potassium
bis(trimethylsilyl)amide (305 mg, 1.53 mmol) in ethanol (10 ml) was
heated at 100.degree. C. for 14 hours, then allowed to cool. The
resulting mixture was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using
dichloromethane: methanol (95:5) as eluant, to provide the title
compound (163 mg, 49%) as a yellow oil. .delta.(CDCl.sub.3): 0.96
(3H,t), 1.01 (3H,t), 1.57 (3H,t), 1.72 (2H,m), 2.40 (2H.q), 2.55
(4H,m), 3.13 (6H,m), 3.77 (3H,s), 4.75 (2H,q), 5.67 (2H,s), 6.85
(1H,s), 7.00 (1H,s), 8.63 (1H,s), 9.00 (1H,s), 10.65 (1H,s). LRMS:
m/z 570 (M+1).sup.+.
EXAMPLE 39
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(-
1-methylimidazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyri-
midin-7-one
[0150] Obtained as a solid (61%) from the title compound of Example
38 and 2-methoxyethanol, using the procedure of Example 9.
.delta.(CDCl.sub.3): 0.97 (3H,t), 1.02 (3H,t), 1.74 (2H,m), 2.41
(2H,q), 2.55 (4H,m), 3.14 (6H,m), 3.57 (3H,s), 3.76 (3H,s), 3.86
(2H,t), 4.78 (2H,t). 5.66 (2H,s), 6.86 (1H,s), 7.00 (1H,s), 8.62
(1H,s), 8.94 (1H,s), 10.82 (1H,s). LRMS: m/z 600 (M+1).sup.+.
EXAMPLE 40
5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(1-methyli-
midazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
[0151] Obtained as a cream coloured foam (76%) from the title
compound of Example 38 and n-butanol, using the procedure of
Example 9. Found: C, 54.83; H. 6.74; N, 20.08.
C.sub.28H.sub.39N.sub.9O.sub.4S; H.sub.2O requires C, 54.62; H,
6.71; N, 20.47%. .delta.(CDCl.sub.3): 0.93 (3H,t), 1.00 (6H,m),
1.54 (2H,m), 1.77 (2H,m), 1.92 (2H,m), 2.40 (2H,q), 2.53 (4H,m),
3.12 (6H,m), 3.76 (3H,s), 4.66 (2H,t,), 5.67 (2H,s), 6.85 (1H,s),
6.98 (1H,s), 8.62 (1H,s), 8.97 (1H,s), 10.64 (1H,s). LRMS: m/z 599
(M+2).sup.+.
EXAMPLE 41
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-3-n-prop-
yl-2-(pyridazin-3-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0152] A mixture of the title compound of Preparation 98 (230 mg,
0.38 mmol). potassium t-butoxide (258 mg, 2.3 mmol) and propan-2-ol
(10 ml) was heated in a sealed vessel at 100.degree. C. for 24
hours, then allowed to cool. The resulting mixture was evaporated
under reduced pressure, then the residue purified by two column
chromatography operations on silica gel, using firstly an elution
gradient of dichloromethane: methanol (100:0 to 95:5) and then an
elution gradient of ethyl acetate: methanol (90:10 to 80:20), to
furnish the title compound (42 mg, 19%) as an orange gum.
.delta.(CDCl.sub.3): 0.93 (3H,t), 1.01 (3H,t). 1.55 (6H,d), 1.75
(2H,m), 2.40 (2H,q), 2.54 (4H,m), 3.02 (2H,t), 3.12 (4H,m). 5.67
(1H,m), 5.88 (2H,s), 7.47 (2H,m), 8.60 (1H,s), 8.98 (1H,s), 9.16
(1H,d). 10.70 (1H,s). LRMS: m/z 582 (M+1).sup.+.
EXAMPLE 42
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]3-n--
propyl-2-(pyrimidin-2-yl)methyl-2
,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7- -one
[0153] Obtained as a yellow foam (14%) from the title compound of
Preparation 102b, using the procedure of Example 10.
.delta.(CDCl.sub.3): 0.99 (3H,t), 1.03 (3H,t), 1.81 (2H,m), 2.42
(2H,q), 2.55 (4H,m), 2.97 (2H,t), 3.14 (4H,m), 3.54 (3H,s), 3.86
(2H,t), 4.78 (2H,t), 5.80 (2H,s), 7.22 (1H,m), 8.62 (1H,s), 8.70
(2H,d), 8.99 (1H,s), 10.72 (1H,s). LRMS: m/z 597 (M).sup.+.
EXAMPLE 43a
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]3-n-propyl-1-(p-
yrimidin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
and
EXAMPLE 43b
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]3-n-propyl-2-(p-
yrimidin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0154] A stirred mixture of the title compounds of Preparation 103a
and Preparation 103b (390 mg, 0.66 mmol), potassium t-butoxide (224
mg, 2.0 mmol), 4.ANG. molecular sieves and ethanol (10 ml) was
heated in a sealed vessel for 18 hours at 100.degree. C., then
allowed to cool and filtered. The filtrate was evaporated under
reduced pressure and the residual brown oil suspended in
dichloromethane (25 ml). This mixture was washed with water (5 ml),
dried (MgSO.sub.4) and evaporated under reduced pressure, then the
residue purified by column chromatography on silica gel, using an
elution gradient of dichloromethane: methanol (99:1 to 95:5) to
give an orange foam. This product was further purified by HPLC
using a C.sub.18 Magellan column and methanol: water:diethylamine
(50:50:0.1) as eluant, at a rate of 20 ml/min, to afford the first
title compound (1-isomer: 20 mg) as a white solid.
.delta.(CDCl.sub.3): 1.04 (6H,m), 1.58 (3H,t), 1.88 (2H,m), 2.42
(2H,q), 2.57 (4H,m), 2.98 (2H,t), 3.14 (4H,m), 4.75 (2H,q), 6.07
(2H,s), 7.18 (1H,m), 8.64 (3H,m), 9.10 (1H,s), 10.75 (1H,s). LRMS:
m/z 568 (M+1).sup.+. followed by the second title compound
(2-isomer; 20 mg) as a white solid. .delta.(CDCl.sub.3): 1.02
(6H,m), 1.58 (3H,t), 1.82 (2H,m), 2.42 (2H,q), 2.55 (4H,m), 2.98
(2H,t). 3.15 (4H,m). 4.74 (2H,q), 5.80 (2H,s), 7.23 (1H,m), 8.63
(1H,s), 8.70 (2H,m), 9.03 (1H,s). 10.56 (1H,s). LRMS: m/z 568
(M+1).sup.+.
EXAMPLE 44
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-1-(-
pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0155] A stirred mixture of the title compound of Preparation 105
(304 mg, 0.52 mmol), potassium t-butoxide (175 mg, 1.56 mmol) and
ethanol (10 ml) was heated in a sealed vessel at 100.degree. C. for
18 hours, then allowed to cool. The resulting mixture was
evaporated under reduced pressure and the residual brown oil
partitioned between dichloromethane (15 ml) and water (5 ml). The
phases were separated, then the organic phase dried (MgSO.sub.4)
and evaporated under reduced pressure to give a brown foam, which
was purified by column chromatography on silica gel, using
dichloromethane: methanol (97:3) as eluant, to provide the title
compound (230 mg, 78%) as a white foam. Found: C, 56.93: H, 6.03;
N, 19.42. C.sub.27H.sub.34N.sub.8O.sub.4S requires C, 57.22; H,
6.04; N, 19.77%. .delta.(CDCl.sub.3) 1.01 (3H,t). 1.59 (6H,m), 1.86
(2H,m), 2.42 (2H,q), 2.57 (4H,m), 2.97 (2H,t), 3.16 (4H,m), 4.74
(2H,q), 5.94 (2H,s), 7.02 (1H,d), 7.18 (1H,m), 7.60 (1H,m), 8.57
(1H,d), 8.63 (1H,s), 9.10 (1H,s), 10.85 (1H,s). LRMS: m/z 567
(M+1).sup.+.
EXAMPLE 45
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(1-m-
ethylimidazol-2-yl)methyl-1
,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0156] Obtained as a pale yellow solid (60%) from the title
compound of Preparation 107, using the procedure of Example 44.
.delta.(CDCl.sub.3): 1.02 (3H,t), 1.38 (3H,t), 1.59 (3H,t), 2.41
(2H,q), 2.56 (4H,m), 2.97 (2H,q), 3.15 (4H,m), 3.78 (3H,s), 4.75
(2H,q), 5.89 (2H,s), 6.85 (1H,s), 7.00 (1H,s), 8.64 (1H,s), 9.07
(1H,s), 10.87 (1H,s). LRMS: m/z 556 (M+1).sup.+.
EXAMPLE 46
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-1-(1-methylimidazol-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimid-
in-7-one
[0157] A stirred mixture of the title compound of Example 45 (150
mg, 0.27 mmol), potassium t-butoxide (126 mg, 1.1 mmol) and
2-methoxyethanol (6 ml) was heated under reflux for 48 hours, then
allowed to cool. The resulting mixture was evaporated under reduced
pressure and the residue purified by column chromatography on
silica gel, using dichloromethane:methanol:0.88 aqueous ammonia
(90:10:1) as eluant. The product was triturated with diisopropyl
ether, the mixture filtered and the filtrate evaporated under
reduced pressure to yield the title compound (43 mg, 27%) as a
foam. .delta.(CDCl.sub.3): 1.10 (3H,t), 1.36 (3H,t), 2.52 (2H,q),
2.65 (4H,m), 2.96 (2H,q), 3.22 (4H,m), 3.56 (3H,s), 3.75 (3H,s),
3.86 (2H,t), 4.78 (2H,t), 5.92 (2H,s), 6.85 (1H,s), 7.01 (1H,s),
8.63 (1H,s), 8.99 (1H,s), 11.10 (1H,s). LRMS: m/z 585
(M).sup.+.
EXAMPLE 47
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-(-
1-methylimidazol-2-yl)methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4.3-d]pyri-
midin-7-one
[0158] Obtained as a solid (11%) from the title compound of
Preparation 109, using the procedure of Example 10. Found: C,
52.43; H, 6.11; N. 20.12. C.sub.27H.sub.37N.sub.9O.sub.5S; H.sub.2O
requires C, 52.50; H, 6.36; N, 20.41%. .delta.(CDCl.sub.3): 0.98
(3H,t), 1.03 (3H,t), 1.81 (2H,m), 2.41 (2H,q), 2.55 (4H,m), 2.90
(2H,t), 3.15 (4H,m), 3.58 (3H,s), 3.75 (3H,s), 3.86 (2H,t), 4.78
(2H,t), 5.92 (2H,s), 6.85 (1H,s), 7.00 (1H,s), 8.63 (1H,s), 9.00
(1H,s), 11.07 (1H,s). LRMS: m/z 600 (M+1).sup.+.
EXAMPLE 48
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-
-propyl-1-(pyrimidin-2-yl)
methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-- 7-one
[0159] Obtained as a yellow foam (5%) from the title compound of
Preparation 102a, using the procedure of Example 10.
.delta.(CDCl.sub.3): 1.02 (6H,m), 1.86 (2H,m), 2.42 (2H,q), 2.56
(4H,m), 2.97 (2H,t), 3.17 (4H,m), 3.54 (3H,s), 3.83 (2H,t), 4.77
(2H,t), 6.09 (2H,s), 7.16 (1H,m), 8.65 (3H,m), 9.03 (1H,s), 11.00
(1H,s). LRMS: m/z 598 (M+1).sup.+.
EXAMPLE 49
5-{2-Ethoxy-5-[4-(pyrrolidin-1-ylcarbonymethyl)piperazin-1-ylsulphonyl]pyr-
idin-3-yl}-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d-
]pyrimidin-7-one
[0160] A mixture of the title compound of Preparation 63 (350 mg,
0.715 mmol), 1-(pyrrolidin-1-ylcarbonylmethyl)piperazine (150 mg,
0.715 mmol) and ethanol (40 ml) was stirred at room temperature for
18 hours, then evaporated under reduced pressure. The residue was
suspended in aqueous sodium bicarbonate solution (30 ml) and the
suspension extracted with ethyl acetate (3.times.30 ml). The
combined extracts were washed with brine (3.times.20 ml), dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
resulting residue was purified by column chromatography on silica
gel, using an elution gradient of dichloromethane: methanol (100:0
to 96:4) to give an oil, which was triturated with ether to fumish
the title compound (240 mg, 52%) as a colourless foam. Found: C,
56.79; H, 6.30; N, 18.49. C.sub.31H.sub.39N.sub.9O.sub.5S: 0.50
H.sub.2O; 0.25 C.sub.4H.sub.10O requires C, 56.75; H, 6.32; N,
18.61%. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.60 (3H,t), 1.66-1.86
(4H,m), 1.92 (2H,m), 2.68 (4H,m), 2.98 (2H,t), 3.14 (2H,s), 3.18
(4H,m), 3.32-3.46 (4H,m), 4.75 (2H,q), 5.70 (2H,s), 7.18 (1H,d),
7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.00 (1H,s),
10.66 (1H,s). LRMS: m/z 650 (M+1).sup.+.
EXAMPLE 50
5-[2-Ethoxy-5-(4-allyl-2(S),5(R)-dimethylpiperazin-1-ylsulphonyl)pyridin-3-
-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrim-
idin-7-one
[0161] A solution of (-)-1-allyl-2(R),5(S)-dimethylpiperazine (WO
93/15062; 502 mg, 3.2 mmol) in ethanol (4 ml) was added dropwise to
a stirred suspension of the title compound of Preparation 63 (800
mg, 1.6 mmol) in ethanol and the reaction mixture stirred at room
temperature for 18 hours, then evaporated under reduced pressure.
The residue was partitioned between aqueous sodium carbonate
solution (20 ml) and ethyl acetate (20 ml), the phases separated
and the aqueous phase extracted with ethyl acetate (2.times.20 ml).
The combined organic solutions were washed with brine (20 ml),
dried (Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residual orange oil was purified by column chromatography on silica
gel, using an elution gradient of dichloromethane: methanol (100:0
to 98:2), followed by trituration with ether, to afford the title
compound (550 mg, 57%) as a colourless foam. Found: C, 59.07; H,
6.37; N, 18.18. C.sub.30H.sub.38N.sub.8O.sub.4S requires C, 59.39;
H, 6.31; N, 18.47%. .delta.(CDCl.sub.3): 0.95 (3H,t), 0.99 (3H,d),
1.24 (3H,d), 1.58 (3H,t), 1.72 (2H,m), 2.27 (1H,dd), 2.73 (1H,dd),
2.92 (1H,m), 3.00 (4H,m), 3.20 (1H,dd), 3.48 (1H,dd), 3.85 (1H,m),
4.75 (2H,q), 5.22 (2H,m), 5.68 (2H,s), 5.74 (1H,m), 7.09 (1H,d),
7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.67 (1H,s), 9.08 (1H,s),
10.69 (1H,s). LRMS: m/z 607 (M-1).sup.+.
Example 50a
3-Ethyl-5-[5-(4-ethylpiperazine-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyleth-
oxy)
pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-2,6-dihydro-7H-pyrazolo-
[4,3-d]pyrimidin-7-one
[0162] Obtained as a white foam (82%), frormrthe title compounds of
Preparations 165 and 170, following a similar procedure to that
described in Example 11. Found: C, 52.14; H, 6.15; N, 19.73.
C.sub.27H.sub.37N.sub.9O.sub.5S;1.5H.sub.2O requires C, 51.74; H,
6.43; N, 20.11%. .delta.(CDCl.sub.3) : 1.02 (3H, t), 1.32 (3H, t),
1.50 (3H, d), 2.40 (2H, q), 2.56 (4H, m), 3.04-3.22 (6H, m), 3.54
(3H, s), 3.62-3.80 (5H, m), 5.59 (1H, m), 5.66 (2H, s), 6.83 (1H,
s), 6.99 (1H, s), 8.60 (1H, s), 8.84 (1H, s), 10.87 (1H, s). LRMS:
m/z 600 (M+1).sup.+
EXAMPLE 51 to 60
[0163] 11
[0164] A group of analogues based on the structural formula
identified above, in which the R.sup.10 substituent is varied, was
obtained by the technique of high-speed analogue synthesis (HSAS)
as described hereinafter.
[0165] A 0.4 M solution of triethylamine in dichioromethane (100
.mu.l, 40 .mu.mol) was added to each well of a 96-well plate
containing the required range of 1-substituted piperazines (10
.mu.mol). A 0.1M solution of the title compound of Preparation 63
in dichloromethane (100 .mu.l, 10 .mu.mol) was added to each well,
then the plate covered and shaken at room temperature for 18 hours.
The reaction mixtures were filtered through a 96-well filtration
block, which was washed with dichloromethane (1 ml), then the
filtrates evaporated under reduced pressure. The residues were
dissolved in dimethylsulphoxide (1 ml) and purified by HPLC using a
5.mu. Hypersil C18 column (10.times.0.46 cm) with a flow rate of 4
ml/min and an elution gradient of 0.1% trifluoroacetic acid in
water: acetonitrile.
1 LRMS Retention time Example R.sup.10 (m/z) (min) 51 12 581 (M +
1).sup.+ 5.25 52 13 581 (M + 1).sup.+ 5.10 53 14 629 (M + 1).sup.+
5.70 54 15 659 (M + 1).sup.+ 6.02 55 16 672 (M).sup.+ 5.36 56 17
706 (M + 2).sup.+ 8.24 57 18 687 (M + 1).sup.+ 6.64 58 19 617 (M +
2).sup.+ 5.45 59 20 616 (M + 1).sup.+ 5.57 60 21 617 (M + 1).sup.+
7.38 *= point of attachment of R.sup.10
EXAMPLE 61
3-Ethyl-5-[2-(2-methoxyethoxy)-5-(3,4,5-trimethylpiperazin-1-ylsulphonyl)p-
yridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidi-
n-7-one
[0166] Obtained as a white solid (170 mg, 47%) from the title
compound of Preparation 64 and 1,2,6-trimethylpiperazine
(J.Med.Chem., 1968, 11, 592), using the procedure of Example 50.
Found: C, 55.78; H, 6.02; N, 18.42.
C.sub.28H.sub.36N.sub.8O.sub.5S; 0.50 H.sub.2O requires C, 55.22;
H, 6.16; N, 18.58%. .delta.(CDCl.sub.3): 1.09 (6H,d), 1.31 (3H,t),
2.01 (5H,m), 2.36 (2H,m), 3.04 (2H,q), 3.60 (5H,m), 3.88 (2H,t),
4.79 (2H,t), 5.68 (2H,s), 7.12 (1H,d), 7.22 (1H,m), 7.64 (1H,m),
8.58 (1H,d), 8.62 (1H,s), 8.95 (1H,s), 10.79 (1H,s). LRMS: m/z 597
(M+1).sup.+.
EXAMPLE 62
3-Ethyl-5-[2-(2-methoxyethoxy)-5-piperazin-1-ylsulphonyl)pyridin-3-yl]-2-(-
pyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0167] A solution of the title compound of Preparation 64 (200 mg,
0.40 mmol) in dichloromethane (10 ml) was added dropwise to a
stirred solution of piperazine (136 mg, 1.58 mmol) and
triethylamine (110 .mu.l, 0.79 mmol) in dichloromethane (10 ml) and
the reaction mixture stirred at room temperature for 1 hour, then
washed with water (10 ml), dried (MgSO.sub.4) and evaporated under
reduced pressure. The residual yellow solid was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (98:2 to 92:8), followed by trituration
with dichloromethane, to give the title compound (189 mg, 86%) as a
white foam. Found: C, 52.75; H, 5.43; N, 19.18.
C.sub.25H.sub.30N.sub.8O.sub.5S; 0.75 H.sub.2O requires C, 52.85;
H. 5.59; N, 19.72%. .delta.(CDCl.sub.3): 1.30 (3H,t), 2.94-3.13
(10H,m), 3.58 (3H,s), 3.88 (2H,t), 4.79 (2H,t), 5.68 (2H,s), 7.10
(1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.98
(1H,s), 10.82 (1H,s). LRMS: m/z 555 (M+1).sup.+.
EXAMPLE 63
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl]-2-methoxypyridin-3-yl]-2-(py-
ridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0168] A stirred mixture of the title compound of Example 1 (350
mg, 0.63 mmol), potassium bis(trimethylsilyl)amide (630 mg, 3.15
mmol) and n-propanethiol (5 ml) was heated in a sealed vessel at
110.degree. C. for 48 hours, then allowed to cool and evaporated
under reduced pressure. The residue was azeotroped with
dichloromethane: methanol (95:5), then partitioned between water
(10 ml) and dichloromethane (15 ml). The phases were separated, the
aqueous phase extracted with dichloromethane (2.times.15 ml) and
the combined organic solutions dried (MgSO.sub.4) and evaporated
under reduced pressure. This residue was purified by column
chromatography on silica gel, using dichloromethane: methanol
(97:3) as eluant, to yield the title compound (170 mg, 50%) as a
yellow solid. Found: C, 54.50; H, 5.64; N, 19.93.
C.sub.25H.sub.30N.sub.8O.sub.4S; 0.75 H.sub.2O requires C, 54.38;
H, 5.75; N, 20.29%. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.32 (3H,t,)
2.40 (2H,q), 2.55 (4H,m), 3.06 (2H,q), 3.14 (4H,m), 4.26 (3H,s),
5.68 (2H,s), 7.14 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d),
8.66 (1H,s), 9.05 (1H,s), 10.59 (1H,s). LRMS: m/z 540
(M+2).sup.+.
EXAMPLE 64
5-[2-Benzyloxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(-
pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0169] Potassium bis(trimethylsilyl)amide (360 mg, 1.81 mmol) was
added to a stirred solution of the title compound of Example 1 (200
mg, 0.36 mmol) in benzyl alcohol (5 ml) at 100.degree. C. and the
reaction mixture stirred for 14 hours, then allowed to cool. The
resulting mixture was partitioned between dichloromethane (10 ml)
and brine (10 ml), the phases separated, the aqueous phase
extracted with dichloromethane (2.times.10 ml) and the combined
organic solutions dried (Na.sub.2SO.sub.4) and evaporated under
reduced pressure. The residual benzyl alcohol was removed by
Kugelrohr distillation, then the crude product purified by column
chromatography on silica gel, using dichloromethane: methanol
(97.5:2.5) as eluant, to provide the title compound (86 mg, 39%) as
a white solid. Found: C, 59.92; H, 5.64; N, 17.60.
C.sub.31H.sub.34N.sub.8O- .sub.4S; 0.40 H.sub.2O requires C, 59.87;
H, 5.64; N, 18.02%. .delta.(CDCl.sub.3): 1.05 (3H,t), 1.29 (3H,t),
2.41 (2H,q), 2.56 (4H,m), 3.05 (2H,q), 3.15 (4H,m), 5.68 (2H,s)
5.75 (2H,s), 7.10 (1H,d), 7.24 (1H,m), 7.42 (3H,m), 7.52 (2H,m),
7.64 (1H,m), 8.58 (1H,d), 8.65 (1H,s), 9.02 (1H,s), 10.58 (1H,s).
LRMS: m/z 615 (M+1).sup.+.
EXAMPLE 65
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(furan-3-ylmethoxy)pyridin-3-yl]-3-
-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
-one
[0170] Potassium bis(trimethylsilyl)amide (176 mg, 0.88 mmol) was
added to a stirred suspension of the title compound of Example 26
(100 mg, 0.17 mmol) in 3-hydroxymethylfuran (4 ml) and the reaction
mixture heated under reflux for 24 hours then allowed to cool. The
resulting mixture was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using
dichloromethane: methanol (95:5) as eluant, to furnish the title
compound (33 mg, 31%) as a pale yellow foam. .delta.(CDCl.sub.3)
0.93 (3H,t), 1.04 (3H,t), 1.72 (2H,m), 2.41 (2H,q), 2.55 (4H,m),
2.99 (2H,t), 3.14 (4H,m), 5.63 (2H,s), 5.68 (2H,s), 6.60 (1H,s),
7.09 (1H,d), 7.22 (1H,m), 7.44 (1H,s), 7.64 (2H,m), 8.57 (1H,d),
8.68 (1H,s), 9.02 (1H,s), 10.53 (1H,s). LRMS: m/z 619
(M+1).sup.+.
EXAMPLE 66
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(pyridin-2-ylmethoxy)pyridin-3-yl]-
-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-
-7-one
[0171] A stirred mixture of potassium bis(trimethylsilyl)amide (260
mg, 1.32 mmol) and 2-hydroxymethylpyridine (5 ml) was heated at
100.degree. C. for 1 hour, then the title compound of Example 26
(150 mg, 0.26 mmol) added and the reaction mixture stirred at
100.degree. C. for 14 hours. The resulting cool mixture was
partitioned between dichloromethane (10 ml) and brine (10 ml), the
phases separated and the aqueous phase extracted with
dichloromethane (2.times.10 ml). The combined organic solutions
were dried (MgSO.sub.4) and evaporated under reduced pressure, then
the residual yellow oil purified by column chromatography on silica
gel, using dichloromethane: ethyl acetate: methanol (47.5:47.5:5)
as eluant, to afford the title compound (35 mg, 21%) as a white
solid. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.03 (3H,t), 1.73 (2H,m),
2.40 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.14 (4H,m), 5.69 (2H,s),
5.92 (2H,s), 7.07 (1H,d), 7.21 (1H,m), 7.33 (2H,m), 7.62 (1H,m),
7.76 (1H,m), 8.58 (2H,m), 8.81 (1H,s), 8.85 (1H,d), 12.80 (1H,s).
LRMS: m/z 630 (M+1).sup.+.
EXAMPLE 67
5-[2-(2-Dimethylaminoethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-y-
l]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimid-
in-7-one
[0172] A mixture of the title compound of Example 26 (200 mg, 0.35
mmol), potassium bis(trimethylsilyl)amide (352 mg, 1.76 mmol) and
2-dimethylaminoethanol (1.5 ml) was stirred at 90.degree. C. for 18
hours, then allowed to cool. Water (5 ml) was added, the mixture
extracted with ethyl acetate (3.times.5 ml) and the combined
extracts dried (MgSO.sub.4) and evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel,
using an elution gradient of dichloromethane: methanol (95:5 to
90:10), to give the title compound (147 mg, 68%) as an off-white
foam. Found: C, 56.35; H, 6.37; N, 20.12.
C.sub.29H.sub.39N.sub.9O.sub.4S; 0.50 H.sub.2O requires C, 56.29;
H, 6.52; N, 20.37%. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.04 (3H,t),
1.72 (2H,m), 2.43 (8H,m), 2.56 (4H,m), 2.74 (2H,t), 2.95 (2H,t),
3.15 (4H,m), 4.80 (2H,t), 5.67 (2H,s), 7.07 (1H,d), 7.21 (1H,m),
7.61 (1H.m), 8.56 (1H,d), 8.62 (1H,s), 8.75 (1H,s), 12.23 (1H,s).
LRMS: m/z 610 (M+1).sup.+.
EXAMPLE 68
5-{5-(4-Ethylpiperazin-1-ylsulphonyl)-2-[2-(morpholin-4-yl)ethoxy]pyridin--
3-yl}-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyri-
midin-7-one
[0173] A mixture of potassium bis(trimethylsilyl)amide (180 mg,
0.88 mmol) and 4-(2-hydroxyethyl)morpholine (4 ml) was stirred at
100.degree. C. for 1 hour. then the title compound of Example 26
(100 mg, 0.17 mmol) added and the reaction mixture stirred at
110.degree. C. for 18 hours. The resulting, cool mixture was
partitioned between water (10 ml) and dichloromethane (20 ml), the
phases separated and the organic phase washed with water (10 ml),
dried (MgSO.sub.4) and evaporated under reduced pressure. The
residual yellow oil was purified by column chromatography on silica
gel, using an elution gradient of ethyl acetate: methanol (90:10 to
80:20), to yield the title compound (33 mg, 30%) as a white solid.
.delta.(CDCl.sub.3): 0.95 (3H,t), 1.04 (3H,t), 1.74 (2H,m), 2.42
(2H,q), 2.56 (4H,m), 2.64 (4H,m), 2.90 (2H,t), 2.99 (2H,t), 3.15
(4H,m), 3.80 (4H,m), 4.75 (2H,t), 5.68 (2H,s), 7.12 (1H,d), 7.25
(1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.92 (1H,s), 11.16
(1H,s). LRMS: m/z 652 (M+1).sup.+.
EXAMPLE 69
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridin-
-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyr-
imidin-7-one
[0174] Caesium t-butoxide (76 mg, 0.37 mmol) was added to a stirred
solution of the title compound of Preparation 119 (160 mg, 0.24
mmol) in 3-methylpentan-3-ol (5 ml) and the reaction mixture
stirred at 120.degree. C. for 3 hours, then allowed to cool. The
resulting mixture was evaporated under reduced pressure and the
residue partitioned between dichloromethane (10 ml) and water (10
ml). The phases were separated, the aqueous phase extracted with
dichloromethane (2.times.10 ml) and the combined organic solutions
dried (MgSO.sub.4) and evaporated under reduced pressure. The
residual yellow oil was purified by column chromatography on silica
gel, using an elution gradient of dichloromethane: methanol (95:5
to 92.5:7.5), to provide the title compound as a yellow foam.
.delta.(CDCl.sub.3): 0.94 (3H,t), 1.03 (3H,t), 1.74 (2H,m), 2.10
(2H,m), 2.22 (2H,m), 2.42 (5H,m), 2.58 (6H,m), 2.78 (2H,m), 2.99
(2H,t), 3.13 (4H,m), 5.59 (1H,m), 5.67 (2H,s), 7.10 (1H,d), 7.22
(1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 9.00 (1H,s), 10.63
(1H,s). LRMS: m/z 636 (M+1).sup.+.
EXAMPLE 70
5-[2-Ethoxy-5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethy-
l-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo
[4,3-d]pyrimidin-7-one
[0175] A mixture of the title compound of Example 1 (180 mg, 0.32
mmol), 3-chlorobenzoic acid (13 mg, 0.08 mmol) and dichloromethane
(10 ml) was stirred at room temperature for 20 minutes,
3-chloroperoxybenzoic acid (112 mg, 0.32 mmol) added and the
reaction mixture stirred for a further 18 hours, then partitioned
between dichloromethane (20 ml) and aqueous sodium bicarbonate
solution (10 ml). The phases were separated, the aqueous phase
extracted with dichloromethane (2.times.20 ml) and the combined
organic solutions dried (MgSO.sub.4) and evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel, using dichloromethane: methanol (80:20) as eluant, to
furnish the title compound (82 mg, 45%) as a white powder. Found:
C, 52.73; H, 5.67; N, 17.69. C.sub.26H.sub.32N.sub.8O.sub.5S; 0.50
CH.sub.2Cl.sub.2 requires C, 52.08; H, 5.44; N, 18.34%.
.delta.(CDCl.sub.3): 1.30 (3H,t), 1.40 (3H,t), 1.58 (3H,t), 3.02
(2H,q), 3.20 (2H,m), 3.32 (4H,m), 3.48 (2H,m), 3.72 (2H,m), 4.76
(2H,q), 5.68 (2H,s), 7.08 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.58
(1H,d), 8.65 (1H,s), 9.03 (1H,s), 10.70 (1H,s).
EXAMPLE 71
5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-3-n-
-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
[0176] 3-Chloroperoxybenzoic acid (93 mg, 0.27 mmol) was added to a
stirred solution of the title compound of Example 28 (155 mg, 0.27
mmol) in dichloromethane (2 ml) and the reaction mixture stirred at
room temperature for 2 hours, then evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel, using dichloromethane:methanol:0.88 aqueous ammonia
(90:10:1) as eluant, to afford the title compound (40 mg, 25%) as a
solid. .delta.(CDCl.sub.3): 0.93 (3H,t), 1.14 (3H,t), 1.41 (3H,t),
1.72 (2H,m), 2.00 (2H,m), 2.97 (2H,t), 3.15 (2H,m), 3.31 (4H,m),
3.50 (2H,m), 3.70 (2H,m), 4.65 (2H,t), 5.68 (2H,s), 7.06 (1H,d),
7.24 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.66 (1H,s), 9.06 (1H,s),
10.67 (1H,s). LRMS: m/z 598 (M+1).sup.+.
EXAMPLE 72
3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)p-
yridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo
[4,3-d]pyrimidin-7-one
and
EXAMPLE 73
3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)p-
yridin-3-yl]-2-(1-oxidopyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]p-
yrimidin-7-one
[0177] 3-Chlorobenzoic acid (15 mg, 0.096 mmol) was added to a
stirred solution of the title compound of Example 4 (223 mg, 0.38
mmol) in dichloromethane (3 ml) and the mixture stirred at room
temperature for 30 minutes. 3-Chloroperoxybenzoic acid (132 mg,
0.38 mmol) was then added and the reaction mixture stirred at room
temperature for 14 hours, then partitioned between dichloromethane
(5 ml) and aqueous sodium bicarbonate solution (5 ml). The phases
were separated, the aqueous phase extracted with dichloromethane
(3.times.10 ml) and the combined organic solutions dried
(MgSO.sub.4) and evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (90:10 to 80:20), to give the
first title compound (78 mg, 34%) as a solid. Found: C, 51.77; H,
5.82; N, 17.33. C.sub.27H.sub.34N.sub.8O.sub.6S; 1.75 H.sub.2O
requires C, 51.46; H, 6.00; N, 17.78%. .delta.(CDCl.sub.3): 1.28
(3H,t), 1.42 (3H,t), 3.02 (2H,q), 3.18 (2H,m), 3.30 (4H,m), 3.50
(2H,m), 3.56 (3H,s), 3.72 (2H,m), 3.88 (2H,t), 4.80 (2H,t), 5.68
(2H,s), 7.08 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.68
(1H,s), 8.99 (1H,s), 10.84 (1H,s); followed by the second title
compound (50 mg, 22%) as a solid. Found: C, 50.15; H, 5.81; N,
16.85. C.sub.27H.sub.34N.sub.8O.sub.6S; 2.0 H.sub.2O requires C,
49.84; H, 5.89; N, 17.22%. .delta.(CDCl.sub.3): 1.32 (3H,t), 1.42
(3H,t), 3.05 (2H,q), 3.18 (2H,m), 3.32 (4H,m), 3.53 (5H,m), 3.72
(2H,m), 3.86 (2H,t), 4.80 (2H,t), 5.81 (2H,s), 6.78 (1H,d), 7.22
(2H,m), 8.29 (1H,d), 8.66 (1H,s), 8.99 (1H,s), 10.90 (1H,s).
EXAMPLE 74
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(2-morpholin-
-4-yl)ethyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0178] Potassium t-butoxide (110 mg, 0.99 mmol) was added to a
stirred solution of the title compound of Preparation 120 (400 mg,
0.66 mmol) in 3-methylpentan-3-ol (20 ml) and the reaction mixture
heated under reflux for 3 hours, then allowed to cool. The
resulting mixture was evaporated under reduced pressure, the
residue suspended in water (10 ml) and the suspension extracted
with dichloromethane (3.times.10 ml). The combined extracts were
dried (MgSO.sub.4) and evaporated under reduced pressure, then the
residual yellow oil purified by column chromatography on silica
gel, using dichloromethane: methanol (97.5:2.5) as eluant, to yield
the title compound (65 mg, 17%) as a white foam. Found: C, 54.51;
H, 6.95; N, 18.18. C.sub.27H.sub.40N.sub.8O.sub.5S; 0.15
CH.sub.2Cl.sub.2 requires C, 54.51; H, 6.92; N, 18.14%.
.delta.(CDCl.sub.3):1.04 (6H,m), 1.58 (3H,t), 1.88 (2H,m), 2.41
(2H,q), 2.54 (8H,m), 2.99 (4H,m), 3.15 (4H,m), 3.68 (4H,m), 4.40
(2H,t), 4.75 (2H,q), 8.62 (1H,s), 9.04 (1H,s), 10.61 (1H,s). LRMS:
m/z 589 (M+1).sup.+.
EXAMPLE 75
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(-
2-morpholin-4-yl)ethyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin--
7-one
[0179] Obtained as a white solid (24%) from the title compound of
Example 74 and 2-methoxyethanol, using the procedure of Example 66.
Found: C, 53.81; H, 6.93; N, 16.89.
C.sub.28H.sub.42N.sub.8O.sub.6S; 0.30 C.sub.4H.sub.8O.sub.2; 0.20
H.sub.2O requires C, 54.06; H, 6.96; N, 17.27%.
.delta.(CDCl.sub.3): 1.04 (6H,m), 1.87 (2H,m), 2.42 (2H,q), 2.55
(8H,m), 2.99 (4H,m), 3.16 (4H,m), 3.56 (3H,s), 3.69 (4H,m), 3.88
(2H,t), 4.40 (2H,t), 4.79 (2H,t), 8.63 (1H,s), 8.98 (1H,s), 10.78
(1H,s). LRMS: m/z 619 (M+1).sup.+.
EXAMPLE 76
3-t-Butyl-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-(p-
yridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0180] A stirred mixture of the title compound of Preparation 121
(150 mg, 0.25 mmol), potassium t-butoxide (71 mg, 0.625 mmol) and
ethanol (10 ml) was heated at 100.degree. C. for 18 hours in a
sealed vessel, then allowed to cool. The resulting mixture was
evaporated under reduced pressure and the residue partitioned
between water (10 ml) and ethyl acetate (15 ml). The phases were
separated, the aqueous phase extracted with ethyl acetate
2.times.15 ml) and the combined organic solutions dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel, using
dichloromethane: methanol (100:0 to 95:5) as eluant, to provide the
title compound (140 mg, 97%) as a white solid. Found: C, 56.30; H,
6.39; N, 18.43. C.sub.28H.sub.36N.sub.6O.sub.4S; H.sub.2O requires
C, 56.17; H, 6.40; N, 18.72%. .delta.(CDCl.sub.3): 1.04 (3H,t),
1.56 (12H,m), 2.42 (2H,q), 2.56 (4H,m), 3.16 (4H,m), 4.76 (2H,q),
5.95 (2H,s), 6.94 (1H,d), 7.18 (1H,m), 7.60 (1H,m), 8.58 (1H,d),
8.64 (1H,s), 9.08 (1H,s), 10.82 (1H,s). LRMS: m/z 581
(M+1).sup.+.
EXAMPLE 77
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-(2-morpholin-
-4-yl)ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0181] Obtained as a white solid (68%) from the title compound of
Preparation 122, using the procedure of Example 74. Found: C,
54.59; H, 6.91; N, 18.08. C.sub.27H.sub.40N.sub.8O.sub.5S; 0.15
CH.sub.2Cl.sub.2 requires C, 54.59; H, 6.89; N, 18.08%.
.delta.(CDCl.sub.3): 1.01 (6H,m), 1.60 (3H,t), 1.84 (2H,m), 2.42
(2H,q), 2.53 (8H,m), 2.86 (2H,t), 2.94 (2H,t), 3.15 (4H,m), 3.62
(4H,m), 4.72 (4H,m), 8.63 (1H,s), 9.09 (1H,s), 10.81 (1H,s). LRMS:
m/z 589 (M+1).sup.+.
EXAMPLE 78
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-meth-
yl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0182] 22
[0183] A mixture of the title compound of Preparation 152 (25.9 g,
52.5 mmol), and potassium bis(trimethylsilyl)amide (22.0 g, 110.0
mmol) in ethanol (1500 ml) was heated at 120.degree. C. for 18
hours in a sealed vessel. The cooled solution was concentrated
under reduced pressure, and pre-adsorbed onto silica gel. The crude
product was purified by column chromatography on silica gel, using
an elution gradient of ethyl acetate: diethylamine (97:3 to 95:5)
and triturated with ether to afford the title compound (11.0 g,
44%) as a white solid.
[0184] .delta.(CDCl.sub.3): 1.03 (3H, t), 1.40 (3H, t), 1.59 (3H,
t), 2.41 (2H, q), 2.57 (4H, m), 3.04 (2H, q), 3.14 (4H, m), 4.09
(3H, s), 4.75 (2H, q), 8.62 (1H, s), 9.04 (1H, s), 10.64 (1H,
s).
[0185] LRMS: m/z 476 (M+1).sup.+
EXAMPLE 79
5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n--
propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0186] 23
[0187] The title compound of Preparation 151 (500 mg, 1.0 mmol) was
added to a solution of potassium bis(trimethylsilyl)amide (610 mg,
3.06 mmol) in ethanol (20 ml), and the reaction heated at
110.degree. C. in a sealed vessel for 18 hours. The cooled mixture
was evaporated under reduced pressure and the residue dissolved in
water and neutralised using hydrochloric acid. This aqueous
suspension was extracted with dichloromethane (3.times.30 ml), the
combined organic extracts washed with brine (3.times.30 ml), dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residual oil was purified by column chromatography on silica gel
using an elution gradient of dichloromethane: methanol (100:0 to
97.5:2.5), and triturated with ether, to afford the title compound
(207 mg, 44%) as an off-white solid.
[0188] .delta.(CDCl.sub.3): 1.03 (3H, t), 1.59 (3H, t), 1.83 (2H,
m), 2.29 (3H, s), 2.53 (4H, m), 3.00 (2H, t), 3.16 (4H, m), 4.10
(3H, s), 4.75 (2H, q), 8.63 (1H, s), 9.06 (1H, s), 10.65 (1H,
s).
[0189] LRMS: m/z 476 (M+1).sup.+
EXAMPLES 80 TO 84
[0190] The compounds of the general formula: 24
[0191] were prepared from the appropriate pyrazole-5-carboxamides,
i.e. Preparations 153, 154, 156, 157 and 155 respectively,
following procedures similar to that described in Example 79. In
Examples 80 to 84, R.sup.1 is methyl and R.sup.13 is
--OR.sup.3.
2 Ex R1 R2 R3 R10 Data 80 CH.sub.3 (CH.sub.2).sub.2CH.sub.3
CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Found: C, 53.97; H, 6.38; N,
19.75. C.sub.22H.sub.31N.sub.7O.- sub.4S requires C, 53.97; H,
6.38; N, 20.03% .delta. (CDCl.sub.3): 1.03 (6H, t), 1.58 (3H, t),
1.82 (2H, m), 2.41 (2H, q), 2.56 2.99 (2H, t), 3.14 (4H, m), 4.09
(3H, s), 4.76 (2H, q), 8.63 (1H, s), 9.05 (1H, s), 10.64 (1H, s).
LRMS: m/z 490 (M + 1).sup.+ 81 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3
CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 .delta. (CDCl.sub.3): 1.02 (3H,
t), 1.40 (3H, t), 1.58 (6H, in), 2.41 (2H, q), 2.55 (4H, m),
3.00-3.18 (6H, m), 4.38 (2H, q), 4.75 (2H, q), 8.63 (1H, s), 9.04
(lH, s), 10.63 (1H, s). LRMS: m/z 490 (M + 1).sup.+ 82 1,2 25
CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 Found: C, 56.66;
H, 6.03; N, 19.57 C.sub.27H.sub.34N.sub.8O.sub.4S;0.25 H.sub.2O
requires C, 56.78; H, 6.09; N, 19.62%. .delta.(CDCl.sub.3): 1.02
(3H, t), # 1.30 (3H, t), 1.58 (3H, t), 2.41 (2H, q), 2.57 (7H, m),
3.04 (2H, q), 3.15 (4H, m), 4.77 (2H, q), 5.64 (2H, s), 6.80 (1H,
d), 7.08 (1H, d), 7.50 (1H, m), 8.62 (1H, s), 9.02 (1H, s), 10.66
(1H, s). LRMS: m/z 567 (M + 1).sup.+ 83 26 CH.sub.2CH.sub.3
CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 .delta. (CDCl.sub.3): 1.04 (3H,
t), 1.40 (3H, t), 1.58 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.01
(2H, q), 3.16 (4H, m), 3.80 (3H, s), 4.75 (2H, q), 5.82 (2H, s),
6.54 (1H, d), 6.60 (1H, d), 7.46 (1H, m), 8.64 (1H, s), 9.10 (1H,
s), 10.85 (1H, s). LRMS: m/z 583 (M + 1).sup.+ 84 1 27
CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 CH.sub.2CH.sub.3 .delta.
(CDCl.sub.3): 1.03 (3H, t), 1.25 (3H, t), 1.58 (3H, t), 2.13 (3H,
d), 2.40 (2H, q), 2.55 (4H, m), 3.01 (2H, q), 3.14 (4H, m), 4.77
(2H, q), 5.84 (1H, q), 7.19 (2H, m), 7.61 (1H, m), 8.56 (1H, d),
8.62 (1H, s), 9.00 (1H, s), 10.60 (1H, s). LRMS: m/z 567 (M +
1).sup.+ 1 = 1.5 equivalents of potassium bis(trimethylsilyl)amide
were used 2 = dichloromethane:methanol:0- .88 ammonia (96:4:0.4)
was used as the chromatographic eluant
EXAMPLE 85
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-methoxypyridin-3-yl]-2-met-
hyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0192] 28
[0193] A mixture of the title compound of Example 78 (100 mg, 0.21
mmol), and copper (II) sulphate heptahydrate (75 mg, 0.3 mmol) in
saturated methanolic ammonia (20 ml) was heated at 100.degree. C.
for 4 hours in a sealed vessel. The cooled mixture was evaporated
under reduced pressure and the residue suspended in aqueous sodium
carbonate solution (20 ml) and extracted with dichloromethane
(3.times.20 ml). The combined organic extracts were washed with
brine (3.times.20 ml), dried (Na.sub.2SO.sub.4) and evaporated
under reduced pressure to give a green solid. The crude product was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 97:3) and
recrystallised from hexane/ethyl acetate/methanol to afford the
title compound (23 mg, 24%) as a white solid.
[0194] Found: C, 51.22; H, 5.81; N, 20.61.
C.sub.20H.sub.27N.sub.7O.sub.4S- :0.5H.sub.2O requires C, 51.05; H,
6.00; N, 20.84%
[0195] .delta.(CDCl.sub.3): 1.07 (3H, t), 1.40 (3H, t), 2.40-2.65
(6H, m), 3.04 (2H, q), 3.19 (4H, m), 4.09 (3H,s), 4.24 (3H, s).
8.65 (1H, s), 9.05 (1H, s), 10.58 (1H, s).
[0196] LRMS: mz 462 (M+1).sup.+
EXAMPLE 86
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1(R)-methyl-n-propoxy)pyr-
idin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0197] 29
[0198] The title compound of Example 78 (400 mg, 0.84 mmol) was
added to a mixture of potassium bis(trimethylsilyl)amide (840 mg,
4.2 mmol) in (R)-2-butanol (4 ml) and the mixture stirred at 110
.degree. C. for 18 hours. The cooled mixture was concentrated under
reduced pressure and the residue suspended in water (10 ml) and
neutralised using 2N hydrochloric acid. This aqueous suspension was
extracted with ethyl acetate (3.times.30 ml), the combined organic
extracts washed with sodium hydroxide solution (20 ml), brine
(2.times.30 ml), dried (Na.sub.2SO.sub.4) and evaporated under
reduced pressure. The crude product was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 97.5:2.5) and the product
suspended in ether and evaporated under reduced pressure. This
solid was recrystallised from hexane/ethyl acetate to afford the
title compound (72 mg, 17%) as a white solid.
[0199] [.alpha.].sub.D=-20.88.degree. (c=0.083,
dichloromethane)
[0200] Found: C, 54.65; H, 6.63; N, 19.25.
C.sub.23H.sub.33N.sub.7O.sub.4S- ;0.5H.sub.2O requires C, 53.89; H,
6.69; N, 19.13%
[0201] .delta.(CDCl.sub.3): 1.06 (6H, m), 1.40 (3H, t), 1.50 (3H,
d), 1.86 (1H, m). 1.99 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.04
(2H, q), 3.16 (4H, m), 4.09 (3H, s), 5.56 (1H, m), 8.62 (1H, s),
9.05 (1H, s),10.70 (1H, s).
[0202] LRMS: m/z 504 (M+1).sup.+
EXAMPLES 87 TO 97
[0203] The compounds of the general formula wherein R.sup.1 is
methyl and R.sup.13 is --OR.sup.3: 30
[0204] were prepared from the appropriate alcohols and
pyrazolo[4,3-d]pyrimidin-7-ones, following procedures similar to
that described in Example 86.
3 Ex R2 R3 R10 Data 87 CH.sub.2CH.sub.3 31 CH.sub.2CH.sub.3 Found:
C, 54.02; H, 6.59; N, 18.87
C.sub.23H.sub.33N.sub.7O.sub.4S;0.5H.sub.2O requires C, 53.89; H,
6.69; N, 19.13% .delta. (CDCl.sub.3): 1.02 (3H, t), 1.14 (6H, d),
1.40 (3H, t), 2.30 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.03 (2H,
q), 3.15 (4H, m), 4.09 (3H, s), 4.44 (2H, d), 8.62 (1H, s), 9.03
(1H, s), 10.62 (1H, s). 88 (CH.sub.2).sub.2CH.sub.3 32
CH.sub.2CH.sub.3 .delta. (CDCl.sub.3): 1.02 (6H, m), 1.14 (6H, d),
1.82 (2H, m), 2.30 (1H, m), 2.42 (2H, q), 2.56 (4H, m), 2.99 (2H,
t), 3.16 (4H, m), 4.08 (3H, s), 4.45 (2H, d), 8.62 (1H, s), 9.03
(1H, s), 10.62 (1H, s). LRMS : m/z 518 (M + 1).sup.+ 89
CH.sub.2CH.sub.3 33 CH.sub.2CH.sub.3 Found: C, 55.11; H, 6.25; N,
19.45. C.sub.23H.sub.31N.sub.7O.sub.4S requires 0, 55.07; H, 6.23;
N, 19.55%. .delta. (CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, t), 1.90
(1 H, m), 1.98 (1H, m), 2.30-2.44 (4H, m), 2.57 # (6H, m), 3.02
(2H, q), 3.14 (4H, m), 4.09 (3H, s), 5.50 (1H, m), 8.60 (1H, s),
9.04 (1H, s), 10.68 (1H, s). LRMS: m/z 502 (M + 1).sup.+ 90 1
(CH.sub.2).sub.2CH.sub.3 34 CH.sub.2CH.sub.3 Found: C, 56.08; H,
6.45; N, 18.72. C.sub.24H.sub.33N.sub.7O.sub.4S requires C, 55.90;
H, 6.45; N. 19.01% .delta. (CDCl.sub.3): 0.47 (2H, m), 0.77 (2H,
m), 1.02 (6H, m), 1.47 (1H, m), # 1.83 (2H, m), 2.41 (2H. q). 2.56
(4H, m), 2.99 (2H, t), 3.15 (4H, m). 4.09 (3H, s), 4.50 (2H, d),
8.60 (1H, s), 9.05 (1H, s), 10.76 (1H, s). LRMS: m/z 516 (M +
1).sup.+ 91 2 (CH.sub.2).sub.2CH.sub.3 35 CH.sub.2CH.sub.3 Found:
C, 56.53; H, 6.68; N, 18.43. C.sub.25H.sub.35N.sub.7O.sub.4S
requires C, 56.69; H, 6.66; N, 18.51% .delta. (CDCl.sub.3): # 1.02
(6H, m), 1.82 (2H, m), 1.91-2.10 (4H, m), 2.26 (2H, m), 2.41 (2H,
q), 2.57 (4H, m), 2.98 (3H, m), 3.14 (4H, m), 4.08 (3H, s), 4.62
(2H, d), 8.61 (1H, s), 9.02 (1H, s), 10.60 (1H, s). LRMS: m/z 530
(M + 1).sup.+ 92 CH.sub.2CH.sub.3 36 CH.sub.2CH.sub.3 Found: C,
52.20; H, 6.16; N, 19.26. C.sub.22H.sub.31N.sub.7O.sub.5S requires
C, 52.26; H, 6.18; N, 19.39% .delta. (CDCl.sub.3): 1.04 (3H, t),
1.40 (3H, t), 2.42 (2H, q), 2.56 (4H, m), 3.03 (2H, q), 3.15 (4H,
m), 3.58 (3H, s), # 3.86 (2H, t), 4.09 (3H, s), 4.79 (2H, t), 8.62
(1H, s), 9.00 (1H, s), 10.78 (1H, s). LRMS: m/z 506 (M + 1).sup.+
93 3 (CH.sub.2).sub.2CH.sub.3 37 CH.sub.2CH.sub.3 Found: C, 52.86;
H, 6.39; N, 18.67. C.sub.23H.sub.33N.sub.7O.sub.5S requires C,
53.16; H, 6.40; N. 18.62% .delta. (CDCl.sub.3): 1.04 (6H, m), 1.82
(2H, m), 2.40 (2H, q), 2.55 (4H, m), # 2.98 (2H, t), 3.14 (4H, m),
3.57 (3H, s), 3.85 (2H, t), 4.07 (3H, s), 4.78 (2H, t), 8.61 (1H,
s), 8.99 (1H, s), 10.76 (1H, s). LRMS m/z 520 (M + 1).sup.+ 94 3
CH.sub.2CH.sub.3 38 CH.sub.2CH.sub.3 Found: C, 53.16; H, 6.48; N,
18.32. C.sub.23H.sub.33N.sub.7O.sub.5S;0.5H.sub.2O requires C,
52.26; H. 6.48; N, 18.55% .delta. (CDCl.sub.3): 1.04 (3H, t), 1.38
(6H, m), # 1.50 (3H, d), 2.41 (2H, q), 2.57 (4H, m), 2.96 (1H, s),
3.01 (2H, m), 3.15 (4H, m), 4.08 (3H, s). 4.18 (1H, m), 5.22 (1H,
m), 8.60 (1H, s), 8.82 (1H, s), 11.27 (1H, s). [.alpha.].sub.D =
+35.46.degree. (c = 0.073, dichloromethane) 95 2
(CH.sub.2).sub.2CH.sub.3 39 CH.sub.2CH.sub.3 .delta. (CDCl.sub.3):
1.04 (6H, m), 1.84 (2H, m), 2.41 (2H, q), 2.56 (4H m), 2.99 (2H,
t), 3.15 (4H, m), 4.08 (3H, s), 5.91 (2H, s), 7.24-7.37 (2H, m),
7.76 (1H, m), 8.59 (1H, s), 8.83 (2H, m), 12.70 (1H, s). LRMS: m/z
553 (M + 1).sup.- 96 1 (CH.sub.2).sub.2CH.sub.3 40 CH.sub.2CH.sub.3
Found: C, 55.22; H, 5.76; N, 19.42,
C.sub.26H.sub.32N.sub.5O.sub.4S;0.2CH.sub.2Cl.sub.2 requires C,
55.24; H, 5.73; N, 19.67% .delta. (CDCl.sub.3): # 1.01 (6H, m),
1.82 (2H, m), 2.41 (2H, q), 2.56 (4H, m), 2.98 (2H, t), 3.15 (4H,
m), 4.09 (3H, s), 5.78 (2H, s), 7.38 (1H, m), 7.88 (1H, d), 8.61
(2H, m), 8.79 (1H, s), 9.02 (1H, s), 10.45 (1H, s). LRMS: m/z 553
(M + 1).sup.+ 97 1 (CH.sub.2).sub.2CH.sub.3 41 CH.sub.2CH.sub.3
.delta. (CDCl.sub.3): 1.02 (6H, m), 1.82 (2H, m), 2.41 (2H, q),
2.56 (4H, m), 2.98 (2H, 1), 3.16 (4H, m), 4.06 (3H, s), 5.62 (2H,
s), 6.60 (1H, s), 7.43 (1H, s), 7.62 (1H, s), 8.66 (1H, s), 9.02
(1H, s), 10.51 (1H, s). LRMS: m/z 542 (M + 1).sup.+ 1 =
dichloromethane:methanol:0- .88 ammonia (100:0:0.5 to 99.5:1:0.5)
used as chromatographic eluant, and the compound was isolated
without crystallisation. 2 = dichloromethane:methanol:0.88 ammonia
(100:0:0.5 to 99.5:1:0.5) used as chromatographic eluant, and the
compound was triturated with ether. 3 = isolated without
crystallisation
EXAMPLE 98
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-(R)-methoxy-1-(R)-methy-
l
propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
-one
[0205] 42
[0206] (R,R)-2,3 butanediol (7.78 ml, 85 mmol) was added dropwise
to an ice-cold solution of sodium hydride (3.74 g, 60% dispersion
in mineral oil, 93.5 mmol) in ether (800 ml), and the solution
stirred at room temperature for 30 minutes. Methyl iodide (5.6 ml,
89.3 mmol) was added dropwise and the reaction stirred under reflux
for 48 hours. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
(10.24 ml, 85 mmol) was added and stirring continued for a further
90 minutes under reflux. The cooled reaction was washed with
aqueous ammonium chloride solution (500 ml), dried (MgSO.sub.4) and
evaporated under reduced pressure. The residual oil was purified by
column chromatography on silica gel using an elution gradient of
ether: pentane (10:90 to 50:50) to give a pale yellow oil. The
title compound of Example 78 (100 mg, 0.2 mmol) and potassium
bis(trimethylsilyl)amide (121 mg, 0.61 mmol) in the intermediate
alcohol (1 ml), was heated at 110.degree. C. for 30 hours, then the
reaction cooled and concentrated under reduced pressure. The
residual brown solid was purified by column chromatography on
silica gel using diethylamine: ethyl acetate (5:95) as eluant, and
repeated using methanol: ethyl acetate (5:95) as eluant. The
product was triturated with ether to afford the title compound (7
mg, 6%) as a white solid.
[0207] .delta.(CDCl.sub.3): 1.03 (3H, t), 1.25 (3H, d), 1.40 (3H,
t), 1.48 (3H, d). 2.41 (2H, q), 2.55 (4H, m), 3.03 (2H, q), 3.15
(4H, m), 3.52 (3H, s), 3.70 (1H. m), 4.09 (3H, s), 5.39 (1H, m),
8.60 (1H, s). 8.97 (1H, s). LRMS: m/z 534 (M+1).sup.+
EXAMPLE 99
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(pyridin-2-yl)methoxypyrid-
in-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0208] 43
[0209] A mixture of the title compound of Example 78 (100 mg, 0.2
mmol), potassium bis(trimethylsilyl)amide (210 mg, 1.1 mmol) in
pyridine-2-methanol (1 ml) was heated to 110.degree. C. for 18
hours. The cooled mixture was partitioned between ethyl acetate (10
ml) and water (10 ml), and the phases separated. The aqueous layer
was extracted with ethyl acetate (2.times.5 ml) and dichloromethane
(10 ml), the combined organic solutions dried (Na.sub.2SO.sub.4)
and evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel, using methanol: ethyl acetate
(10:90) as eluant, and triturated with ether, to afford the title
compound (49 mg, 43%) as a solid.
[0210] .delta.(CDCl.sub.3): 1.02 (3H, t), 1.40 (3H, t), 2.40 (2H,
q), 2.55 (4H, m), 3.04 (2H, q), 3.14 (4H, m), 4.10 (3H, s), 5.90
(2H, s), 7.32 (2H, m), 7.76 (1H, m), 8.58 (1H, s), 8.82 (2H, m),
12.72 (1H, s).
[0211] LRMS: m/z 539 (M+1).sup.+.
EXAMPLE 100
5-[2-Cyclobutylmethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-e-
thyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0212] 44
[0213] Obtained (69%) from the title compound of Example 78 and
cyclobutanemethanol, following a procedure similar to that
described in Example 99.
[0214] Found: C, 55.71; H, 6.44; N, 18.83.
C.sub.24H.sub.33N.sub.7O.sub.4S requires C, 55.90; H, 6.45; N,
19.01%.
[0215] .delta.(CDCl.sub.3) 1.03 (3H, t), 1.40 (3H, t), 1.98 (4H,
m), 2.26 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 3.02 (3H, m), 3.15
(4H, m), 4.10 (3H, s), 4.62 (2H, d), 8.62 (1H, s), 9.04 (1H, s),
10.61 (1H, s).
[0216] LRMS: m/z 516 (M+1).sup.+
EXAMPLE 101
5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-
-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0217] 45
[0218] A mixture of the title compound of Example 90 (104 mg, 0.2
mmol) and potassium bis(trimethylsilyl)amide (200 mg, 1.0 mmol) in
n-butanol (5 ml) was stirred under reflux for 5 days. The cooled
mixture was concentrated under reduced pressure, the residue
suspended in ethyl acetate (20 ml) and the mixture neutralised
using 1M hydrochloric acid. The layers were separated, the organic
phase washed with brine (10 ml), dried (MgSO.sub.4) and evaporated
under reduced pressure. The crude product was triturated with
ether, and the resulting solid, filtered and further purified by
column chromatography on silica gel using an elution gradient of
dichloromethane:methanol:0.88 ammonia (100:0:0.5 to 99:1:0.5) to
afford the title compound, (86 mg, 82%) as a solid.
[0219] .delta.(CDCl.sub.3): 1.02 (9H, m), 1.57 (2H, m), 1.82 (2H,
m), 1.95 (2H, m), 2.42 (2H, q), 2.58 (4H, m), 2.99 (2H, t), 3.15
(4H, m). 4.08 (3H, s), 4.68 (2H, t), 8.62 (1H, s), 9.02 (1H, s),
10.62 (1H, s).
[0220] LRMS: m/z 518 (M+1).sup.+
EXAMPLE 102
3-Ethyl-5-[2-(2-methoxy-1-methylethoxy)-5-(4-n-propylpiperazin-1-ylsulphon-
yl)
pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 1)
and
EXAMPLE 103
3-Ethyl-5-[2-(2-methoxy-1-methylethoxy)-5-(4-n-propyylpiperazin-1-ylsulpho-
nyl)
pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 2)
[0221] 46
[0222] Potassium bis(trimethylsilyl)amide (325 mg, 1.63 mmol) was
added to a solution of the title compound of Example 119 (200 mg,
0.41 mmol) in 1-methoxy-2-propanol (6 ml) and the reaction stirred
under reflux for 18 hours. The cooled mixture was evaporated under
reduced pressure and the residue purified by column chromatography
on silica gel, using dichloromethane: methanol (95:5) as eluant to
give 193 mg of a colourless oil. This product was further purified
by HPLC using an AD250 column, using
hexane:isopropanol:diethylamine (70:30:0.3) as eluant to afford,
the title compound of Example 102 (58 mg, 26%, 99.5%ee).
.delta.(CDCl.sub.3): 0.86 (3H, t), 1.40 (5H, m), 1.50 (3H, d), 2.32
(2H, t), 2.56 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.55 (3H, s),
3.66 (1H, m), 3.76 (1H, m), 4.08 (3H, s), 5.61 (1H, m), 8.61 (1H,
s), 8.92 (1H, s), 10.82 (1H, s).
[0223] LRMS: m/z 534 (M+1).sup.+, and the title compound of Example
103 (47 mg, 21%, 98.7%ee). .delta.(CDCl.sub.3): 0.86 (3H, t), 1.41
(5H, m), 1.50 (3H, d), 2.32 (2H, t), 2.56 (4H, m), 3.04 (2H, q),
3.14 (4H, m), 3.55 (3H, s), 3.66 (1H, m), 3.76 (1H, m), 4.08 (3H,
s), 5.61 (1H. m), 8.60 (1H, s), 8.92 (1H, s), 10.82 (1H, s).
[0224] LRMS: m/z 534 (M+1).sup.+
EXAMPLE 104
(+)-5-[2-(2-Methoxy-1-methylethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyr-
idin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
(isomer 1)
and
EXAMPLE 105
(-)-5-[2-(2-Methoxy-1-methylethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyr-
idin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne
(isomer 2)
[0225] 47
[0226] The title compound of Example 79 (198 mg, 0.42 mmol) was
added to a solution of potassium bis(trimethylsilyl)amide (415 mg,
2.1 mmol) in 1-methoxy-2-propanol (5 ml), and the reaction heated
at 110.degree. C. for 72 hours. The cooled mixture was evaporated
under reduced pressure, the residue dissolved in water and
neutralised using 2M hydrochloric acid. This aqueous solution was
extracted with ethyl acetate (3.times.30 ml), the combined organic
extracts washed with brine (3.times.20 ml), dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residual yellow oil was purified by column chromatography on silica
gel using an elution gradient of dichloromethane: methanol (100:0
to 97:3), and evaporated from ether to give a white solid.
[0227] The racemic product was purified by chiral HPLC using an
AD250 column, and hexane: isopropanol:trifluoroacetic acid
(80:20:0.5) as eluant. The first enantiomer was redissolved in
water, basified using aqueous sodium carbonate solution, and this
mixture extracted with ethyl acetate (3.times.20 ml). The combined
organic extracts were washed with brine (2.times.20 ml) dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. This
product was then further purified by column chromatography on
silica gel, using an elution gradient of dichloromethane: methanol
(100:0 to 97:3), and evaporated from ether, to afford the title
compound of Example 104 (39 mg, 18%, 98.1%ee) as a colourless
solid.
[0228] [.alpha.].sub.D=+30.31.degree. (c=0.067,
dichloromethane)
[0229] Found: C, 53.32; H, 6.49; N, 18.48.
C.sub.23H.sub.33N.sub.7O.sub.5S requires C, 53.16; H, 6.40; N,
18.87%.
[0230] .delta.(CDCl.sub.3) 1.02 (3H, t), 1.50 (3H, d), 1.82 (2H,
m), 2.28 (3H, s), 2.53 (4H, m), 2.98 (2H, t), 3.16 (4H, m), 3.55
(3H, s), 3.66 (1H, m), 3.76 (1H, m), 4.07 (3H, s), 5.61 (1H, m),
8.61 (1H, s), 8.92 (1H, s), 10.82 (1H, s).
[0231] LRMS: m/z 520 (M+1).sup.+
[0232] The title compound of Example 105 was isolated using the
same procedure as for Example 104, (26 mg, 12%, 94.0%ee).
[0233] [.alpha.].sub.D=-30.31.degree. (c=0.067,
dichloromethane)
[0234] .delta.(CDCl.sub.3): 1.02 (3H, t), 1.51 (3H, d), 1.82 (2H,
m), 2.29 (3H, s), 2.53 (4H, m), 2.98 (2H, t), 3.14 (4H, m), 3.55
(3H, s), 3.65 (1H, m), 3.77 (1H, m), 4.08 (3H, s), 5.61 (1H, m),
8.61 (1H, s), 8.92 (1H, s), 10.82 (1H, s).
[0235] LRMS: m/z 520 (M+1).sup.+
EXAMPLE 106
(+)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyri-
din-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on-
e
and
EXAMPLE 107
(-)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyri-
din-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on-
e
(isomers 1 and 2)
[0236] 48
[0237] Potassium bis(trimethylsilyl)amide (1.47 g, 7.4 mmol) was
added to a solution of the title compound of Example 80 (720 mg,
1.5 mmol) in 1-methoxy-2-propanol (10 ml) and the reaction stirred
under reflux for 72 hours. The cooled mixture was evaporated under
reduced pressure and the residual brown gum purified by column
chromatography on silica gel, using ethyl acetate: diethylamine
(97:3) as eluant. This racemic mixture was purified by chiral HPLC
using an AD 250 column, and hexane: isopropanol: diethylamine
(70:30:0.3) as eluant, to give each enantiomer. The first
enantiomer was partitioned between dichloromethane (20 ml) and
aqueous sodium carbonate solution (10 ml), the phases separated,
and the organic layer dried (Na.sub.2SO.sub.4), and evaporated
under reduced pressure. The product was further purified by column
chromatography on silica gel, using ethyl acetate: methanol (95:5)
as eluant, to afford the title compound of Example 106 (130 mg,
16%, 99.76%ee) as a white foam.
[0238] [.alpha.].sub.D=+15.65.degree. (c=0.093, methanol).
[0239] Found: C, 53.47; H, 6.66; N, 17.92.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.3H.sub.2O requires C, 53.48; H,
6.66; N, 18.19%
[0240] .delta.(CDCl.sub.3): 1.02 (6H, m), 1.52 (3H, t), 1.82 (2H,
m), 2.42 (2H, q), 2.57 (4H, m), 2.98 (2H, t), 3.14 (4H, m), 3.55
(3H, s), 3.65 (1H, m), 3.76 (1H, m), 4.08 (3H, s), 5.60 (1H, s),
8.61 (1H, s), 8.90 (1H, s), 10.81 (1H, s).
[0241] LRMS: m/z 534 (M+1).sup.+
[0242] The title compound of Example 107 was obtained (94 mg, 12%,
97.2%ee) as a white foam, using the same procedure as in Example
106.
[0243] [.alpha.].sub.D=-14.52.degree. (c=0.10, methanol)
[0244] Found: C, 53.66; H, 6.73; N, 17.89.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.25H.sub.2O requires C, 53.57;
H, 6.65; N, 18.22%
[0245] .delta.(CDCl.sub.3): 1.03 (6H, m), 1.50 (3H, d), 1.82 (2H,
m), 2.42 (2H, q), 2.57 (4H, m), 2.98 (2H, m), 3.17 (4H, m), 3.55
(3H, s), 3.65 (1H, m), 3.75 (1H, m), 4.08 (3H, s), 5.60 (1H, m),
8.60 (1H, s), 8.91 (1H, s), 10.81 (1H, s).
[0246] LRMS: m/z 534 (M+1).sup.+
EXAMPLE 108
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-n-propoxy)pyrid-
in-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 1)
and
EXAMPLE 109
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-n-proroxy)vfrid-
in-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 2)
[0247] 49
[0248] The title compounds were prepared from the title compound of
Example 78, and 2-methoxy-1-propanol following a similar procedure
to that described for Examples 104 and 105.
[0249] The racemate was further purified by HPLC using an AD250
column and hexane: ethanol:diethylamine (60:40:1) as eluant, to
give isomer 1. This product was re-purified by column
chromatography on silica gel using an elution gradient of
dichloromethane: methanol (100:0 to 97:3) and triturated with ether
to afford the title compound of Example 108 (8 mg, 2%, 82%ee) as a
white solid.
[0250] .delta.(CDCl.sub.3): 1.19-1.36 (6H, m), 1.40 (3H, t),
2.68-3.10 (8H, m), 3.32-3.59 (7H, m), 3.92 (1H, m), 4.09 (3H, s),
4.47 (1H, m). 4.72 (1H, m), 8.62 (1H, s), 8.97 (1H, s), 10.90 (1H,
s).
[0251] LRMS: m/z 520 (M+1).sup.+
[0252] The title compound of Example 109 was isolated (5 mg, 1%,
93%ee) as a white solid, using the same procedure as described for
Example 108.
[0253] .delta.(CDCl.sub.3): 1.26 (3H, t), 1.32 (3H, d), 1.40 (3H.
t), 2.80-3.10 (8H, m), 3.38-3.60 (7H, m), 3.92 (1H, m), 4.09 (3H,
s), 4.48 (1H, m), 4.72 (1H, m), 8.61 (1H, s), 8.98 (1H, s), 10.89
(1H, s).
[0254] LRMS: m/z 520 (M+1).sup.+
EXAMPLE 110
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxy-1-methyl-n-prop-
oxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
and
EXAMPLE 111
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxy-1-methyl-n-prop-
oxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomers 1 and 2)
[0255] 50
[0256] A mixture of the title compound of Example 78 (330 mg. 0.70
mmol) and potassium bis(trimethylsilyl)amide (693 mg, 3.47 mmol) in
the title compound of preparation 166 (2.5 ml) was heated at
110.degree. C. for 16 hours. The cooled reaction was suspended in
ethyl acetate (25 ml), and washed with saturated ammonium chloride
solution (5 ml), then saturated sodium bicarbonate solution (10
ml), dried (MgSO.sub.4) and evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel using
methanol: dichloromethane (5:95) as eluant, and repeated using
diethylamine: ethyl acetate (10:90) as eluant to give a gum.
[0257] This racemate was purified by HPLC using an AD250 column,
and hexane: ethanol:diethylamine (85:15:1) as eluant to afford the
title compound of Example 110 (25 mg, 6.7%,98.9%ee)
[0258] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.39 (3H, t). 1.49 (3H,
d), 2.04 (1H, m), 2.24 (1H, m). 2.42 (2H, q), 2.56 (4H, m), 3.01
(2H, m), 3.16 (4H, m), 3.33 (3H, s), 3.57 (1H, m), 3.68 (1H, m),
4.06 (3H, s), 5.75 (1H, m). 8.61 (1H, s), 8.88 (1H, s), 10.99 (1H,
s).
[0259] LRMS: m/z 534 (M+1).sup.+and the title compound of Example
111 (29 mg, 7.8%, 99.7%ee).
[0260] .delta.(CDCl.sub.3): 1.03 (3H, t), 1.40 (3H, t). 1.48 (3H,
d), 2.04 (1H, m), 2.24 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.02
(2H. q), 3.16 (4H, m), 3.34 (3H, s), 3.57 (1H, m), 3.66 (1H, m),
4.08 (3H, s), 5.74 (1H, m). 8.60 (1H, s), 8.98 (1H, s), 10.98 (1H,
s).
[0261] LRMS: m/z 534 (M+1).sup.+
EXAMPLE 112
(+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-ethoxy-1-methyletho-
xy)pyridin-3-yl]-2-methyl-2.6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 1)
and
EXAMPLE 113
(-)-3-Ethyl-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-ethoxy-1-methyletho-
xy)pyridin-3-yl]-2-methyl-2.6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 2)
[0262] 51
[0263] The racemate was prepared (70%) from the title compound of
Example 78 and 1-ethoxy-2-propanol, following the procedure
described for Examples 104 and 105.
[0264] This racemate was purified by chiral HPLC using an AD 250
column, and hexane: isopropanol:diethylamine (70:30:0.3) as eluant,
to give enantiomer 1. This product was further purified by column
chromatography on silica gel, using dichloromethane: methanol
(97:3) as eluant, and evaporated from ether, to afford the title
compound of Example 112 (52 mg, 15%, 99.5%ee) as a foam.
[0265] [.alpha.].sub.D=+18.60.degree. (c=0.067,
dichloromethane)
[0266] Found: C, 53.20; H, 6.70; N, 17.78.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.5H.sub.2O requires C, 53.12; H,
6.69; N, 18.07%
[0267] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.25 (3H, t), 1.40 (3H,
t), 1.52 (3H, d), 2.42 (2H, q), 2.57 (4H, m), 3.02 (2H, q), 3.15
(4H, m), 3.60-3.82 (4H, m), 4.08 (3H, s), 5.60 (1H, m), 8.61 (1H,
s), 8.94 (1H, s), 10.81 (1H, s).
[0268] LRMS: m/z 534 (M+1).sup.+
[0269] The title compound of Example 113 was isolated (11 mg, 3%,
99.5%ee) following the same procedure to that described for Example
112.
[0270] [.alpha.].sub.D=-19.43.degree. (c=0.070,
dichloromethane)
[0271] Found: C, 53.34; H, 6.66; N, 17.86.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.5H.sub.2O requires C, 53.12; H,
6.69; N, 18.07%
[0272] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.25 (3H, t), 1.40 (3H,
t), 1.52 (3H, d), 2.42 (2H, q), 2.57 (4H, m), 3.03 (2H, q), 3.16
(4H, m), 3.60-3.82 (4H, m), 4.09 (3H, s), 5.60 (1H, m), 8.62 (1H,
s), 8.92 (1H, s), 10.82 (1H, s).
[0273] LRMS: m/z 534 (M+1).sup.+
EXAMPLE 114
(+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxymethyl-n-pro-
poxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
and
EXAMPLE 115
(-)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxymethyl-n-pro-
poxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomers 1 and 2)
[0274] 52
[0275] The title compounds of Examples 114 and 115 were obtained
(11%, 93%ee) and (6.7%, 97%ee) respectively from the title compound
of Example 78 and 1-methoxy-2-butanol, using the procedure
described in Examples 108 and 109.
[0276] [.alpha.].sub.D=+37.04.degree. (c=0.097,
dichloromethane)
[0277] Found: C, 53.36; H, 6.73; N, 17.84.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.5H.sub.2O requires C, 53.12; H,
6.69; N, 18.07%
[0278] .delta.(CDCl.sub.3): 1.03 (6H, m), 1.39 (3H, t), 1.92 (2H,
m), 2.42 (2H, q), 2.57 (4H, m), 3.02 (2H, q), 3.16 (4H, m), 3.51
(3H, s), 3.66 (1H, m), 3.77 (1H, m), 4.08 (3H, s), 5.57 (1H, m),
8.60 (1H, s), 8.88 (1H, s), 10.84 (1H, s).
[0279] LRMS: m/z 534 (M+1).sup.+; and .alpha..sub.D=-40.08.degree.
(c=0.093, dichloromethane)
[0280] Found: C, 53.44; H, 6.75; N, 17.76.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.5H.sub.2O requires C, 53.12; H,
6.69; N, 18.07%
[0281] .delta.(CDCl.sub.3): 1.03 (6H, m), 1.40 (3H, t), 1.92 (2H,
m), 2.42 (2H, q); 2.57 (4H, m), 3.02 (2H, q), 3.16 (4H, m), 3.51
(3H, s), 3.68 (1H, m), 3.78 (1H, m), 4.10 (3H, s), 5.57 (1H, m),
8.61 (1H, m), 8.89 (1H, s), 10.83 (1H, s).
EXAMPLE 116
(-)-3-Ethyl-5-{5-(4-ethylpiperazin-1-ylsulphonyl)-2-[1-(pyridin-2-yl)ethox-
y]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 1)
and
EXAMPLE 117
(+)-3-Ethyl-5-{5-(4-ethylpiperazin-1-ylsulphonyl)-2-[1-(pyridin-2-yl)ethox-
y]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo
[4,3-d]pyrimidin-7-one (isomer 2)
[0282] 53
[0283] The title compounds of Example 116 and 117 were obtained as
solids, (4%, 99.0%ee) and (2%, 99.0%ee) respectively, from the
title compound of Example 78 and 1-(pyridin-2-yl) ethanol
(Helv.Chim.Acta., 1955, 38, 1114), following a similar procedure to
that described for Examples 112 and 113, except that hexane:
isopropanol: diethylamine (70:30:1) was used as the HPLC
eluant.
[0284] [.alpha.].sub.D=-90.11.degree. (c=0.033,
dichloromethane)
[0285] .delta.(CDCl.sub.3): 1.02 (3H, t), 1.40 (3H, t), 1.80 (3H,
d), 2.41 (2H, q), 2.54 (4H, m), 3.00-3.17 (6H, m), 4.10 (3H, s),
6.69 (1H, q), 7.32 (2H, m), 7.75 (1H, m), 8.54 (1H, s), 8.75 (1H,
s), 8.80 (1H, d), 13.14 (1H, s).
[0286] LRMS: m/z 553 (M+1).sup.+
[0287] [.alpha.].sub.D=+82.02.degree. (c=0.040,
dichloromethane)
[0288] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, m), 1.80 (3H,
d), 2.41 (2H. q), 2.55 (4H, m), 3.00-3.18 (6H, m), 4.10 (3H, s),
6.69 (1H, q), 7.34 (2H, m), 7.75 (1H, m), 8.52 (1H, s), 8.76 (1H,
s), 8.80 (1H, d), 13.16 (1H, s).
[0289] LRMS: m/z 553 (M+1).sup.+
EXAMPLE 118
(+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyl
ethoxy)
pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7--
one
[0290] 54
[0291] A mixture of the title compound of example 78 (2.0 g, 4.2
mmol) and potassium bis(trimethylsilyl)amide (4.2 g, 21.0 mmol) in
the title compound of Preparation 165 (16 ml), was heated at
110.degree. C. for 18 hours. The cooled mixture was concentrated
under reduced pressure and the residue purified by column
chromatography on silica gel using an elution gradient of
diethylamine: methanol:ethyl acetate (2.5:0:97.5 to 0:10:90). The
product was purified further by column chromatography on silica gel
using methanol: ethyl acetate (2.5:97.5) as eluant to afford the
title compound (640 mg, 29%) as a solid.
[0292] Found: C, 53.16; H, 6.54; N, 18.37.
C.sub.23H.sub.33N.sub.7O.sub.5S- ;0.2CH.sub.3CO.sub.2C.sub.2H.sub.5
requires C. 53.21; H, 6.49; N, 18.25%
[0293] [.alpha.].sub.D=+16.6.degree. (c=0.10 methanol)
[0294] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, t), 1.52 (3H,
d), 2.42 (2H, q), 2.57 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.56
(3H, s), 3.66 (1H, m), 3.77 (1H, m), 4.09 (3H, s), 5.61 (1H, m),
8.62 (1H, s), 8.93 (1H, s), 10.82 (1H, s).
[0295] LRMS: m/z 520 (M+1).sup.+
EXAMPLE 119
5-[2-Ethoxy-5-(4-n-propylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-m-
ethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0296] 55
[0297] 1-n-Propylpiperazine (308 mg, 1.01 mmol) and triethylamine
(440 ml, 3.2 mmol) were added to a solution of the title compound
of Preparation 164 (211 mg, 0.53 mmol) in dichloromethane (6 ml),
and the reaction mixture stirred at room temperature for 2 hours.
The mixture was purified directly by column chromatography on
silica gel, using dichloromethane: methanol (95:5) as eluant to
afford the title compound (210 mg, 85%) as a white foam.
[0298] .delta.(CDCl.sub.3): 0.86 (3H, t), 1.42 (5H, m), 1.58 (3H,
t), 2.29 (2H, t), 2.56 (4H, m), 3.03 (2H, q), 3.14 (4H, m), 4.10
(3H, s), 4.76 (2H, q), 8.62 (1H, s), 9.04 (1H, s), 10.67 (1H, s).
LRMS: m/z 490 (M+1).sup.+
EXAMPLE 120
5-{2-Ethoxy-5-[4-(prop-2-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-ethyl--
2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0299] 56
[0300] Obtained as a white solid (71%), from the title compound of
Preparation 164 and 1-(prop-2-yl)-piperazine, following the
procedure described in Example 119.
[0301] .delta.(CDCl.sub.3): 0.99 (6H, d), 1.40 (3H, t), 1.57 (3H,
t), 2.62 (4H, m), 2.70 (1H, m), 3.02 (2H, q), 3.13 (4H, m), 4.08
(3H, s), 4.74 (2H, q), 8.62 (1H, s), 9.03 (1H, s), 10.64 (1H,
s).
[0302] LRMS: m/z 490 (M+1).sup.+
EXAMPLE 121
5-{2-Ethoxy-5-[4-(pyridin-2-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-eth-
yl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0303] 57
[0304] Obtained as a white solid (58%), from the title compound of
Preparation 164 and 1-(pyridin-2-yl)piperazine, following the
procedure described in Example 119.
[0305] .delta.(CDCl.sub.3): 1.41 (3H, t), 1.59 (3H, t), 3.05 (2H,
q), 3.22 (4H, m), 3.70 (4H, m), 4.10 (3H, s), 4.75 (2H, q), 6.62
(2H, m), 7.47 (1H, m), 8.16 (1H, d), 8.64 (1H, s), 9.07 (1H. s),
10.65 (1H, s).
[0306] LRMS: m/z 525 (M+1).sup.+
EXAMPLE 122
3-Ethyl-5-{2-(2-methoxy-1-methylethoxy)-5-[4-(pyridin-2-yl)piperazin-1-yls-
ulphonyl]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7--
one
[0307] 58
[0308] Potassium bis(trimethylsilyl)amide (76 mg, 0.38 mmol) was
added to a solution of the title compound of Example 121 (50 mg,
0.095 mmol) in 1-methoxy-2-propanol (5 ml) and the reaction heated
under reflux for 18 hours. The cooled mixture was purified directly
by column chromatography on silica gel, using dichloromethane:
methanol (95:5) as eluant to afford the title compound (32 mg, 59%)
as a yellow oil.
[0309] .delta.(CDCl.sub.3): 1.40 (3H, t), 1.50 (3H, d), 3.04 (2H,
q), 3.22 (4H. m), 3.54 (3H, s), 3.69 (6H, m), 4.09 (3H, s), 5.60
(1H, m), 6.63 (2H, m), 7.47 (1H, m), 8.16 (1H, d), 8.63 (1H, s),
8.94 (1H, s), 10.81 (1H, s).
[0310] LRMS: m/z 569 (M+1).sup.+
EXAMPLE 123
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-meth-
yl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0311] 59
[0312] A mixture of the title compound of Preparation 158 (596 mg,
1.21 mmol) and potassium bis(trimethylsilyl)amide (723 mg, 3.62
mmol) in ethanol (20 ml) was heated at 120.degree. C. for 18 hours
in a sealed vessel. The cooled mixture was evaporated under reduced
pressure and the residue purified by column chromatography on
silica gel twice, using dichloromethane: methanol (95:5) as eluant.
The product was triturated with ether to afford the title compound
(358 mg. 62%) as an off-white solid.
[0313] Found: C, 52.71; H, 6.00; N, 20.48.
C.sub.21H.sub.29N.sub.7O.sub.4S requires C, 53.04; H, 6.15; N,
20.62%
[0314] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, t), 1.60 (3H,
t), 2.42 (2H q), 2.58 (4H, m), 2.99 (2H, q), 3.16 (4H, m), 4.28
(3H, s), 4.78 (2H, q), 8.64 (1H, s), 9.08 (1H, s), 10.80 (1H,
s).
[0315] LRMS: 476 (M+1).sup.+
EXAMPLE 124
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-methyl-3-n-p-
ropyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0316] 60
[0317] Obtained (42%) from the title compound of Preparation 159,
following a similar procedure to that described in Example 123.
[0318] Found: C, 53.68; H, 6.34; N, 19.97.
C.sub.22H.sub.31N.sub.7O.sub.4S requires C, 53.97; H, 6.38; N,
20.03%
[0319] .delta.(CDCl.sub.3): 1.02 (6H, m). 1.60 (3H, t), 1.85 (2H,
m), 2.42 (2H, q), 2.58 (4H, m), 2.95 (2H, t), 3.16 (4H, m), 4.29
(3H, s), 4.78 (2H, q), 8.63 (1H, s), 9.08 (1H, s), 10.78 (1H, s).
LRMS: m/z 491 (M+1).sup.+
EXAMPLE 125
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyletho-
xy)pyridin-3-yl]-1-methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0320] 61
[0321] A mixture of the title compound of Example 123 (70 mg, 0.15
mmol) and potassium bis(trimethylsilyl)amide (150 mg, 0.74 mmol) in
the title compound of Preparation 165 (1 ml), was stirred at
110.degree. C. for 18 hours. The cooled mixture was concentrated
under reduced pressure and the residue partitioned between water (5
ml) and dichloromethane (5 ml), and the mixture neutralised by the
addition of solid carbon dioxide. The layers were separated, the
aqueous phase extracted with dichloromethane (2.times.5 ml), the
combined organic solutions dried (Na.sub.2SO.sub.4), and evaporated
under reduced pressure. The crude product was purified by column
chromatography on silica gel, using ethyl acetate: diethylamine
(97:3) as eluant to afford the title compound (62 mg, 80%).
[0322] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.39 (3H, t), 1.50 (3H,
d), 2.42 (2H, q), 2.58 (4H, m), 2.98 (2H, q), 3.15 (4H, m), 3.58
(3H, s), 3.70 (2H, m), 4.28 (3H, s), 5.58 (1H, m), 8.62 (1H, s),
8.90 (1H, s), 11.07 (1H, s).
[0323] LRMS: m/z 520 (M+1).sup.+
EXAMPLE 126
5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-m-
ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0324] 62
[0325] A mixture of the title compound of Example 124 (111 mg, 0.23
mmol) and potassium bis(trimethylsilyl)amide (226 mg, 1.13 mmol) in
2-methoxyethanol (5 ml) was stirred under reflux for 18 hours. The
cooled mixture was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using
dichloromethane: methanol (96:4) as eluant, and triturated with
ether to afford the title compound (75 mg, 64%) as a white
crystalline solid.
[0326] Found: C, 52.87; H, 6.35; N, 18.68.
C.sub.23H.sub.33N.sub.7O.sub.5S requires C, 53.16; H, 6.40; N,
18.87%
[0327] .delta.(CDCl.sub.3): 1.02 (6H, m), 1.85 (2H, m), 2.42 (2H,
q), 2.57 (4H, m), 2.94 (2H, t), 3.16 (4H, m), 3.60 (3H, s), 3.86
(2H, t), 4.27 (3H, s), 4.78 (2H, t), 8.62 (1H, s), 9.00 (1H, s),
10.51 (1H, s).
[0328] LRMS: m/z 521 (M+2).sup.+
EXAMPLE 127
5-{5-(4-Ethylpiperazin-1-ylsulphonyl)-2-[(pyridin-2-yl)methoxy]pyridin-3-y-
l}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0329] 63
[0330] A mixture of the title compound of Example 124 (100 mg, 0.20
mmol) and potassium bis(trimethylsilyl)amide (204 mg, 1.02 mmol) in
pyridine-2-methanol (2 ml) was stirred at 110.degree. C. for 18
hours, then cooled. The solvent was removed by Kugelrohr
distillation, and the residue was purified by column chromatography
on silica gel, using dichloromethane: methanol (95:5) as eluant.
This product was triturated with ether to afford the title compound
(8 mg, 7%) as a solid.
[0331] .delta.(CDCl.sub.3): 1.03 (6H, m), 1.87 (2H, m), 2.42 (2H,
q), 2.56 (4H, m), 2.95 (2H, t), 3.16 (4H, m), 4.30 (3H, s), 5.94
(2H, s), 7.36 (2H, m), 7.68 (1H, m), 8.60 (1H, s), 8.86 (2H, d),
13.34 (1H, s).
[0332] LRMS: m/z 554 (M+1l).sup.+
EXAMPLE 128
(+)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyri-
din-3-yl]-1-methyl
3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on- e
and
EXAMPLE 129
(-)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyri-
din-3-yl]-1-methyl
3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on- e
(isomer 1 and isomer 2)
[0333] 64
[0334] The title compounds of Examples 128 and 129 were prepared
from Example 124 (17%, 99.5%ee) and (15%, 98.6%ee) respectively,
following a procedure similar to that described in Examples 106 and
107, except that hexane :isopropanol : diethylamine
:trifluoroacetic acid (85:15:0.2:0.3) was used as the HPLC eluant.
[.alpha.].sub.D=+31.21.degree. (c=0.067 dichloromethane)
[0335] Found: C. 53.77; H, 6.71; N, 17.89.
C.sub.24H.sub.35N.sub.7O.sub.5S- ;0.5H.sub.2O requires C, 53.12; H,
6.69; N, 18.07%
[0336] .delta.(CDCl.sub.3): 1.02 (6H, m), 1.50 (3H. d), 1.84 (2H,
m), 2.42 (2H, q), 2.58 (4H, m), 2.94 (2H, t), 3.17 (4H, m), 3.58
(3H, s), 3.72 (2H, m), 4.28 (3H. s), 5.58 (1H, m), 8.62 (1H, s),
8.90 (1H, s), 11.08 (1H, s); and
[0337] [.alpha.].sub.D=-34.10.degree. (c=0.072 dichloromethane)
[0338] Found: C, 53.75; H, 6.67; N, 18.04.
C.sub.24H.sub.35N.sub.7O.sub.5S requires C, 54.02; H. 6.61; N,
18.37%
[0339] .delta.(CDCl.sub.3): 1.02 (6H, m), 1.50 (3H. d), 1.84 (2H,
m), 2.42 (2H. q), 2.58 (4H, m), 2.94 (2H, t), 3.15 (4H, m), 3.59
(3H, s), 3.70 (2H, m), 4.28 (3H. s), 5.59 (1H, m), 8.62 (1H, s),
8.92 (1H, s), 11.17 (1H, s), respectively.
EXAMPLE 130
5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0340] 65
[0341] A mixture of the title compound of Example 93 (130 mg, 0.25
mmol) and 3-chloroperbenzoic acid (95 mg, 0.275 mmol) in
dichloromethane (6 ml) was stirred at room temperature for 21/2
hours. The reaction mixture was washed with aqueous sodium
bicarbonate solution (5 ml), dried (MgSO.sub.4), and evaporated
under reduced pressure. The residual foam was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane:methanol:0.88 ammonia (93:7:0 to 93:7:1) to afford
the title compound (110 mg, 82%) as a white solid.
[0342] Found: C, 50.71; H, 6.27; N, 17.82.
C.sub.23H.sub.33N.sub.7O.sub.6S requires C, 50.72; H, 6.30; N,
18.00%
[0343] .delta.(CDCl.sub.3): 1.00 (3H, t), 1.40 (3H, t), 1.81 (2H,
m), 2.98 (2H, t), 3.19 (2H, m), 3.33 (4H, m), 3.54 (5H, m), 3.70
(2H, m), 3.86 (2H, t), 4.06 (3H, s), 4.78 (2H, t), 8.63 (1H, s),
8.97 (1H, s), 10.87 (1H, s).
[0344] LRMS: m/z 536 (M+1).sup.+
EXAMPLE 131
5-[2-Ethoxy-5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)pyridin-3-yl]-2-meth-
yl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0345] 66
[0346] Obtained as a white foam (81%), from the title compound of
Example 80 following the procedure described in Example 130.
[0347] .delta.(CDCl.sub.3): 1.00 (3H, t), 1.40 (2H, t), 1.38 (3H,
t), 1.81 (2H, m), 2.97 (2H, t), 3.16 (2H, m), 3.30 (4H, m), 3.50
(2H, m), 3.70 (2H, m), 4.08 (3H, s), 4.74 (2H, q), 8.64 (1H, s),
9.00 (1H, s), 10.75 (1H, s). LRMS: m/z 506 (M+1).sup.+
EXAMPLE 132
3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-me-
thyl
ethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-
-7-one
[0348] 67
[0349] 3-Chloroperbenzoic acid (95 mg, 0.28 mmol) was added to a
solution of the title compound of Example 118 (130 mg, 0.25 mmol)
in dichloromethane (2 ml), and the reaction stirred at room
temperature for 3 hours. The mixture was concentrated under reduced
pressure and the residue was purified by column chromatography on
silica gel, using an elution gradient of
dichloromethane:methanol:0.88 ammonia (95:5:0 to 90:10:1) to afford
the title compound (130 mg, 87%).
[0350] .delta.(CDCl.sub.3): 1.40 (6H, m), 1.52 (3H, d), 3.01 (2H,
q), 3.22 (2H, m), 3.34 (4H, m), 3.54 (5H, m), 3.73 (4H, m), 4.08
(3H,s), 5.62 (1H, m), 8.64 (1H, s), 8.94 (1H, s). LRMS: m/z 536
(M+1).sup.+
EXAMPLE 133
5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyraxolo[4,3-d]pyrimidin-7-one
[0351] 68
[0352] Obtained as a white solid (51%) from the title compound of
Example 126 using a similar procedure to that described in Example
130.
[0353] .delta.(CDCl.sub.3): 1.02 (3H, t) 1.41 (3H, t), 1.84 (2H,
q), 2.92 (2H, t), 3.32 (2H, d), 3.36 (4H, m), 3.46-3.60 (5H. m),
3.74 (2H, m), 3.86 (2H. t), 4.29 (3H, s), 4.78 (2H, t), 8.64 (1H,
s), 9.01 (1H, s), 11.05 (1H, s). LRMS: m/z 535 (M).sup.+
EXAMPLE 134
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-
-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0354] 69
[0355] A mixture of the title compound of Example 81 (200 mg, 0.41
mmol), and potassium bis(trimethylsilyl)amide (407 mg, 2.04 mmol)
in n-propanol (5 ml) was stirred at 110.degree. C. for 18 hours and
the cooled reaction, evaporated under reduced pressure. The residue
was purified by column chromatography on silica gel, using an
elution gradient of ethyl acetate: diethylamine (100:0 to 95:5) and
triturated with ether to afford the title compound (160 mg, 68%) as
a solid. (CDCl.sub.3): 1.02 (3H, t), 1.10 (3H, t), 1.42 (3H, t),
1.59 (3H, t), 2.00 (4H, m), 2.42 (2H, q), 2.58 (4H, m), 3.02 (2H,
q), 3.14 (4H, m), 4.38 (2H, q), 4.63 (2H, t), 8.63 (1H, s), 9.04
(1H, s). LRMS: m/z 504 (M+1).sup.+
EXAMPLE 135
5-[2-i-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2,3-diethyl--
2.6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0356] 70
[0357] Obtained as a solid (65%) from the title compound of Example
81 and i-butanol, using the procedure described in Example 134.
.delta.(CDCl.sub.3): 1.02 (3H, t), 1.15 (6H, d), 1.42 (3H, t), 1.58
(3H, t), 2.30 (1H, m), 2.42 (2H, q), 2.57 (4H, m), 3.06 (2H, q),
3.16 (4H, m), 4.38 (2H, q), 4.45 (2H, d), 8.62 (1H, s), 9.03 (1H,
s). LRMS: m/z 518 (M+1).sup.+
EXAMPLE 136
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyrid-
in-3-15 yl]-2,6-dihydro-7H-pyrazolo
H-pyrazolo[4,3-d]pyrimidin-7-one
[0358] 71
[0359] Obtained as a solid (33%) from the title compound of Example
81 and 2-methoxyethanol, using the procedure described in Example
134.
[0360] Found: C, 53.29; H, 6.20; N, 18.19.
C.sub.23H.sub.33N.sub.7O.sub.5S requires C, 53.16; H, 6.40; N,
18.87% .delta.(CDCl.sub.3): 1.02 (3H, t), 1.42 (3H, t), 1.59 (3H,
t), 2.44 (2H, q), 2.57 (4H, m), 3.05 (2H, q), 3.16 (4H, m), 3.58
(3H, s), 3.86 (2H, t), 4.28 (2H, q), 4.79 (2H, t), 8.62 (1H, s),
8.99 (1H, s). LRMS: m/z 520 (M+1).sup.+
EXAMPLE 137
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-hydroxy-n-propoxy)p-
yridin-3-yl]-2,6-dihydro-7H-pyrazolo
H-pyrazolo[4,3-d]pyrimidin-7-one
[0361] 72
[0362] A mixture of the title compound of Example 81 (200 mg, 0.41
mmol) and potassium bis(trimethylsilyl)amide (407 mg, 2.04 mmol) in
1,3-propanediol (3 ml) was stirred at 110.degree. C. for 18 hours,
then cooled and evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel, using an elution
gradient of ethyl acetate: diethylamine (100:0 to 95:5). The
product was partitioned between water (5 ml) and dichloromethane
(10 ml), and the phases separated. The organic layer was washed
with water (2.times.5 ml), dried (MgSO.sub.4), evaporated under
reduced pressure and triturated with ether, to afford the title
compound (90 mg, 42%) as a solid. .delta.(CDCl.sub.3): 1.02 (3H,
t), 1.40 (3H, t), 1.57 (3H, t), 2.16 (2H, m), 2.42 (2H, q), 2.55
(4H, m), 3.02 (2H, q), 3.15 (4H, m), 4.00 (2H, t), 4.37 (2H, q),
4.80 (2H, t), 8.62 (1H, s), 8.96 (1H, s). LRMS: m/z 520 (M+1
).sup.+
EXAMPLE 138
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methyl-n-propoxy)py-
ridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer
1)
and
EXAMPLE 139
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methyl-n-propoxy)py-
ridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer
2)
[0363] 73
[0364] A mixture of the title compound of Example 81 (500 mg, 1.02
mmol) and potassium bis(trimethylsilyl)amide (1.01 g 5.11 mmol) in
1-methyl-n-propanol (5 ml) was stirred at 110.degree. C. for 18
hours, then cooled and evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel, using
an elution gradient of ethyl acetate: diethylamine (100:0 to 95:5)
and triturated with ether to give a solid. This racemate was
further purified by chiral HPLC using an AD 250 column using
hexane: isopropanol:diethylamine (90:10:1) as eluant, to afford the
title compound of Example 138 (40 mg, 8%, 95%ee) as a solid. Found:
C, 54.41; H, 6.71; N, 18.17;
C.sub.24H.sub.35N.sub.7O.sub.4S;0.2CH.sub.2Cl.sub.2 requires C,
54.37; H, 6.67; N, 18.34% .delta.(CDCl.sub.3): 1.04 (6H, m), 1.41
(3H, t), 1.50 (3H, d), 1.58 (3H, t), 1.86 (1H, m), 1.98 (1H, m),
2.41 (2H, q), 2.58 (4H, m), 3.02 (2H, q), 3.15 (4H, m), 4.38 (2H,
q), 5.55 (1H, m), 8.61 (1H, s), 9.02 (1H, s). 10.66 (1H, s); and
the title compound of Example 139 (70 mg, 13%, 86%ee) as a solid.
Found: C, 55.91; H, 7.11; N, 18.55 C.sub.24H.sub.35N.sub.7O.sub.4S
requires C, 55.69; H, 6.82; N, 18.95% .delta.(CDCl.sub.3): 1.05
(6H, m), 1.40 (3H, t), 1.50 (3H, d), 1.57 (3H, t), 1.84 (1H, m),
1.98 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.04 (2H, q), 3.15 (4H,
m), 4.38 (2H, q), 5.54 (1H, m), 8.61 (1H, s), 9.03 (1H, s), 10.67
(1H, s).
EXAMPLE 140
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methyleth-
oxy) pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 1)
and
EXAMPLE 141
2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methyleth-
oxy) pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(isomer 2)
[0365] 74
[0366] Obtained as solids (10%, 99.5%ee) and (10%, 99.1%ee)
respectively, from the title compound of Example 81 and
1-methoxy-2-propanol (5 ml), following a similar procedure to that
described above, except, that hexane: isopropanol: diethylamine
(70:30:1) was used as the HPLC eluant. .delta.(CDCl.sub.3): 1.03
(3H, t), 1.40 (3H, t), 1.50 (3H, d), 1.58 (3H, t), 2.42 (2H, q),
2.58 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.55 (3H, s), 3.64 (1H,
m), 3.76 (1H, m), 4.37 (2H, q), 5.60 (1H, m), 8.60 (1H, s), 8.90
(1H, s). LRMS: m/z 535 (M+2).sup.+Found: C, 54.09; H, 6.91; N,
17.03. C.sub.24H.sub.35N.sub.7O.sub.5S requires C, 54.02; H, 6.61;
N, 18.38% .delta.(CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, t), 1.50
(3H, d), 1.58 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.02 (2H, q),
3.12 (4H, m), 3.56 (4H, m), 3.65 (1H, m), 3.74 (1H, m), 4.37 (2H,
q), 5.60 (1H, m), 8.60 (1H, s), 8.90 (1H, s). LRMS: m/z 535
(M+2).sup.+, respectively.
EXAMPLE 142
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-(6-methyl-pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimid-
in-7-one
[0367] 75
[0368] A mixture of the title compound of Example 82 (100 mg, 0.176
mmol), and potassium bis(trimethylsilyl)amide (175 mg, 0.88 mmol)
in 2-methoxyethanol (1 ml) was heated under reflux for 18 hours,
then cooled. The solution was concentrated under reduced pressure
and the residue partitioned between water (5 ml) and
dichloromethane (10 ml), and the mixture neutralised using (2N)
hydrochloric acid. The phases were separated, the aqueous layer
extracted with dichloromethane (10 ml), and the combined organic
solutions dried (MgSO.sub.4), and evaporated under reduced
pressure. The crude product was purified by column chromatography
on silica gel, using dichloromethane:methanol:0.88 ammonia
(96:4:0.4) as eluant, and triturated with pentane, to afford the
title compound (27 mg, 26%) as an off-white solid. Found: C, 56.14;
H, 6.09; N, 18.53. C.sub.28H.sub.36N.sub.8O.sub.5S requires C,
56.36; H, 6.08: N, 18.78% .delta.(CDCl.sub.3): 1.02 (3H, t), 1.30
(3H, t), 2.42 (2H, q), 2.57 (7H, m), 3.04 (2H, q), 3.16 (4H, m),
3.58 (3H, s), 3.86 (2H, t), 4.79 (2H, t), 5.63 (2H, s), 6.78 (1H,
d), 7.08 (1H, d), 7.48 (1H, m), 8.61 (1H, s), 8.98 (1H, s), 10.82
(1H, s).
EXAMPLE 143
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyletho-
xy) pyridin-3-yl]-2-(6-methylpyridin-2-yl)
methyl-2,6-dihydro-7H-pyrazolo[- 4,3-d]pyrimidin-7-one
[0369] 76
[0370] Obtained as a white solid (12%) from the title compounds of
Examples 82 and 165, using a similar procedure to that described in
Example 142, except the product was additionally purified by column
chromatography on silica gel, using an elution gradient of ethyl
acetate:methanol:0.88 ammonia (100:0:0 to 90:10: 1), and then
triturated with pentane. .delta.(CDCl.sub.3): 1.03 (3H, t), 1.30
(3H, t), 1.50 (3H, d), 2.42 (2H, q), 2.55 (6H, m), 3.02 (2H, q),
3.15 (4H, m), 3.56 (4H, m), 3.66 (1H, m), 3.76 (1H, m), 5.62 (3H,
m), 6.78 (1H, d), 7.06 (1H, d), 7.49 (1H, m), 8.61 (1H, s), 8.90
(1H, s), 10.84 (1H, s). LRMS: m/z 611 (M+1).sup.+
EXAMPLE 144
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-o-
ne (isomer 1)
and
EXAMPLE 145
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-yl]-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d])pyrimidin-7--
one(isomer2)
[0371] 77
[0372] A mixture of the title compound of Example 84 (200 mg, 0.35
mmol) and potassium bis(trimethylsilyl)amide (350 mg, 1.76 mmol) in
2-methoxyethanol (5 ml) was stirred at 120.degree. C. for 18 hours.
The cooled mixture was concentrated under reduced pressure and the
residue partitioned between aqueous saturated sodium bicarbonate
solution (20 ml) and ethyl acetate (20 ml). The phases were
separated, the aqueous layer extracted with ethyl acetate
(2.times.10 ml), and the combined organic solutions dried
(MgSO.sub.4), and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel, using
an elution gradient of dichloromethane: methanol (100:0 to 95:5) to
give a foam. This racemate was further purified by HPLC using an
AD250 column and hexane: isopropanol:diethylamine (50:50:1) as
eluant to afford the title compound of Example 144 (24 mg, 11%,
100.0%ee) .delta.(CDCl.sub.3): 1.02 (3H, t), 1.25 (3H, t), 2.10
(3H, d), 2.40 (2H, q), 2.56 (4H, m), 3.00 (2H, q), 3.13 (4H, m),
3.58 (3H, s), 3.86 (2H, t). 4.77 (2H, t), 5.83 (1H, q), 7.18 (2H,
m), 7.60 (1H, m), 8.55 (1H, d), 8.60 (1H, s). 8.96 (1H, s), 10.82
(1H, s). LRMS: m/z 598 (M+1).sup.+and the title compound of Example
145 (28 mg. 13%, 99.8%ee). .delta.(CDCl.sub.3): 1.00 (3H, t), 1.24
(3H, t), 2,10 (3H, d), 2.40 (2H, q), 2.55 (4H, m), 3.00 (2H, q),
3.14 (4H, m), 3.57 (3H, s), 3.84 (2H, t), 4.78 (2H, t), 5.82 (1H,
q), 7.18 (2H, m), 7.60 (1H, m), 8.54 (1H, d), 8.60 (1H, s). 8.94
(1H, s), 10.82 (1H, s). LRMS: m/z 598 (M+1).sup.+
EXAMPLE 146
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyr-
idazin-3-yl)methyl-2,6-dihydro-7H-pyrazolo
[4,3-d]pyrimidin-7-one
[0373] 78
[0374] A suspension of the title compound of Preparation 142 (1.12
g, 4.55 mmol) and triethylamine (1.5 g, 13.7 mmol) was added to an
ice-cold suspension of the title compound of Preparation 28 (2.0 g,
5.0 mmol) in dichloromethane (25 ml), and the reaction stirred at
room temperature for 2 hours. The reaction mixture was washed with
brine (15 ml), saturated aqueous sodijm bicarbonate solution
(2.times.10 ml), more brine (15 ml), dried (MgSO.sub.4) and
evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel using an elution gradient of
dichloromethane:methanol:0.88 ammonia (99:0:1 to 96:3:1) to give a
solid (1.73 g).
[0375] A mixture of this intermediate (829 mg, 1.45 mmol) and
potassium bis(trimethylsilyl)amide (347 mg, 1.74 mmol) in
3-methyl-3-pentanol (3 ml) was heated under reflux for 6 hours, and
then stirred for 72 hours at room temperature. Additional potassium
bis(trimethylsilyl)amide (87 mg, 0.43 mmol) was added, the reaction
heated under reflux for a further 5 hours, then cooled, 2M
hydrochloric acid (2 ml) added and the mixture concentrated under
reduced pressure. The residue was partitioned between
dichloromethane (20 ml) and water (10 ml), the layers separated,
the organic phase washed consecutively with water (10 ml),
saturated sodium bicarbonate solution (10 ml), brine (10 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel using
an elution gradient of dichloromethane: methanol (100:0 to 98:2) to
afford the title compound (1.24 g, 49%) as a light brown foam.
.delta.(CDCl.sub.3) 1.02 (3H, t), 1.36 (3H, t), 1.59 (3H, t), 2.40
(2H, q), 2.55 (4H, m), 3.14 (6H, m), 4.76 (2H, q), 5.90 (2H, s),
7.46 (1H, m), 7.56 (1H, m), 8.63 (1H, s), 9.01 (1H, s), 9.18 (1H,
d), 10.70 (1H, s). LRMS: m/z 554 (M+1).sup.+
EXAMPLE 147
5-[2-n-Butoxy-5-(4-ethylpirerazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(p-
yridazin-3-yl)
methyl-2,6-dihydro-7H-pyrazolo[4.3-d]pyrimidin-7-one
[0376] 79
[0377] Potassium bis(trimethylsilyl)amide (35 mg, 0.176 mmol) was
added to a solution of the title compound of Example 146 (80 mg,
0.145 mmol) in n-butanol (2 ml), and the reaction stirred at
110.degree. C. for 61/2 hours. The cooled mixture was concentrated
under reduced pressure and the residue partitioned between ethyl
acetate (20 ml) and sodium bicarbonate solution (10 ml). The phases
were separated, the organic layer washed with additional sodium
bicarbonate solution (10 ml), brine (10 ml), dried (MgSO.sub.4) and
evaporated under reduced pressure. The crude product was purified
by column chromatography on silica gel using an elution gradient of
dichloromethane:methanol:0.88 ammonia (100:0:0 to 99.6:0.4:0.5) to
afford the title compound (50 mg, 59%) as a white foam.
.delta.(CDCl.sub.3) 1.04 (6H, m), 1.35 (3H, t), 1.58 (2H, m), 1.95
(2H, m), 2.41 (2H, q), 2.57 (4H, m), 3.10 (6H, m), 4.66 (2H, t),
5.90 (2H, s), 7.46 (1H, m), 7.56 (1H, m), 8.62 (1H, s), 9.01 (1H,
s), 9.17 (1H, d). 10.79 (1H, s). LRMS: m/z 582 (M+1).sup.+
EXAMPLE 148
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethylamino)pyrid-
in-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0378] 80
[0379] A mixture of the title compound of Example 78 (200 mg, 0.42
mmol), and copper (II) sulphate pentahydrate (150 mg, 0.60 mmol) in
2-methoxyethylamine (2 ml) was heated under reflux for 2 hours,
then cooled. The reaction was partitioned between dichloromethane
(20 ml) and aqueous sodium carbonate solution (5 ml), and the
layers separated. The organic phase was dried (Na.sub.2SO.sub.4)
and evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel using an elution gradient of
dichloromethane: methanol (98:2 to 95:5) to afford the title
compound (150 mg, 69%). .delta.(CDCl.sub.3): 1.04 (3H, t), 1.40
(3H, t), 2.42 (2H, q), 2.55 (4H, m), 2.92 (3H, s), 3.01 (2H, q),
3.13 (4H, m), 3.50 (4H, m), 3.48 (3H, s), 3.68 (2H, t), 3.88 (2H,
t), 4.07 (3H, s), 8.34 (1H, s). 8.58 (1H, s). LRMS: m/z 519
(M+1).sup.+
EXAMPLES 149 TO 153
The compounds of the general formula:
[0380] 81
[0381] were prepared from the appropriate
pyrazolo[4,3-d]pyrimidin-7-ones and amines, using procedures
similar to that described in Example 148.
4 Example R1 R13 Data 149 CH.sub.3 82 .delta. (CDCl.sub.3): 1.02
(3H, t), 1.37 (3H, t), 2.26-2.42 (4H, m), 2.54 (4H, m), 3.01 (2H,
q), 3.10 (4H, m), 4.05 (7H, m), 8.00 (1H, s), 8.57 (1H, s). LRMS:
m/z 487 (M + 1).sup.+ 150 CH.sub.3 83 .delta. (CDCl.sub.3): 1.02
(3H, t), 1.35 (3H, t), 1.89 (4H, m), 2.39 (2H, q), 2.55 (4H, m),
3.00 (2H, q), 3.11 (4H, m), 3.40 (4H, m), 4.08 (3H, s), 8.00 (1H,
s), 8.57 (1H, s). LRMS: m/z 501 (M + 1).sup.+ 151 CH.sub.2CH.sub.3
84 Found: C, 55.53; H, 6.70; N, 21.52.
C.sub.24H.sub.34N.sub.8O.sub.3S requires C, 56.01; H, 6.66: N,
21.77% .delta. (CDCl.sub.3): 1.03 (3H, t), 1.38 (3H, t), 1.60 (3H,
1), 1.88 (4H, m), 2.41 (2H, q), 2.57 # (4H, m), 3.01 (2H,q), 3.10
(4H, m), 3.42 (4H, m), 4.38 (2H, q), 8.00 (1H. s), 8.55 (1H, s),
9.20 (1H, s). LRMS: m/z 515 (M + 1).sup.+ 152 85 86 Found: C,
54.63; H, 6.15; N. 20.97. C.sub.27H.sub.35N.sub.9O.sub.4S requires
C, 54.89; H, 6.14: N, 21.34% .delta. (CDCl.sub.3): 1.01 (3H, t),
1.33 (3H, t), 2.35 (2H, q), 2.54 (4H, m), 3.07 (2H, q), 3.15 (4H,
m), # 3.41 (3H, s), 3.65 (2H, t), 3.85 (2H, q), 5.67 (2H, s), 7.19
(1H, d), 7.25 (1H, m), 7.68 (1H, m), 8.14 (1H, s), 8.56 (1H, s),
8.58 (1H, d), 9.92 (1H, s), 10.07 (1H, m). LRMS: m/z 582 (M +
1).sup.+ 153 87 88 .delta. (CDCl.sub.3): 1.03 (3H, t), 1.26 (3H.
t), 1.92 (4H, m), 2.41 (2H, q), 2.56 (4H, m), 3.02 (2H, q), 3.10
(4H, m), 3.42 (4H, m), 5.68 (2H, s), 7.19 (1H, d), 7.26 (1H, m),
7.67 (1H, m), 8.01 (1H, s), 8.58 (2H, m), 9.24 (1H, s). LRMS: m/z
578 (M + 1).sup.+
EXAMPLE 154
5-[2-(N-Cyclopropylmethyl-N-methylamino)-5-(4-ethylpiperazin-1-ylsulphonyl-
)
pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
-one
[0382] 89
[0383] A mixture of the title compound of Example 78 (200 mg, 0.42
mmol), and N-cyclopropylmethyl-N-methylamine (600 mg, 7.05 mmol;
obtained from the title compound of Preparation 168) and potassium
bis(trimethylsilyl)amide (250 mg, 1.26 mmol) in
N,N-dimethylformamide (2 ml), was stirred at 100.degree. C. for 18
hours. The cooled mixture was partitioned between ethyl acetate (20
ml) and aqueous sodium bicarbonate solution (10 ml), and the phases
separated. The organic layer was dried (MgSO.sub.4), and evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel using an elution gradient of
dichloromethane: methanol (100:0 to 95:5) to afford the title
compound (100 mg, 46%) as a solid. .delta.(CDCl.sub.3): 0.54 (2H,
m), 0.71 (2H, m), 1.02 (3H, t), 1.37 (4H, m), 2.40 (2H, q), 2.56
(4H, m), 2.78-3.13 (11H, m), 4.08 (3H, s), 8.32 (1H, s), 8.60 (1H,
s). LRMS: m/z 515 (M+1).sup.+
EXAMPLES 155 TO 156
The compounds of the general formula:
[0384] 90
[0385] were prepared from the title compound of Example 78 and the
appropriate amines. using procedures similar to that described in
Example 154.
5 Example R13 Data 155 91 .delta. (CDCl.sub.3): 1.01 (3H, t), 1.40
(3H, t), 1.58 (2H, m), 1.64 (2H, m), 1.77 (4H, m), 2.41 (2H, q),
2.55 (4H, m), 3.02 (2H, q), 3.12 (4H, m), 3.26 (2H, m), 4.10 (3H,
s), 8.55 (1H, s), 8.63 (1H, s), 10.63 (1H, s). LRMS: m/z 515 (M +
1).sup.+ 156 92 .delta. (CDCl.sub.3): 1.04 (3H, t), 1.40 (3H, t),
2.42 (2H, q), 2.58 (4H, m), 3.03 (2H, q), 3.16 (4H, m), 3.35 (4H,
m), 3.86 (4H, m), 4.10 (3H, s), 8.55 (1H, s), 8.68 (1H, s), 10.40
(1H, s). LRMS: m/z 517 (M + 1).sup.+
EXAMPLE 157
3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridin-3-yl]-
-2-(pyridin-2-yl) methyl-2.6-dihydro-7H-pyrazolo[4
3-d]pyrimidin-7-one
[0386] 93
[0387] A mixture of the title compound of Preparation 160 (226 mg,
0.39 mmol) and potassium t-butoxide (112 mg, 1.0 mmol) in
n-propanol (20 ml), was stirred under reflux for 5 days, then
cooled. Saturated ammonium chloride solution (5 ml) was added, this
solution poured into ethyl acetate (50 ml), and the layers
separated. The organic phase was washed with sodium bicarbonate
solution (20 ml), then brine (20 ml), dried (MgSO.sub.4) and
evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel. using an elution gradient of
dichloromethane: methanol (100:0 to 94:6) to give an oil. This was
crystallised from ether to afford the title compound (9 mg, 4%) as
a white solid. .delta.(CDCl.sub.3): 1.00 (3H, t), 1.18 (3H, t),
1.28 (3H, t), 1.70 (2H, m), 2.38 (2H, q), 2.50 (4H, m), 3.00 (2H,
q), 3.07 (4H, m), 3.57 (2H, q), 5.62 (2H, s), 7.19 (1H, m), 7.63
(1H, m), 8.02 (1H, s), 8.55 (2H, m), 9.60 (1H, s), 9.80 (1H, s).
LRMS: m/z 566 (M+1).sup.+
PREPARATION 1
2-Ethoxypyridine-3-carboxylic acid
[0388] A solution of potassium t-butoxide (44.9 g, 0.40 mol) in
absolute ethanol (300 ml) was added slowly to a solution of
2-chloronicotinic acid (30 g, 0.19 mol) in absolute ethanol (100
ml) and the reaction mixture heated in a sealed vessel at
170.degree. C. for 20 hours, then allowed to cool. The resulting
mixture was evaporated under reduced pressure, the residue
dissolved in water (200 ml) and the solution acidified to pH 3 with
hydrochloric acid and extracted with dichloromethane (4.times.200
ml). The combined extracts were dried (Na.sub.2SO.sub.4) and
evaporated under reduced pressure to give the title compound (27.4
g, 41%) as a white solid. .delta.(CDCl.sub.3): 1.53 (3H,t), 4.69
(2H,q), 7.13 (1H,m), 8.37 (1H,d), 8.48 (1H,d).
PREPARATION 2
2-(2-Methoxyethoxy)pyridine-3-carboxylic acid
[0389] Obtained as a brown solid (92%) from 2-chloronicotinic acid
and 2-methoxyethanol, using the procedure of Preparation 1. Found:
C, 54.89; H, 5.61; N, 7.03. C.sub.9H.sub.11NO.sub.4 requires C,
54.82; H, 5.62; N, 7.10%. .delta.(CDCl.sub.3): 3.45 (3H,s), 3.79
(2H,t), 4.74 (2H,t), 7.14 (1H,m), 8.36 (1H,d), 8.46 (1H,d). LRMS:
m/z 198 (M+1).sup.+.
PREPARATION 3
2-Ethoxypyridine-3-carboxylic acid ethyl ester
[0390] A suspension of the title compound of Preparation 1 (16.4 g,
98 mmol) and caesium carbonate (32 g, 98 mmol) in dimethylformamide
(240 ml) was stirred at room temperature for 2 hours. Ethyl iodide
(7.85 ml, 98 mmol) was added and the reaction mixture stirred for
24 hours, then evaporated under reduced pressure. The residue was
partitioned between aqueous sodium carbonate solution (100 ml) and
ethyl acetate (100 ml), the phases separated and the aqueous phase
extracted with ethyl acetate (2.times.100 ml). The combined organic
solutions were washed with brine, dried (Na.sub.2SO.sub.4) and
evaporated under reduced pressure to yield the title compound (18.0
g, 94%) as a pale yellow oil. .delta.(CDCl.sub.3): 1.41 (6H,m),
4.36 (2H,q), 4.48 (2H,q), 6.90 (1H,m), 8.12 (1H,d), 8.28
(1H,d).
PREPARATION 4
2-(2-Methoxyethoxy)pyridine-3-carboxylic acid ethyl ester
[0391] Obtained as a brown oil (98%) from the title compound of
Preparation 2, using the procedure of Preparation 3. Found: C,
58.36; H, 6.74; N, 6.04. C.sub.11H.sub.15NO.sub.4 requires C,
58.66; H, 6.71; N, 6.23%. .delta.(CDCl.sub.3): 1.37 (3H,t), 3.44
(3H,s), 3.78 (2H,t), 4.34 (2H,q), 4.56 (2H,t), 6.92 (1H,m), 8.13
(1H,d), 8.26 (1H,d). LRMS: m/z 226 (M+1).sup.+.
PREPARATION 5
2-Ethoxy-5-nitropyridine-3-carboxylic acid ethyl ester
[0392] Ammonium nitrate (5.36 g, 66 mmol) was added portionwise to
a stirred, ice-cooled solution of the title compound of Preparation
3 (4.66 g, 22.3 mmol) in trifluoroacetic anhydride (50 ml) and the
reaction mixture stirred for 18 hours at room temperature, then
carefully poured into stirred ice-water (200 g). The resulting
suspension was stirred for 1 hour, then the precipitate collected,
washed with water and dried under suction to provide the title
compound (3.29 g, 61%). .delta.(CDCl.sub.3): 1.41 (3H,t), 1.48
(3H,t), 4.41 (2H,q), 4.62 (2H,q), 8.89 (1H,s), 9.16 (1H,s).
PREPARATION 6
2-(2-Methoxyethoxy)-5-nitropyridine-3-carboxylic acid ethyl
ester
[0393] Ammonium nitrate (10.57 g, 131 mmol) was added portionwise
to a stirred, ice-cooled solution of the title compound of
Preparation 4 (14.80 g, 65.7 mmol) in trifluoroacetic anhydride
(150 ml) and the reaction mixture stirred for 3 hours at room
temperature, then carefully poured onto stirred ice (120 g). The
resulting solution was extracted with dichloromethane (3.times.150
ml), then the combined extracts dried (MgSO.sub.4) and evaporated
under reduced pressure. The residual orange oil was purified by
column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 97:3), to furnish the title
compound (11.49 g, 65%) as a white solid. Found: C, 48.78; H, 5.13;
N, 10.29. C.sub.11H.sub.14N.sub.2O.sub.6 requires C, 48.89; H,
5.22; N, 10.37%. .delta.(CDCl.sub.3): 1.42 (3H,t), 3.46 (3H,s),
3.83 (2H,t), 4.41 (2H,q), 4.70 (2H,t), 8.92 (1H,s), 9.16 (1H,s).
LRMS: m/z 271 (M+1).sup.+.
PREPARATION 7
5-Amino-2-ethoxypyridine-3-carboxylic acid ethyl ester
[0394] A stirred mixture of the title compound of Preparation 5
(5.3 g, 22 mmol), Raney nickel (2.50 g) and ethanol (150 ml) was
hydrogenated at 345 kPa (50 psi) and 50.degree. C. for 18 hours,
then allowed to cool and filtered. The filtrate was combined with
an ethanol wash (150 ml) of the filter pad and then evaporated
under reduced pressure. The residue was triturated with
dichloromethane and the resulting solid collected and dried to
afford the title compound (4.56 g, 98%) as a tan-coloured solid.
Found: C, 57.12; H, 6.79; N, 12.98. C.sub.10H.sub.14N.sub.2O.sub.3
requires C, 57.13; H, 6.71; N, 13.33%. .delta.(CDCl.sub.3): 1.39
(6H, 2xd), 3.41 (2H,s), 4.35 (4H,m), 7.55 (1H,s), 7.78 (1H,s).
LRMS: m/z 211 (M+1).sup.+.
PREPARATION 8
2-Ethoxy-5-nitropyridine-3-carboxylic acid
[0395] 5M Aqueous sodium hydroxide solution (4 ml, 20 mmol) was
added dropwise to a stirred solution of the title compound of
Preparation 5 (5.1 g, 20 mmol) in ethanol (100 ml) and the reaction
mixture stirred at room temperature for 18 hours, then evaporated
under reduced pressure. The residue was suspended in water (50 ml)
and the stirred suspension acidified to pH 3 with hydrochloric
acid. The resulting aqueous solution was extracted with ethyl
acetate (3.times.100 ml), then combined extracts washed with brine
(100 ml), dried (Na.sub.2SO.sub.4) and evaporated under reduced
pressure to afford a beige solid. The crude product was
crystallised from hexane-ethyl acetate to give the title compound
(3.32 g, 78%) as beige crystals. .delta.(CDCl.sub.3): 1.55 (3H,t),
4.78 (2H,q), 9.17 (1H,s), 9.23 (1H,s).
PREPARATION 9
2-(2-Methoxyethoxy)-5-nitropyridine-3-carboxylic acid
[0396] 1M Aqueous sodium hydroxide solution (40 ml, 40 mmol) was
added to a stirred, ice-cooled solution of the title compound of
Preparation 6 (4.0 g, 14.8 mmol) in 1,4-dioxan (40 ml) and the
reaction mixture stirred for 1.5 hours, then concentrated under
reduced pressure to half its volume and acidified with hydrochloric
acid to pH 3. The resulting suspension was extracted with
dichloromethane (3.times.50 ml), then the combined extracts dried
(MgSO.sub.4) and evaporated under reduced pressure to yield the
title compound (2.61 g, 73%) as a buff-coloured solid. Found: C,
44.11; H, 4.04; N, 11.46. C.sub.9H.sub.10N.sub.2O.sub.6 requires C,
44.63; H, 4.16; N, 11.57%. .delta.(CDCl.sub.3): 3.47 (3H,s), 3.83
(2H,t), 4.82 (2H,t), 9.15 (1H,s), 9.21 (1H,s). LRMS: m/z 243
(M+1).sup.+.
PREPARATION 10
2-Aminopyridine-5-sulphonic acid
[0397] 2-Aminopyridine (80 g, 0.85 mol) was added portionwise over
30 minutes to stirred oleum (320 g) and the resulting solution
heated at 140.degree. C. for 4 hours, then allowed to cool. The
reaction mixture was poured onto stirred ice (200 g) and this
mixture stirred at ice-salt bath temperature for a further 2
hours.
[0398] The resulting suspension was filtered, then the collected
solid washed successively with ice-water (200 ml) and cold
industrial methylated spirit (IMS) (200 ml) and, finally, dried
under suction to provide the title compound (111.3 g, 75%) as a
solid. LRMS: m/z 175 (M+1).sup.+.
PREPARATION 11
2-Amino-3-bromopyridine-5-sulphonic acid
[0399] Bromine (99 g, 0.62 mol) was added dropwise, over 1 hour, to
a stirred, hot solution of the title compound of Preparation 10
(108 g, 0.62 mol) in water (600 ml), at such a rate as to maintain
steady reflux. When the addition was complete, the reaction mixture
was allowed to cool and then filtered. The resulting solid was
washed with water and dried under suction to furnish the title
compound (53.4 g, 34%). .delta.(DMSOd.sub.6): 8.08 (1H,s), 8.14
(1H,s). LRMS: m/z 253 (M).sup.+.
PREPARATION 12
3-Bromo-2-chloropyridine-5-sulphonyl chloride
[0400] A solution of sodium nitrite (7.6 g, 110 mmol) in water (30
ml) was added dropwise to a stirred, ice-cooled solution of the
title compound of Preparation 11 (25.3 g, 100 mmol) in 20%
hydrochloric acid (115 ml), at such a rate as to maintain the
temperature below 6.degree. C. The reaction mixture was stirred for
30 minutes at 0.degree. C. for a further 1 hour at room
temperature, then evaporated under reduced pressure. The residue
was dried under vacuum at 70.degree. C. for 72 hours, then a
mixture of the resulting solid, phosphorus pentachloride (30 g, 144
mmol) and phosphorus oxychloride (1 ml) was heated at 125.degree.
C. for 3 hours and then allowed to cool. The reaction mixture was
poured onto stirred ice (100 g) and the resulting solid collected
and washed with water. The crude product was dissolved in
dichloromethane, then the solution dried (MgSO.sub.4) and
evaporated under reduced pressure to afford the title compound
(26.58 g, 91%) as a yellow solid. .delta.(CDCl.sub.3): 8.46 (1H,s),
8.92 (1H,s).
PREPARATION 13
3-Bromo-2-chloro-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine
[0401] A solution of 1-ethylpiperazine (11.3 ml, 89 mmol) and
triethylamine (12.5 ml, 89 mmol) in dichloromethane (150 ml) was
added dropwise to a stirred, ice-cooled solution of the title
compound of Preparation 12 (23 g, 79 mmol) in dichloromethane (150
ml) and the reaction mixture stirred at 0.degree. C. for 1 hour,
then evaporated under reduced pressure. The residual brown oil was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (99:1 to 97:3), to give the
title compound (14.5 g, 50%) as an orange solid.
.delta.(CDCl.sub.3): 1.05 (3H,t), 2.42 (2H,q), 2.55 (4H,m), 3.12
(4H,m), 8.24 (1H,s), 8.67 (1H,s).
PREPARATION 14
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine
[0402] A 0.5M solution of potassium bis(trimethylsilyl)amide in
toluene (8.1 ml, 4.07 mmol) was added to a stirred, ice-cooled
solution of 2-methoxyethanol (416 .mu.l, 5.4 mmol) in anhydrous
tetrahydrofuran (30 ml) and the resulting solution stirred at
0.degree. C. for 1 hour. Next, the title compound of Preparation 13
(1.0 g, 2.71 mmol) was added portionwise and the reaction mixture
stirred at room temperature for 2 hours, then diluted with ethyl
acetate (40 ml). The resulting mixture was washed with water (10
ml), dried (MgSO.sub.4) and evaporated under reduced pressure to
yield a yellow oil which was purified by column chromatography on
silica gel, using dichloromethane: methanol (97:3) as eluant, to
provide the title compound (1.02 g, 92%) as a colourless oil.
Found: C, 40.83; H, 5.32; N, 9.99.
C.sub.14H.sub.22BrN.sub.3O.sub.4S requires C, 41.18; H, 5.43; N,
10.29%. .delta.(CDCl.sub.3): 1.04 (3H,t), 2.42 (2H,q), 2.53 (4H,m),
3.07 (4H,m), 3.46 (3H,s), 3.78 (2H,t), 4.60 (2H,t), 8.10 (1H,s),
8.44 (1H,s). LRMS: m/z 408 (M).sup.+.
PREPARATION 15
3-Bromo-2-(2-ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine
[0403] Sodium metal (93 mg, 4 mmol) was added to a stirred solution
of 2-ethoxyethanol (537 .mu.l, 5.5 mmol) in anhydrous
tetrahydrofuran (5 ml). When the sodium had dissolved, the title
compound of Preparation 13 (1.0 g, 2.7 mmol) was added portionwise
and the reaction mixture stirred for 18 hours at room temperature,
then concentrated under reduced pressure. The residue was
partitioned between ethyl acetate (10 ml) and brine (10 ml), the
phases separated and the aqueous phase extracted with ethyl acetate
(2.times.10 ml). The combined organic solutions were washed with
brine, dried (MgSO.sub.4) and evaporated under reduced pressure,
then the residue purified by column chromatography on silica gel,
using an elution gradient of hexane: dichloromethane: methanol
(50:50:0 to 0:98:2), to furnish the title compound (985 mg, 86%) as
a yellow oil. .delta.(CDCl.sub.3): 1.03 (3H,t), 1.22 (3H,t), 2.40
(2H,q), 2.54 (4H,m), 3.07 (4H,m), 3.61 (2H,q), 3.82 (2H,t), 4.59
(2H,t), 8.10 (1H,s), 8.43 (1H,s). LRMS: m/z 423 (M+1).sup.+.
PREPARATION 16
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridine
[0404] Obtained as an oil (95%) from the title compound of
Preparation 13 and 3-methoxypropan-1-ol, using the procedure of
Preparation 15. .delta.(CDCl.sub.3): 1.04 (3H,t), 2.09 (2H,m), 2.42
(2H,q). 2.52 (4H,m), 3.08 (4H,m), 3.37 (3H,s), 3.57 (2H,t), 4.54
(2H,t), 8.09 (1H,s), 8.45 (1H,s). LRMS: m/z 423 (M+1).sup.+.
PREPARATION 17
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3S)-yloxy)py-
ridine
[0405] A mixture of a 2M solution of sodium
bis(trimethylsilyl)amide in tetrahydrofuran (1.83 ml, 3.66 mmol),
(S)-(+)-3-hydroxytetrahydrofuran (272 .mu.l, 6 mmol) and
tetrahydrofuran (40 ml) was stirred for 30 minutes at room
temperature. Next, the title compound of Preparation 13 (750 mg, 2
mmol) was added and the reaction mixture stirred for 18 hours, then
evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel, using an elution gradient of
hexane: ethyl acetate (25:75 to 0:100), to afford the title
compound (430 mg, 51%) as an oil. .delta.(CDCl.sub.3): 1.06 (3H,t),
2.20 (1H,m), 2.30 (1H,m), 2.42 (2H,q), 2.56, (4H,m), 3.08 (4H,m),
3.94 (2H,m), 4.02 (1H,m), 4.11 (1H,m), 5.62 (1H,m), 8.12 (1H,s),
8.44 (1H,s). LRMS: m/z 420 (M).sup.+.
PREPARATION 18
2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid ethyl ester
[0406] Sodium nitrite (2.22 g, 32.1 mmol) was added to a stirred
solution of the title compound of Preparation 7 (4.5 g, 21.4 mmol)
in a mixture of concentrated hydrochloric acid (90 ml) and glacial
acetic acid (90 ml) at -20.degree. C. and the resulting mixture
stirred for 2 hours, whilst allowing the temperature to rise to
0.degree. C. The mixture was cooled again to -20.degree. C., liquid
sulphur dioxide (50 ml) and a solution of copper(II) chloride (8.4
g, 62.5 mmol) in a mixture of water (9 ml) and acetic acid (80 ml)
added, then the reaction mixture stirred for 30 minutes at
0.degree. C., followed by a further 2 hours at room temperature.
The resulting mixture was poured onto stirred ice (80 g) and the
aqueous solution thus obtained was extracted with dichloromethane
(3.times.50 ml). The combined extracts were dried (MgSO.sub.4) and
evaporated under reduced pressure to give the crude sulphonyl
chloride as a brown oil.
[0407] 1-Ethylpiperazine (10.9 ml, 85.6 mmol) was added to a
stirred solution of the sulphonyl chloride in ethanol (60 ml) and
the reaction mixture stirred for 18 hours at room temperature, then
evaporated under reduced pressure. The residue was partitioned
between water (20 ml) and dichloromethane (30 ml), the separated
aqueous phase extracted with dichloromethane (2.times.30 ml), then
the combined organic solutions dried (MgSO.sub.4) and evaporated
under reduced pressure. The residual brown oil was purified by
column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 98:2), to yield the title
compound (5.0 g, 63%) as a pale brown oil. Found: C, 51.40; H,
6.77; N, 11.15. C.sub.16H.sub.25N.sub.3O.sub.5S requires C, 51.74;
H, 6.78; N, 11.31%. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.39 (3H,t),
1.45 (3H,t), 2.40 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 4.38 (2H,q),
4.55 (2H,q), 8.37 (1H,s), 8.62 (1H,s). LRMS: m/z 372
(M+1).sup.+.
PREPARATION 19
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxyli-
c acid ethyl ester
[0408] Triethylamine (3 ml, 19 mmol) and tetrakis
(triphenylphosphine) palladium (0) (260 mg, 0.22 mmol) were added
to a solution of the title compound of Preparation 14 (1.30 g, 3
mmol) in ethanol (15 ml) and the mixture heated under carbon
monoxide at 100.degree. C. and 1034 kPa (150 psi) in a sealed
vessel for 18 hours, then allowed to cool. The reaction mixture was
filtered and the filtrate evaporated under reduced pressure to
provide a yellow solid. The crude product was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 97.3), to furnish the title
compound (1.10 g, 92%) as a yellow oil. .delta.(CDCl.sub.3): 1.02
(3H,t), 1.38 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 3.08 (4H,m), 3.43
(3H,s), 3.80 (2H,t), 4.38 (2H,q), 4.63 (2H,t), 8.40 (1H,s), 8.61
(1H,s). LRMS: m/z 402 (M+1).sup.+.
PREPARATION 20
2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid ethyl ester
[0409] Obtained as a gum (96%) from the title compound of
Preparation 15, using the procedure of Preparation 19.
.delta.(CDCl.sub.3): 1.03 (3H,t), 1.22 (3H,t), 1.38 (3H,t), 2.40
(2H,q), 2.52 (4H,m), 3.08 (4H,m), 3.60 (2H,q), 3.83 (2H,t), 4.38
(2H,q), 4.62 (2H,t), 8.40 (1H,s), 8.62 (1H,s). LRMS: m/z 416
(M+1).sup.+.
PREPARATION 21
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)-pyridine-3-carb-
oxylic acid ethyl ester
[0410] A mixture of triethylamine (5 ml, 35.9 mmol), tetrakis
(triphenylphosphine) palladium (0) (200 mg, 0.17 mmol), the title
compound of Preparation 16 (1.08 g, 2.54 mmol) and ethanol (25 ml)
was heated under carbon monoxide at 100.degree. C. and 1034 kPa
(150 psi) in a sealed vessel for 18 hours, then allowed to cool.
The mixture was filtered and the filtrate evaporated under reduced
pressure. The residue was dissolved in ethyl acetate (40 ml) and
the solution washed consecutively with saturated aqueous sodium
bicarbonate solution (20 ml), brine (20 ml) and 2M hydrochloric
acid (5.times.10 ml). The combined acidic extracts were basified
using solid sodium bicarbonate and the solution extracted with
ethyl acetate (2.times.25 ml). The combined organic extracts were
dried (MgSO.sub.4) and evaporated under reduced pressure to afford
the title compound (640 mg, 68%) as an oil. .delta.(CDCl.sub.3):
1.05 (3H,t), 1.39 (3H,t), 2.09 (2H,m), 2.41 (2H,q), 2.54 (4H,m),
3.08 (4H,m), 3.36 (3H,s), 3.58 (2H,t), 4.39 (2H,q), 4.57 (2H,t),
8.40 (1H,s), 8.64 (1H,s). LRMS: m/z 416 (M+1).sup.+.
PREPARATION 22
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-yloxy)pyridine--
3-carboxylic acid ethyl ester
[0411] Obtained as a yellow oil (78%) from the title compound of
Preparation 17, using the procedure of Preparation 19.
.delta.(CDCl.sub.3): 1.05 (3H,t), 1.39 (3H,t), 2.20 (1H,m), 2.30
(1H,m), 2.42 (2H,q), 2.55 (4H,m), 3.09 (4H,m), 3.97 (3H,m), 4.14
(1H,m), 4.38 (2H,q), 5.70 (1H,m) 8.41 (1H,s), 8.62 (1H,s). LRMS:
m/z 414 (M+1).sup.+.
PREPARATION 23
2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid
[0412] A mixture of the title compound of Preparation 18 (4.96 g,
13.35 mmol), 2M aqueous sodium hydroxide solution (25 ml, 50 mmol)
and ethanol (25 ml) was stirred at room temperature for 2 hours.
The resulting mixture was concentrated under reduced pressure to
half its volume, washed with ether and acidified to pH 5 using 4M
hydrochloric acid. This aqueous solution was extracted with
dichloromethane (3.times.30 ml), then the combined extracts dried
(MgSO.sub.4) and evaporated under reduced pressure to give the
title compound (4.02 g, 88%) as a tan-coloured solid.
.delta.(DMSOd.sub.6): 1.18 (3H,t), 1.37 (3H,t), 3.08 (2H,q),
3.17-3.35 (8H,m), 4.52 (2H,q), 8.30 (1H,s), 8.70 (1H,s).
PREPARATION 24
2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid sodium salt
[0413] 1M Aqueous sodium hydroxide solution (85 ml, 85 mmol) was
added slowly to a stirred, ice-cooled solution of the title
compound of Preparation 18 (30.2 g, 85 mmol) in ethanol (300 ml)
and the reaction mixture stirred at room temperature for 18 hours.
The resulting mixture was evaporated under reduced pressure and the
residue partitioned between water (225 ml) and ethyl acetate (250
ml). The phases were separated, then the aqueous phase washed with
ethyl acetate (2.times.200 ml) and evaporated under reduced
pressure to yield the title compound (29.6 g, 81%) as a white
solid. .delta.(DMSOd.sub.6): 0.90 (3H,t), 1.25 (3H,t), 2.24 (2H,q),
2.40 (4H,m), 2.82 (4H,m), 4.39 (2H,q), 7.76 (1H,s), 8.28
(1H,s).
PREPARATION 25
4-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxyli-
c acid hydrochloride
[0414] A solution of the title compound of Preparation 19 (1.18 g,
2.94 mmol) in a mixture of ethanol (10 ml) and 1M aqueous sodium
hydroxide solution (10 ml, 10 mmol) was stirred for 1 hour at room
temperature. The resulting mixture was concentrated under reduced
pressure to half its volume and the residual aqueous solution
washed with ethyl acetate (10 ml), then acidified to pH 3 with
dilute hydrochloric acid. The acidic solution was extracted with
dichloromethane: methanol (95:5) (6.times.20 ml), then the combined
extracts dried (MgSO.sub.4) and evaporated under reduced pressure
to provide the title compound (995 mg, 82%) as a white foam.
.delta.(DMSOd.sub.6): 1.06 (3H,t), 2.28 (2H,q), 2.75-3.20 (8H,m),
3.28 (3H,s), 3.69 (2H,t), 4.56 (2H,t), 8.29 (1H,s), 8.68 (1H,s).
LRMS: m/z 374 (M+1).sup.+.
PREPARATION 26
2-(2-Ethoxyethoxy)-5-4-(ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid hydrochloride
[0415] A mixture of the title compound of Preparation 20 (859 mg,
2.07 mmol), 1M aqueous sodium hydroxide solution (4.6 ml, 4.6 mmol)
and 1,4-dioxan (5 ml) was stirred at room temperature for 2 hours.
The 1,4-dioxan was removed by evaporation under reduced pressure
and the pH of the remaining aqueous solution was adjusted to 3 with
hydrochloric acid. The resulting solution was evaporated under
reduced pressure, the residue triturated with hot ethanol and the
mixture filtered. The filtrate was then evaporated under reduced
pressure to furnish the title compound (760 mg, 87%) as a
tan-coloured solid. .delta.(DMSOd.sub.6): 1.08 (3H,t), 1.18 (3H,t),
2.98 (2H,m), 3.07 (4H,m), 3.37 (2H,m), 3.48 (2H,q), 3.72 (4H,m),
4.55 (2H,t), 8.30 (1H,s), 8.72 (1H,s). LRMS: m/z 387 (M).sup.+.
PREPARATION 27
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridine-3-carbo-
xylic acid hydrochloride
[0416] Obtained as a solid (87%) from the title compound of
Preparation 21, using the procedure of Preparation 26.
.delta.(DMSOd.sub.6): 1.17 (3H,t), 1.96 (2H,m), 3.08 (2H,q), 3.22
(3H,s), 3.33 (8H,m), 3.48 (2H,t), 4.48 (2H,t), 8.30 (1H,s), 8.73
(1H,s). LRMS: m/z 388 (M+1).sup.+.
PREPARATION 28
2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid chloride hydrochloride
[0417] Oxalyl chloride (0.77 ml, 8.85 mmol) was added dropwise to a
stirred, ice-cooled solution of the title compound of Preparation
23 (1.52 g, 4.42 mmol) and dimethylformamide (2 drops) in
dichloromethane (30 ml) and the reaction mixture stirred for 18
hours at room temperature, then evaporated under reduced pressure.
The residue was triturated with ethyl acetate and the resulting
solid collected, washed with ether and dried under suction to
afford the title compound (1.68 g, 95%). Found: C, 41.51; H, 5.27;
N, 10.32. C.sub.14H.sub.21Cl.sub.2N.sub.3- O.sub.4S; 0.10
CH.sub.2Cl.sub.2 requires C, 41.73; H, 5.02; N, 10.36%.
.delta.(CDCl.sub.3): 1.46 (6H,m), 2.95 (2H,q), 3.11 (2H,m), 3.48
(2H,m), 3.55 (2H,m), 3.92 (2H,m), 4.60 (2H,q), 8.58 (1H,s), 8.66
(1H,s), 13.16 (1H,s).
PREPARATION 29
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxyli-
c acid chloride hydrochloride
[0418] Oxalyl chloride (270 .mu.l, 3.13 mmol) was added dropwise to
a stirred, ice-cooled suspension of the title compound of
Preparation 25 (390 mg, 1.04 mmol), dimethylformamide (100 .mu.l)
and dry dichloromethane (20 ml), then the reaction mixture stirred
for 3 hours at room temperature. The resulting mixture was
evaporated under reduced pressure and the residue azeotroped with
toluene (2.times.20 ml) to give the title compound (390 mg, 95%) as
a white solid. .delta.(DMSOd.sub.6): 1.20 (3H,t), 2.92 (2H,q), 3.08
(4H,m), 3.30 (3H,s), 3.49 (2H,m), 3.70 (2H,t), 3.76 (2H,m), 4.58
(2H,t), 8.32 (1H,s), 8.72 (1H,s), 14.20 (1H,s).
PREPARATION 30
Ethyl 3-ethyl-1H-pyrazole-5-carboxylate
[0419] Ethanolic sodium ethoxide solution (21% w/w; 143 ml, 0.39
mol) was added dropwise to a stirred, ice-cooled solution of
diethyl oxalate (59.8 ml, 0.44 mol) in absolute ethanol (200 ml)
under nitrogen and the resulting solution stirred for 15 minutes.
Butan-2-one (39 ml, 0.44 mol) was then added dropwise, the cooling
bath removed, the reaction mixture stirred for 18 hours at room
temperature and then for 6 hours at 40.degree. C., then the cooling
bath reintroduced. Next, glacial acetic acid (25 ml, 0.44 mol) was
added dropwise, the resulting solution stirred for 30 minutes at
0.degree. C., hydrazine hydrate (20 ml, 0.44 mol) added dropwise,
then the reaction mixture allowed to warm to room temperature and
maintained there over a period of 18 hours, before being evaporated
under reduced pressure. The residue was partitioned between
dichloromethane (300 ml) and water (100 ml), then the organic phase
separated, washed with water (2.times.100 ml), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure to give
the title compound (66.0 g). .delta.(CDCl.sub.3): 1.04 (3H,t), 1.16
(3H,t), 2.70 (2H,q), 4.36 (2H,q), 6.60 (1H,s). LRMS: m/z 169
(M+1).sup.+.
PREPARATION 31
3-Ethyl-1H-pyrazole-5-carboxylic acid
[0420] Aqueous sodium hydroxide solution (10M; 100 ml, 1.0 mol) was
added dropwise to a stirred suspension of the title compound of
Preparation 30 (66.0 g, 0.39 mol) in methanol (400 ml) and the
resulting solution heated under reflux for 4 hours. The cool
reaction mixture was concentrated under reduced pressure to ca. 200
ml, diluted with water (200 ml) and this mixture washed with
toluene (3.times.100 ml). The resulting aqueous phase was acidified
with concentrated hydrochloric acid to pH 4 and the white
precipitate collected and dried by suction to provide the title
compound (34.1 g). .delta.(DMSOd.sub.6): 1.13 (3H,t), 2.56 (2H,q),
6.42 (1H,s).
PREPARATION 32
4-Nitro-3-n-propyl-1H-pyrazole-5-carboxylic acid
[0421] Fuming sulphuric acid (17.8 ml) was added dropwise to
stirred, ice-cooled fuming nitric acid (16.0 ml), the resulting
solution heated to 50.degree. C., then
3-n-propyl-1H-pyrazole-5-carboxylic acid (Chem. Pharm. Bull., 1984,
32, 1568; 16.4 g, 0.106 mol) added portionwise over 30 minutes
whilst maintaining the reaction temperature below 60.degree. C. The
resulting solution was heated for 18 hours at 60.degree. C.,
allowed to cool, then poured onto ice. The white precipitate was
collected, washed with water and dried by suction to yield the
title compound (15.4 g), m.p. 170-172.degree. C. Found: C, 42.35;
H, 4.56; N, 21.07. C.sub.7H.sub.9N.sub.3O.sub.4 requires C, 42.21;
H, 4.55; N, 21.10%. .delta.(DMSOd.sub.6): 0.90 (3H,t), 1.64 (2H,m),
2.83 (2H,m), 14.00 (1H,s).
PREPARATION 33
3-Ethyl-4-nitro-1H-pyrazole-5-carboxylic acid
[0422] Obtained from the title compound of Preparation 31, by
analogy with Preparation 32, as a brown solid (64%).
.delta.(DMSOd.sub.6): 1.18 (3H,t), 2.84 (2H,m), 13.72 (1H,s).
PREPARATION 34
4-Nitro-3-n-propyl-1H-pyrazole-5-carboxamide
[0423] A solution of the title compound of Preparation 32 (15.4 g,
0.077 mol) in thionyl chloride (75 ml) was heated under reflux for
3 hours and then the cool reaction mixture evaporated under reduced
pressure. The residue was azeotroped with tetrahydrofuran
(2.times.50 ml) and subsequently suspended in tetrahydrofuran (50
ml), then the stirred suspension ice-cooled and treated with
gaseous ammonia for 1 hour. Water (50 ml) was added and the
resulting mixture evaporated under reduced pressure to give a solid
which, after trituration with water and drying by suction,
furnished the title compound (14.3 g), m.p. 197-199.degree. C.
Found: C, 42.35; H, 5.07; N, 28.38. C.sub.7H.sub.10N.sub.4O.sub.3
requires C, 42.42; H, 5.09; N, 28.27%. .delta.(DMSOd.sub.6): 0.90
(3H,t), 1.68 (2H,m), 2.86 (2H,t), 7.68 (1H,s), 8.00 (1H,s).
PREPARATION 35
3-Ethyl-4-nitro-1H-pyrazole-5-carboxamide
[0424] Obtained from the title compound of Preparation 33, by
analogy with Preparation 34, as a white solid (90%).
.delta.(DMSOd.sub.6): 1.17 (3H,t), 2.87 (2H,m), 7.40 (1H,s), 7.60
(1H,s), 7.90 (1H,s). LRMS: m/z 185 (M+1).sup.+.
PREPARATION 36
4-Amino-3-n-propyl-1H-pyrazole-5-carboxamide
[0425] A stirred mixture of the title compound of Preparation 34
(10.0 g, 0.050 mol), 10% palladium on charcoal (1.5 g) and ethanol
(400 ml) was hydrogenated for 18 hours at 345 kPa (50 psi) and
50.degree. C., then filtered. The filtrate was combined with an
ethanol wash (200 ml) of the filter pad and then evaporated under
reduced pressure to give an orange solid which, on crystallisation
from ethyl acetate-methanol, afforded the title compound (6.8 g) as
a white solid, m.p. 196-201.degree. C. Found: C, 48.96; H, 6.98; N,
32.08. C.sub.7H.sub.12N.sub.4O; 0.25 H.sub.2O requires C, 48.68; H,
7.30; N, 32.44%. .delta.(DMSOd.sub.6): 0.88 (3H,t), 1.55 (2H,m),
2.46 (2H,t), 4.40 (2H,s), 7.00 (1H,s), 7.12 (1H,s), 12.20
(1H,s).
PREPARATION 37
4-Amino-3-ethyl-1H-pyrazole-5-carboxamide
[0426] Obtained from the title compound of Preparation 35, by
analogy with Preparation 36, as a brown solid (80%).
.delta.(DMSOd.sub.6): 1.08 (3H,t), 2.45 (2H,q), 4.50 (1H,s), 6.88
(1H,s), 7.10 (1H,s), 7.26 (2H,s). LRMS: m/z 155 (M+1).sup.+.
PREPARATION 38a
3-Ethyl-4-nitro-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
and
PREPARATION 38b
3-Ethyl-4-nitro-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0427] A mixture of the title compound of Preparation 35 (20.0 g,
109 mmol), 2-(chloromethyl)pyridine hydrochloride (17.9 g, 109
mmol), caesium carbonate (74.7 g, 222 mmol) and dimethylformamide
(120 ml) was stirred for 18 hours at room temperature, then
evaporated under reduced pressure. The residue was partitioned
between water (100 ml) and dichloromethane (100 ml) and the phases
separated. The aqueous layer was extracted with dichloromethane
(3.times.100 ml) and the combined extracts dried (MgSO.sub.4) and
evaporated under reduced pressure. The residue was crystallised
from dichloromethane-methanol to yield the first title compound
(1-isomer; 6.5 g, 21%). .delta.(CDCl.sub.3): 1.24 (3H,t), 2.90
(2H,q), 5.54 (2H,s), 6.03 (1H,s), 7.27 (1H,m), 7.36 (1H,d), 7.76
(1H,m), 8.52 (1H,d), 8.58 (1H,s).
[0428] The mother liquor was evaporated under reduced pressure and
the residue purified by column chromatography on silica gel, using
an elution gradient of dichloromethane: methanol (100:0 to 95:5),
to provide the second title compound (2-isomer; 17.36 g, 58%) as a
white solid. .delta.(CDCl.sub.3): 1.16 (3H,t), 3.06 (2H,q), 5.48
(2H,s), 5.88 (1H,s), 7.19 (1H,d), 7.27 (1H,m), 7.70 (1H,m), 8.57
(1H,d).
PREPARATION 39a
4-Nitro-3-n-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
and
PREPARATION 39b
4-Nitro-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0429] 2-(Chloromethyl)pyridine hydrochloride (24.6 g, 150 mmol)
was added portionwise to a stirred solution of the title compound
of Preparation 34 (30.0 g, 150 mmol) and caesium carbonate (123.5
g, 380 mmol) in dimethylformamide (300 ml) and the reaction mixture
stirred at room temperature for 18 hours, then evaporated under
reduced pressure. The residue was suspended in water and the
resulting solid collected and dried under suction. The crude
product was purified by two column chromatographic operations on
silica gel, respectively using dichloromethane: methanol (98:2) and
ethyl acetate: pentane (20:80) as eluants, to furnish the first
title compound (1-isomer; 424 mg, 1%) as a white solid. Found: C,
53.74; H, 5.20; N, 23.91. C.sub.13H.sub.15N.sub.5O- .sub.3 requires
C, 53.97; H, 5.23; N, 24.21%. .delta.(CDCl.sub.3): 0.94 (3H,t),
1.68 (2H,m), 2.86 (2H,t), 5.55 (2H,s), 6.07 (1H,s), 7.35 (1H,d),
7.75 (1H,m), 8.51 (1H,d), 8.56 (1H,s). LRMS: m/z 290 (M+1).sup.+;
and the second title compound (2-isomer; 16.7 g, 38%) as a white
solid. .delta.(DMSOd.sub.6): 0.84 (3H,t), 1.46 (2H,m), 2.95 (2H,t),
5.49 (2H,s), 7.31 (2H,m), 7.60 (1H,s), 7.79 (1H,m), 7.90 (1H,s),
8.49 (1H,d).
PREPARATION 40
4-Amino-3-ethyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0430] A stirred mixture of the title compound of Preparation 38b
(16.36 g, 59 mmol), 10% palladium on charcoal (4 g) and ethanol
(150 ml) was hydrogenated at 345 kPa (50 psi) for 4 hours, then
filtered. The filtrate was combined with an ethyl acetate wash (150
ml) of the filter pad and then concentrated under reduced pressure
to a volume of ca. 70 ml. The resulting precipitate was collected
and dried under suction to afford the title compound (12.6 g, 87%)
as a white solid. .delta.(CDCl.sub.3): 1.03 (3H,t), 2.53 (2H,q),
4.00 (2H,s), 5.22 (1H,s), 5.36 (2H,s), 6.60 (1H,s), 6.81 (1H,d),
7.20 (1H,m), 7.62 (1H,m), 8.57 (1H,d). LRMS: m/z 246
(M+1).sup.+.
PREPARATION 41
4-Amino-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0431] A stirred mixture of the title compound of Preparation 39b
(1.0 g, 3.46 mmol), Raney nickel (1 g) and ethanol (50 ml) was
hydrogenated at 345 kPa (50 psi) and 50.degree. C. for 18 hours,
then allowed to cool and filtered. The filtrate was combined with
an ethanol wash (50 ml) of the filter pad and then evaporated under
reduced pressure to give the title compound (830 mg, 93%) as a
crystalline solid. .delta.(DMSOd.sub.6): 0.79 (3H,t), 1.33 (2H,m),
3.28 (2H,t), 4.60 (2H,s), 5.30 (2H,s), 6.88 (1H,d), 6.98 (1H,s),
7.13 (1H,s), 7.30 (1H,m), 7.74 (1H,m), 8.50 (1H,d). LRMS: m/z 274
(M).sup.+.
PREPARATION 42
4-Amino-3-ethyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0432] Obtained as a solid (94%) from the title compound of
Preparation 38a, using the procedure of Preparation 40.
.delta.(CDCl.sub.3): 1.20 (3H,t), 2.52 (2H,q), 3.72 (2H,s), 5.50
(2H,s), 7.21 (1H,m), 7.34 (1H,d), 7.68 (1H,m), 8.49 (1H,d). LRMS:
m/z 246 (M+1).sup.+.
PREPARATION 43
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-1H-pyrazole-5-carboxamide hydrochloride
[0433] A mixture of the title compound of Preparation 28 (1.0 g,
2.51 mmol), Preparation 37 (387 mg, 2.51 mmol) and pyridine (15 ml)
was stirred at room temperature for 18 hours. The resulting mixture
was evaporated under reduced pressure and the residue triturated
with ether to yield the title compound (1.05 g, 87%) as a purple
solid. Found: C, 44.82; H, 5.72; N, 18.62.
C.sub.20H.sub.29N.sub.7O.sub.5S; HCl; H.sub.2O requires C, 44.98;
H, 6.04; N, 18.36%. .delta.(DMSOd.sub.6): 1.17 (6H,m), 1.46 (3H,t),
2.77 (2H,q), 3.09 (2H,q), 3.49 (4H.m), 3.78 (4H,m), 4.68 (2H,q),
7.30 (1H,s), 7.49 (1H,s), 8.52 (1H,s), 8.76 (1H,s), 10.54 (1H,s).
LRMS: m/z 480 (M+1).sup.+.
PREPARATION 44
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0434] Potassium t-butoxide (943 g, 8.41 mmol) was added to a
stirred suspension of the title compound of Preparation 43 (1.10 g,
2.1 mmol) in absolute ethanol (50 ml) and the reaction mixture
heated in a sealed vessel at 100.degree. C. for 18 hours, then
allowed to cool. The resulting mixture was evaporated under reduced
pressure and the residue dissolved in water (15 ml). The aqueous
solution was acidified to pH 6 using hydrochloric acid and the
resulting solid collected, washed with water and dried under
suction. The crude product was purified by column chromatography on
silica gel, using dichloromethane: methanol (97:3) as eluant, to
provide the title compound (445 mg, 46%) as a yellow solid. Found:
C, 51.95; H, 5.89; N, 20.87. C.sub.20H.sub.27N.sub.7O.sub.4S
requires C, 52.05; H, 5.90; N, 21.24%. .delta.(DMSOd.sub.6): 0.92
(3H,t), 1.30 (6H,m), 2.30 (2H.q), 2.42 (4H,m), 2.86 (2H,q), 2.95
(4H,m), 4.49 (2H.q), 8.20 (1H,s), 8.64 (1H,s), 12.19 (1H,s), 13.80
(1H,s). LRMS: m/z 462 (M+1).sup.+.
PREPARATION 45
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0435] Alternative A
[0436] A mixture of the title compounds of Preparation 28 (1.0 g,
2.5 mmol), Preparation 40 (620 mg, 2.5 mmol), triethylamine (1.35
ml, 10 mmol) and dichloromethane (50 ml) was stirred at room
temperature for 18 hours. The resulting mixture was poured into
stirred water (50 ml), the phases separated and the aqueous phase
extracted with dichloromethane (2.times.50 ml). The combined
organic solutions were dried (MgSO.sub.4) and evaporated under
reduced pressure, then the residue purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 95:5), to furnish the title
compound (1.29 g, 90%) as a foam. .delta.(CDCl.sub.3): 1.00 (6H,m),
1.55 (3H,t), 2.37 (2H,q), 2.50 (4H,m), 2.87 (2H,q), 3.08 (4H,m),
4.77 (2H,q), 5.28 (1H,s), 5.45 (2H,s), 6.68 (1H,s), 6.90 (1H,d),
7.18 (1H,m), 7.61 (1H,m), 8.57 (1H,d), 8.62 (1H.s), 8.80 (1H,s),
10.57 (1H,s).
[0437] Alternative B
[0438] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(17.6 g, 91.8 mmol) was added portionwise over 5 minutes to a
stirred, ice-cooled suspension of 1-hydroxybenzotriazole hydrate
(12 g, 88.9 mmol) and the title compound of Preparation 24 (24 g,
65.7 mmol) in tetrahydrofuran (300 ml), then the mixture stirred
for 1 hour. N-Ethyidiisopropylamine (12.7 g, 98.3 mmol) and the
title compound of Preparation 40 (12.9 g, 52.6 mmol) were added and
the reaction mixture stirred at room temperature for 14 hours, then
evaporated under reduced pressure. The residue was partitioned
between water (100 ml) and ethyl acetate (200 ml), the phases
separated and the organic phase washed consecutively with water (50
ml), saturated aqueous sodium bicarbonate solution (50 ml) and
brine (50 ml), then dried (MgSO.sub.4) and concentrated under
reduced pressure to a low volume. The resulting suspension was
cooled in ice for 1 hour, then the precipitate collected and dried
under suction to afford the title compound (14.1 g, 47%) as a white
crystalline solid, m.p. 185-187.degree. C. Found: C, 54.59; H,
6.05; N, 19.32. C.sub.26H.sub.34N.sub.8O.sub.3S requires C, 54.72;
H, 6.00; N, 19.63%.
PREPARATION 46
2-n-Propoxypyridine-3-carboxylic acid
[0439] Obtained as a pale brown oil (50%) from 2-chloronicotinic
acid and n-propanol, using the procedure of Preparation 1.
.delta.(CDCl.sub.3): 1.08 (3H,t), 1.92 (2H,m), 4.56 (2H,t), 7.10
(1H,m), 8.35 (1H,d), 8.45 (1H,d).
PREPARATION 47
2-n-Propoxypyridine-3-carboxylic acid methyl ester
[0440] Diethyl azodicarboxylate (2.2 ml, 14 mmol) was added
dropwise to a stirred solution of the title compound of Preparation
46 (2.30 g, 12.7 mmol), triphenylphosphine (3.67 g, 14 mmol) and
methanol (0.60 ml, 15 mmol) in tetrahydrofuran (20 ml) and the
reaction mixture stirred for 18 hours at room temperature, then
evaporated under reduced pressure. The residue was triturated with
pentane: ether (80:20) and the mixture filtered. The filtrate was
evaporated under reduced pressure and the residue purified by
column chromatography on silica gel, using pentane: ether (50:50)
as eluant, to give the title compound (2.2 g, 89%) as a pale yellow
oil. .delta.(CDCl.sub.3): 1.07 (3H,t), 1.86 (2H,m), 3.92 (3H,s),
4.38 (2H,t), 6.93 (1H,m), 8.15 (1H,d), 8.30 (1H,d).
PREPARATION 48
5-Nitro-2-n-propoxypyridine-3-carboxylic acid methyl ester
[0441] Obtained as pale yellow needles (32%), after crystallisation
from methanol, from the title compound of Preparation 47, using the
procedure of Preparation 5. .delta.(CDCl.sub.3): 1.04 (3H,t), 1.84
(2H,m), 3.92 (3H,s), 4.48 (2H,t), 8.88 (1H,s), 9.14 (1H,s).
PREPARATION 49
5-Amino-2-n-propoxypyridine-3-carboxylic acid methyl ester
[0442] A mixture of the title compound of Preparation 48 (1.8 g,
7.46 mmol), Raney nickel (500 mg) and methanol (50 ml) was
hydrogenated at 345 kPa (50 psi) and 50.degree. C. for 3 hours,
then allowed to cool and filtered. The filtrate was combined with a
methanol wash (100 ml) of the filter pad and then evaporated under
reduced pressure to yield the title compound (1.5 g, 95%) as a
brown oil. .delta.(CDCl.sub.3): 1.04 (3H,t), 1.80 (2H,m), 3.40
(2H,s), 3.89 (3H,s), 4.28 (2H,t), 7.57 (1H,s), 7.80 (1H,s). LRMS:
m/z 211 (M+1).sup.+.
PREPARATION 50
5-(4-Methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridine-3-carboxylic
acid methyl ester
[0443] Obtained as an oil (56%) from the title compound of
Preparation 49 and 1-methylpiperazine, using the procedure of
Preparation 18.
PREPARATION 51
5-(4-Methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridine-3-carboxyIic
acid
[0444] Obtained as a white solid (82%) from the title compound of
Preparation 50, using the procedure of Preparation 23.
.delta.(DMSOd.sub.6): 0.97 (3H,t), 1.74 (2H,m), 2.15 (3H,s), 2.38
(4H,m), 2.93 (4H,m), 4.37 (2H,t), 8.15 (1H,s), 8.56 (1H,s).
PREPARATION 52
3-Ethyl-4-[5-(4-methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-ylcarb-
oxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0445] Oxalyl chloride (550 .mu.l , 6.37 mmol), followed by
dimethylformamide (2 drops), were added carefully to a stirred,
ice-cooled suspension of the title compound of Preparation 51 (605
mg, 1.59 mmol) in dichloromethane (10 ml) and the reaction mixture
stirred at room temperature for 2 hours, then evaporated under
reduced pressure. The residue was azeotroped with toluene to
produce a powder.
[0446] A solution of crude acid chloride in dichloromethane (10 ml)
was added dropwise to a stirred, ice-cooled suspension of the title
compound of Preparation 40 (430 mg, 1.76 mmol), triethylamine (558
.mu.l, 4 mmol) and dichloromethane (10 ml) and the reaction mixture
stirred at room temperature for 1.5 hours. The resulting mixture
was washed successively with saturated aqueous sodium bicarbonate
solution and brine, then the organic phase dried (MgSO.sub.4) and
evaporated under reduced pressure. The crude product was purified
by column chromatography on silica gel, using an elution gradient
of hexane: ethyl acetate: methanol (70:30:0 to 0:90:10), to provide
the title compound (695 mg, 76%) as a solid. Found: C, 53.96; H,
6.09; N, 19.00. C.sub.26H.sub.34N.sub.8O.sub.5S requires C, 54.22;
H, 6.00; N, 19.64%. .delta.(CDCl.sub.3): 1.07 (6H,m), 2.01 (2H,m),
2.26 (3H,s), 2.48 (4H,m), 2.88 (2H,q), 3.10 (4H,m), 4.67 (2H,t),
5.34 (1H,s), 5.48 (2H,s), 6.70 (1H,s), 6.94 (1H,d), 7.22 (1H,m),
7.66 (1H,m), 8.59 (1H,d), 8.65 (1H,s), 8.82 (1H,s), 10.48 (1H,s).
LRMS: m/z 572 (M+2).sup.+.
PREPARATION 53
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarbo-
xamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0447] Obtained as a white foam (70%) from the title compounds of
Preparation 29 and Preparation 41, using the procedure of
Preparation 45A. .delta.(CDCl.sub.3): 0.81 (3H,t), 1.02 (3H,t),
1.46 (2H,m), 2.39 (2H,q), 2.51 (4H,m), 2.82 (2H,t), 3.10 (4H,m),
3.39 (3H,s), 3.94 (2H,t), 4.85 (2H,t), 5.30 (1H,s), 5.46 (2H,s),
6.69 (1H,s), 6.90 (1H,d), 7.21 (1H,m), 7.65 (1H,m), 8.60 (1H,d),
8.65 (1H,s), 8.82 (1H,s), 10.46 (1H,s). LRMS: m/z 615
(M+1).sup.+.
PREPARATION 54
4-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarbox-
amido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0448] Obtained as a foam (69%) from the title compounds of
Preparation 26 and Preparation 41, using the procedure of
Preparation 52. Found: C, 55.13; H, 6.45; N, 17.27.
C.sub.29H.sub.40N.sub.8O.sub.6S requires C, 55.39; H, 6.41; N,
17.82%. .delta.(CDCl.sub.3): 0.80 (3H,t), 1.02 (3H,t), 1.10 (3H,t),
1.45 (2H,m), 2.40 (2H,q), 2.50 (4H,m), 2.81 (2H,t), 3.09 (4H,m),
3.54 (2H,q), 3.98 (2H,t), 4.80 (2H,t), 5.30 (1H,s), 5.47 (2H,s),
6.70 (1H,s), 6.89 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.59 (1H,d),
8.65 (1H,s), 8.82 (1H,s), 10.45 (1H,s). LRMS: m/z 629
(M+1).sup.+.
PREPARATION 55
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridin-3-
ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0449] Obtained as a foam (52%) from the title compounds of
Preparation 27 and Preparation 41, using the procedure of
Preparation 52. .delta.(CDCl.sub.3): 0.82 (3H,t), 1.02 (3H,t), 1.44
(2H,m), 2.25 (2H,m), 2.40 (2H,q), 2.53 (4H,m), 2.84 (2H,t), 3.10
(4H,m), 3.29 (3H,s), 3.57 (2H,t), 4.79 (2H,t), 5.34 (1H,s), 5.47
(2H,s), 6.70 (1H,s), 6.92 (1H,d), 7.22 (1H,m), 7.66 (1H,m), 8.59
(1H,d), 8.65 (1H,s), 8.81 (1H,s), 10.45 (1H,s). LRMS: m/z 629
(M+1).sup.+.
PREPARATION 56
3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-ylox-
y)pyridin-3-ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0450] A solution of the title compound of Preparation 22 (330 mg,
0.80 mmol) and 1M aqueous sodium hydroxide solution (800 .mu.l,
0.80 mmol) in ethanol (3 ml) was stirred for 3 hours at room
temperature, then evaporated under reduced pressure.
[0451] A mixture of the resulting solid, the title compound of
Preparation 40 (196 mg, 0.80 mmol), 1-hydroxybenzotriazole hydrate
(135 mg, 0.88 mmol), N-ethyldiisopropylamine (307 .mu.l, 1.76
mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(169 mg, 0.88 mmol) and tetrahydrofuran (15 ml) was stirred for 72
hours at room temperature, then evaporated under reduced pressure.
The residue was partitioned between ethyl acetate (50 ml) and water
(15 ml), the phases separated and tvhe organic phase dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel, using
an elution gradient of dichloromethane: methanol (95:5 to 90:10),
to furnish the title compound (382 mg, 78%) as a foam.
.delta.(CDCl.sub.3): 1.05 (6H,m), 2.40 (3H,m), 2.54 (5H,m), 2.85
(2H,q), 3.11 (4H,m), 3.54 (1H,m), 4.15 (3H,m), 5.31 (1H,s), 5.48
(2H,s), 5.90 (1H,m), 6.69 (1H,s), 6.94 (1H,d), 7.24 (1H,m), 7.67
(1H,m), 8.60 (1H,m), 8.66 (1H,s), 8.87 (1H,s), 10.27 (1H,s). LRMS:
m/z 613 (M+1).sup.+.
PREPARATION 57
4-(2-Ethoxy-5-nitropyridin-3-ylcarboxamido)-3-n-propyl-2-(pyridin-2-yl)met-
hylpyrazole-5-carboxamide
[0452] Oxalyl chloride (2.73 ml, 31 mmol) was added dropwise to a
stirred suspension of the title compound of Preparation 8 (3.31 g,
15.7 mmol) in dichloromethane (50 ml), followed by
dimethylformamide (2 drops), and the reaction mixture stirred at
room temperature for 3 hours. The resulting mixture was evaporated
under reduced pressure and the residue azeotroped with hexane to
give a white solid.
[0453] A solution of the crude acid chloride in dichloromethane (20
ml) was added dropwise to a stirred suspension of the title
compound of Preparation 41 (4.06 g, 15.7 mmol), triethylamine (4.37
ml, 31 mmol) and dichloromethane (80 ml) and the reaction mixture
stirred at room temperature for 20 hours. The resulting mixture was
evaporated under reduced pressure and the residue partitioned
between saturated aqueous sodium bicarbonate solution (200 ml) and
dichloromethane (300 ml). The phases were separated, and the
aqueous phase extracted with dichloromethane (2.times.300 ml). The
combined organic solutions were washed with brine, dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure to give a
purple solid. The crude product was triturated with ether and the
resulting solid collected and dried under suction to afford the
title compound (6.26 g, 88%) as an off-white solid. Found: C,
55.42; H, 5.05: N, 21.49. C.sub.21H.sub.23N.sub.7O.sub.5 requires
C, 55.62; H, 5.11; N, 21.62%. .delta.(CDCl.sub.3): 0.83 (3H,t),
1.46 (2H,m), 1.60 (3H,t), 2.89 (2H,t), 4.85 (2H,q), 5.32 (1H,s),
5.48 (2H,s), 6.72 (1H,s), 6.95 (1H,d), 7.24 (1H,m), 7.67 (1H,m),
8.60 (1H,d), 9.16 (1H,s), 9.30 (1H,s), 10.59 (1H,s). LRMS: m/z 454
(M+1).sup.+.
PREPARATION 58
3-Ethyl-4-[2-(2-methoxyethoxy)-5-nitropyridin-3-ylcarboxamido]-2-(pyridin--
2-yl) methylpyrazole-5-carboxamide
[0454] 1-Hydroxybenzotriazole hydrate (1.87 g, 12.2 mmol), N-ethyl
diisopropyl amine (2.13 ml, 12.2 mmol),
1-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (2.34
g, 12.2 mmol) and the title compound of Preparation 40 (3.0 g, 12.2
mmol) were added, in turn, to a stirred, ice-cooled suspension of
the title compound of Preparation 9 (2.96 g, 12.2 mmol) in
dichloromethane (80 ml) and the reaction mixture stirred for 18
hours at room temperature. The resulting mixture was washed
consecutively with water (25 ml), 2M hydrochloric acid (2.times.25
ml), saturated aqueous sodium bicarbonate solution (25 ml) and
brine (25 ml), then dried (MgSO.sub.4) and evaporated under reduced
pressure. The residual solid was purified by column chromatography
on silica gel, using an elution gradient of dichloromethane:
methanol (99:1 to 97:3) to give the title compound (3.36, 58%) as a
white solid. Found: C, 53.41; H, 4.90; N, 20.65.
C.sub.21H.sub.23N.sub.7O.sub.6 requires C, 53.72; H, 4.94; N,
20.89%. .delta.(CDCl.sub.3): 1.08 (3H,t), 2.88 (2H,q), 3.40 (3H,s),
3.98 (2H,t), 4.90 (2H,t), 5.28 (1H,s). 5.48 (2H,s), 6.70 (1H,s),
6.92 (1H,d), 7.23 (1H,m), 7.66 (1H,m), 8.60 (1H,d), 9.15 (1H,s),
9.31 (1H,s), 10.50 (1H,s). LRMS: m/z 470 (M+1).sup.+.
PREPARATION 59
4-(5-Amino-2-ethoxypyridin-3-ylcarboxamido)-3-n-propyl-2-(pyridin-2-yl)met-
hylpyrazole-5-carboxamide
[0455] A stirred mixture of the title compound of Preparation 57 (5
g, 11 mmol), Raney nickel (2.5 g) and ethanol (150 ml) was
hydrogenated at 345 kPa (50 psi) and 40.degree. C. for 3 hours,
then for a further 72 hours at room temperature. The resulting
mixture was filtered and the filtrate evaporated under reduced
pressure to give a pale yellow solid. The crude product was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (99:1 to 95:5), followed by
trituration with ether, to yield the title compound (4.4 g, 94%) as
a beige solid. Found: C, 59.42; H, 5.96; N, 22.98.
C.sub.21H.sub.25N.sub.7O- .sub.3 requires C, 59.56: H, 5.95; N,
23.15%. .delta.(CDCl.sub.3): 0.78 (3H,t), 1.43 (2H,m), 1.52 (3H,t),
2.82 (2H,t), 3.49 (2H,s), 4.59 (2H,q), 5.30 (1H,s), 5.46 (2H,s),
6.70 (1H,s), 6.93 (1H,d), 7.22 (1H,m), 7.65 (1H,m), 7.78 (1H,s),
7.94 (1H,s), 8.58 (1H,d), 10.53 (1H,s).
PREPARATION 60
4-[5-Amino-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-3-ethyl-2-(pyridin--
2-yl)methylpyrazole-5-carboxamide
[0456] A stirred mixture of the title compound of Preparation 58
(3.3 g, 7.0 mmol), Raney nickel (2 g) and ethanol (120 ml) was
hydrogenated at 345 kPa (50 psi) and 50.degree. C. for 18 hours.
The resulting mixture was filtered and the filtrate evaporated
under reduced pressure to provide the title compound (3.01 g, 98%)
as a pale grey foam. Found: C, 56.47, H, 5.82; N, 21.40.
C.sub.21H.sub.25N.sub.7O.sub.4; 0.40 H.sub.2O requires C, 56.47; H,
5.82; N, 21.95%. .delta.(CDCl.sub.3): 1.06 (3H,t), 2.81 (2H.q),
3.38 (3H,s), 3.50 (2H,s), 3.92 (2H,t), 4.65 (2H,t), 5.33 (1H,s),
5.46 (2H,s), 6.70 (1H,s), 6.92 (1H,d), 7.22 (1H,m), 7.64 (1H,m),
7.76 (1H,s), 7.94 (1H,s), 8.60 (1H,d), 10.47 (1H,s). LRMS: m/z 440
(M+1).sup.+.
PREPARATION 61
5-(5-Amino-2-ethoxypyridin-3-yl)-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dih-
ydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0457] Potassium t-butoxide (2.32 g, 20 mmol) was added carefully
to a stirred suspension of the title compound of Preparation 59
(2.11 g, 5 mmol) and 4 .ANG. molecular sieves in ethanol (50 ml)
and the reaction mixture heated under reflux for 18 hours, allowed
to cool and filtered. The filtrate was evaporated under reduced
pressure and the residue partitioned between 1M hydrochloric acid
(30 ml) and ethyl acetate (30 ml). The phases were separated, the
aqueous phase extracted with ethyl acetate (2.times.30 ml) and the
combined organic solutions washed with brine, dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residual brown oil was purified by column chromatography on silica
gel, using an elution gradient of dichloromethane: methanol (100:0
to 96:4), to furnish the title compound (1.22 g, 60%) as a pale
yellow solid. Found: C, 61.92; H, 5.69; N. 23.95.
C.sub.21H.sub.23N.sub.7O.sub.2 requires C, 62.21; H, 5.72; N,
24.18%. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.51 (3H,t), 1.62 (2H,m),
2.95 (2H,t), 3.57 (2H,s), 4.50 (2H,q), 5.68 (2H.s), 7.06 (1H,d),
7.21 (1H,m), 7.60 (1H,m), 7.78 (1H,s), 8.16 (1H,d), 8.57 (1H,s),
11.07 (1H,s).
PREPARATION 62
5-[5-Amino-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-
-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0458] Potassium bis(trimethylsilyl)amide (6.58 g, 33.0 mmol) was
added to a stirred suspension of the title compound of Preparation
60 (2.90 g, 6.60 mmol) in 2-methoxyethanol (70 ml) and the reaction
mixture stirred under reflux for 18 hours. The resulting mixture
was allowed to cool and then evaporated under reduced pressure to
give a beige solid. The crude product was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (98:2 to 95:5), to afford the title
compound (2.21 g, 79%) as a white solid. Found: C, 59.10; H, 5.44;
N, 22.86. C.sub.21H.sub.23N.sub.7O.sub.3 requires C, 59.85, H,
5.50; N, 23.26%. .delta.(CDCl.sub.3): 1.28 (3H,t), 3.01 (2H,q),
3.53 (3H,s), 3.58 (2H,s), 3.82 (2H,t), 4.62 (2H,t,), 5.66 (2H,s),
7.08 (1H,d), 7.20 (1H,m), 7.61 (1H,m), 7.75 (1H.s), 8.09 (1H,s),
8.57 (1H,d), 11.14 (1H,s),. LRMS: m/z 422 (M+1).sup.+.
PREPARATION 63
5-(5-Chlorosulphonyl-2-ethoxypyridin-3-yl)-3-n-propyl-2-(pyridin-2-yl)meth-
yl-2,6-dihydro-7H-pyrazolo[4,3,d]pyrimidin-7-one
[0459] Sodium nitrite (295 mg, 4.4 mmol) was added portionwise to a
stirred, ice-cooled solution of the title compound of Preparation
61 (900 mg, 2.2 mmol) in a mixture of glacial acetic acid (20 ml)
and concentrated hydrochloric acid (20 ml) at such a rate as to
maintain the temperature below -20.degree. C. When the addition was
complete, the mixture was allowed to warm slowly to 0.degree. C.
over 2 hours and then re-cooled to -15.degree. C. Liquid sulphur
dioxide (22 ml) and a solution of copper(II) chloride (860 mg, 6.6
mmol) in a mixture of water (2 ml) and glacial acetic acid (14 ml)
were then added and the reaction mixture stirred at 0.degree. C.
for 30 minutes, followed by a further 2 hours at room temperature.
The resulting mixture was carefully poured into stirred ice-water
(300 ml) and the suspension thus obtained was extracted with
dichloromethane (3.times.100 ml). The combined extracts were washed
with brine, dried (MgSO.sub.4) and evaporated under reduced
pressure, then the residual oil triturated with ether to afford the
title compound (720 mg, 67%) as an off-white solid.
.delta.(CDCl.sub.3): 0.97 (3H,t), 1.60 (3H,t), 1.73 (2H,m), 3.01
(2H,t), 4.82 (2H,q), 5.70 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.64
(1H,m), 8.58 (1H,d), 8.90 (1H,s), 9.29 (1H,s), 10.55 (1H,s).
PREPARATION 64
5-[5-Chlorosulphonyl-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-
-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0460] Obtained as a cream solid (84%) from the title compound of
Preparation 62, using the procedure of Preparation 63.
.delta.(CDCl.sub.3): 1.32 (3H,t), 3.08 (2H,q), 3.58 (3H,s), 3.89
(2H,t), 4.85 (2H,t), 5.69 (2H,s), 7.12 (1H,d), 7.22 (1H,m), 7.64
(1H,m), 8.57 (1H,d), 8.89 (1H,s), 9.26 (1H,s), 10.75 (1H,s). LRMS:
m/z 505 (M+1).sup.+.
PREPARATION 65
3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-ylcarboxamido]-1-(pyridin-2-yl)methylpyrazolo-5-carboxamide
[0461] Obtained as a white crystalline solid (44%) from the title
compounds of Preparation 19 and Preparation 42, using the procedure
of Preparation 56. .delta.(CDCl.sub.3): 1.02 (3H,t), 1.20 (3H,t),
2.40 (2H,q), 2.52 (4H,m), 2.66 (2H,q), 3.10 (4H,m), 3.39 (3H,s),
3.90 (2H,t), 4.81 (2H,t), 5.62 (2H,s), 5.70 (1H,s), 7.26 (2H,m),
7.71 (1H,m), 8.53 (1H,d), 8.66 (1H,s), 8.82 (1H,s), 9.04 (1H,s).
LRMS: m/z 601 (M+1).sup.+.
PREPARATION 66
3-Bromo-2-(1,3-dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyri-
dine
[0462] 60% Sodium hydride dispersion in mineral oil (133 mg, 3.33
mmol) was added to a stirred, ice-cooled solution of
1,3-dimethoxypropan-2-ol (J. Amer. Chem. Soc., 1939, 61, 433; 400
mg, 3.33 mmol) in tetrahydrofuran (30 ml) and the mixture stirred
for 30 minutes. The title compound of Preparation 13 (500 mg, 1.35
mmol) was added and the reaction mixture stirred under reflux for 1
hour, then allowed to cool. The resulting mixture was evaporated
under reduced pressure and the residue partitioned between water
(30 ml) and ethyl acetate (30 ml). The phases were separated and
the aqueous phase extracted with ethyl acetate (2.times.30 ml),
then the combined extracts washed with brine (30 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure to give the
title compound (566 mg, 93%) as a yellow solid.
.delta.(CDCl.sub.3): 1.06 (3H,t), 2.43 (2H,q), 2.55 (4H,m), 3.08
(4H,m), 3.40 (6H,2xs), 3.70 (4H, 2xd), 5.60 (1H,m), 8.10 (1H,s),
8.44 (1H,s). LRMS: m/z 452.
PREPARATION 67
2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-c-
arboxylic acid ethyl ester
[0463] Obtained as a yellow solid (84%) from the title compound of
Preparation 66, using the procedure of Preparation 19.
.delta.(CDCl.sub.3): 1.05 (3H,t), 1.40 (3H,t), 2.42 (2H,q), 2.55
(4H,m), 3.09 (4H,m), 3.40 (6H, 2xs), 3.70 (4H, 2xd), 4.37 (2H,q),
5.70 (1H,m), 8.40 (1H,s), 8.62 (1H,s). LRMS: m/z 446
(M+1).sup.+.
PREPARATION 68
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyri-
dine
[0464] Obtained as a clear oil (70%) from the title compound of
Preparation 13 and 4-hydroxytetrahydropyran, following the
procedure of Preparation 14, after purification by column
chromatography on silica gel, using ethyl acetate as eluant.
.delta.(CDCl.sub.3): 1.05 (3H,t), 1.88 (2H,m), 2.08 (2H,m), 2.42
(2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.66 (2H,m), 3.99 (2H,m) 5.40
(1H,m), 8.10 (1H,s), 8.42 (1H,s). LRMS: m/z 434 (M).sup.+.
PREPARATION 69
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridine-3-c-
arboxylic acid ethyl ester
[0465] Obtained as an oil (92%) from the title compound of
Preparation 68, using the procedure of Preparation 19.
.delta.(CDCl.sub.3): 1.04 (3H,t), 1.40 (3H,t), 1.88 (2H,m), 2.08
(2H,m), 2.43 (2H,q), 2.55 (4H,m), 3.09 (4H,m), 3.66 (2H,m), 4.00
(2H,m), 4.40 (2H,q), 5.50 (1H,m), 8.40 (1H,s), 8.60 (1H,s). LRMS:
m/z 427 (M).sup.+.
PREPARATION 70
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridine-3-c-
arboxylic acid sodium salt
[0466] A mixture of the title compound of Preparation 69 (611 mg,
1.4 mmol), 1M aqueous sodium hydroxide solution (1.6 ml, 1.6 mmol)
and ethanol (6 ml) was stirred at room temperature for 6 hours,
then evaporated under reduced pressure. The residue was dissolved
in water (16 ml), then the solution washed with ethyl acetate
(2.times.10 ml) and evaporated under reduced pressure to provide
the title compound (520 mg, 93%) as a tan-coloured solid.
.delta.(DMSOd.sub.6): 1.19 (3H,t), 1.70 (2H,m), 2.00 (2H,m),
2.80-3.88 (14H,m), 8.32 (1H,s), 8.73 (1H,s), 10.93 (1H,s). LRMS:
m/z 400 (M+1).sup.+.
PREPARATION 71
2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-c-
arboxylic acid sodium salt
[0467] Obtained as a solid (92%) from the title compound of
Preparation 67, using the procedure of Preparation 70. LRMS: m/z
418 (M+1).sup.+.
PREPARATION 72
4-[2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine--
3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0468] A mixture of the title compounds of Preparation 71 (418 mg,
0.95 mmol) and Preparation 41 (250 mg, 1.0 mmol),
1-hydroxybenzotriazole hydrate (270 mg, 2.0 mmol),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (380
mg, 2.0 mmol), triethylamine (280 .mu.l, 2.0 mmol) and
tetrahydrofuran (10 ml) was stirred at room temperature for 36
hours, then evaporated under reduced pressure. The residue was
partitioned between dichloromethane (10 ml) and brine (10 ml), the
phases separated, the aqueous phase extracted with dichloromethane
(2.times.10 ml) and the combined organic solutions dried
(MgSO.sub.4) and evaporated under reduced pressure. The residual
yellow oil was purified by column chromatography on silica gel,
using an elution gradient of dichloromethane: methanol (98:2 to
96:4) to furnish the title compound (350 mg, 56%) as an off-white
solid. .delta.(CDCl.sub.3): 0.81 (3H,t), 1.03 (3H,t), 1.44 (2H,m),
2.40 (2H,q), 2.52 (4H,m), 2.80 (2H,t), 3.10 (4H,m), 3.38 (6H,s),
3.78 (2H,dd), 3.92 (2H,dd), 5.31 (1H,s), 5.47 (2H,s), 5.93 (1H,m),
6.70 (1H,s), 6.92 (1H,d), 7.23 (1H,m), 7.65 (1H,m), 8.58 (1H,d),
8.65 (1H,s), 8.80 (1H,s), 10.26 (1H,s). LRMS: m/z 660
(M+2).sup.+.
PREPARATION 73
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)p-
yridine
[0469] Obtained as an oil (89%) from the title compound of
Preparation 13 and (R)-(-)-3-hydroxytetrahydrofuran, using the
procedure of Preparation 17. .delta.(CDCl.sub.3): 1.05 (3H,t), 2.20
(1H,m), 2.30 (1H,m), 2.42 (2H,q), 2.54 (4H,m), 3.07 (4H,m), 3.94
(2H,m), 4.02 (1H,m), 4.10 (1H,m), 5.63 (1H,m), 8.11 (1H,s), 8.43
(1H,s). LRMS: m/z 421 (M+1).sup.+.
PREPARATION 74
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)pyridine--
3-carboxylic acid ethyl ester
[0470] Obtained as an oil (84%), from the title compound of
Preparation 73, using the procedure of Preparation 19.
.delta.(CDCl.sub.3): 1.03 (3H,t), 1.40 (3H,t), 2.26 (2H,m), 2.42
(2H,q), 2.55 (4H,m), 3.10 (4H,m), 3.98 (3H,m), 4.12 (1H,m), 4.38
(2H,q), 5.70 (1H,m), 8.42 (1H,s), 8.62 (1H,s). LRMS: m/z 414
(M+1).sup.+.
PREPARATION 75
3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-ylox-
y)pyridin-3-ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0471] Obtained as a foam (78%) from the title compounds of
Preparation 74 and Preparation 40, using the procedure of
Preparation 56. .delta.(CDCl.sub.3): 1.04 (6H,m), 2.40 (3H,m), 2.52
(5H,m), 2.84 (2H,q), 3.10 (4H,m), 3.94 (1H,m), 4.15 (3H,m), 5.28
(1H,s), 5.48 (2H,s), 5.90 (1H,m), 6.68 (1H,s), 6.92 (1H,d), 7.22
(1H,m), 7.67 (1H,m), 8.60 (1H,d), 8.64 (1H,s), 8.86 (1H,s), 10.28
(1H,s). LRMS: m/z 613 (M+1).sup.+.
PREPARATION 76
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridin-3-
-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0472] A mixture of the title compounds of Preparation 70 (520 mg,
1.3 mmol) and Preparation 41 (285 mg, 1.1 mmol),
1-(3-dimethylaminopropyl)-3-- ethylcarbodiimide hydrochloride (250
mg, 1.3 mmol), 1-hydroxybenzotriazole hydrate (199 mg, 1.3 mmol),
N-ethyldiisopropylamine (226 .mu.l, 1.3 mmol) and tetrahydrofuran
(20 ml) was stirred for 1 week at room temperature. Ethyl acetate
(150 ml) was then added and the resulting mixture washed with brine
(2.times.50 ml), dried (MgSO.sub.4) and evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel, using an elution gradient of ethyl acetate:
dichloromethane:methanol (32:64:4 to 0:95:5), to afford the title
compound (603 mg, 86%) as a white foam. .delta.(DMSOd.sub.6): 0.74
(3H,t), 0.91 (3H,t), 1.39 (2H,m), 1.90 (2H,m), 2.05 (2H,m), 2.30
(2H,q), 2.42 (4H,m), 2.74 (2H,t), 2.95 (4H,m), 3.50 (2H,m), 3.85
(2H,m), 5.48 (2H,s), 5.52 (1H,m), 7.09 (1H,d), 7.35 (3H,m), 7.48
(1H,m), 8.39 (1H,s), 8.54 (1H,d), 8.65 (1H,s), 10.18 (1H,s). LRMS:
m/z 641 (M+1).sup.+.
PREPARATION 77
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-
-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0473] A stirred mixture of the title compounds of Preparation 28
(3.07 g, 7.71 mmol) and Preparation 41 (2.0 g, 7.71 mmol) in
pyridine (50 ml) was heated at 50.degree. C. for 48 hours, then
allowed to cool and evaporated under reduced pressure. The residue
was partitioned between dichloromethane (100 ml) and water (20 ml),
then the organic phase separated, dried (MgSO.sub.4) and evaporated
under reduced pressure. The residual brown foam was purified by
column chromatography on silica gel, using an elution gradient of
ethyl acetate: methanol (100:0 to 90:10), to give the title
compound (3.19 g, 71%) as a white foam. Found: C, 54.66; H, 6.17;
N, 18.38. C.sub.27H.sub.36N.sub.8O.sub.5S: 0.40 H.sub.2O requires
C, 54.79; H, 6.27; N, 18.93%. .delta.(CDCl.sub.3): 0.82 (3H,t),
1.03 (3H,t), 1.45 (2H,m), 1.58 (3H,t), 2.40 (2H,q), 2.52 (4H,m),
2.86 (2H,t), 3.10 (4H,m), 4.79 (2H,q), 5.29 (1H,s), 5.46 (2H,s),
6.70 (1H,s), 6.93 (1H,d), 7.21 (1H,m), 7.64 (1H,m), 8.59 (1H,d),
8.64 (1H,s), 8.81 (1H.s), 10.56 (1H,s). LRMS: m/z 585
(M+1).sup.+.
PREPARATION 78
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-propoxypyridine-3-carboxylic
acid methyl ester
[0474] Obtained as an oil (53%) from the title compound of
Preparation 49 and 1-ethylpiperazine, using the procedure of
Preparation 18. .delta.(CDCl.sub.3): 1.05 (6H,m), 1.86 (2H,m), 2.41
(2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.92 (3H,s), 4.46 (2H,t), 8.40
(1H,s), 8.62 (1H,s). LRMS: m/z 372 (M+1).sup.+.
PREPARATION 79
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxapyridine-3-carboxylic
acid
[0475] A mixture of the title compound of Preparation 78 (370 mg,
1.0 mmol), 2M aqueous sodium hydroxide solution (1 ml, 2 mmol) and
methanol (10 ml) was stirred at room temperature for 2 hours. The
resulting mixture was treated with solid carbon dioxide in order to
adjust its pH to 7 and then evaporated under reduced pressure. The
residue was triturated with dichloromethane (3.times.50 ml) and the
combined organic solutions evaporated under reduced pressure to
yield the title compound (340 mg, 95%) as a white solid. LRMS: m/z
357 (M).sup.+.
PREPARATION 80
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-ylcarboxamido]--
3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0476] Oxalyl chloride (122 .mu.l, 5.6 mmol) was added dropwise to
a stirred solution of the title compound of Preparation 79 (478 mg,
1.4 mmol) and dimethylformamide (3 drops) in dichloromethane (10
ml) and the reaction mixture stirred at room temperature for 18
hours, then evaporated under reduced pressure. The residue was
azeotroped with dichloromethane (3.times.10 ml), then added to a
stirred, ice-cooled solution of the title compound of Preparation
41 (360 mg, 1.4 mmol) in pyridine (10 ml) and the reaction mixture
stirred at room temperature for 18 hours, then evaporated under
reduced pressure. The residue was partitioned between water (50 ml)
and dichloromethane (50 ml), the phases separated and the aqueous
phase extracted with dichloromethane (2.times.50 ml). The combined
organic solutions were dried (Na.sub.2SO.sub.4) and evaporated
under reduced pressure, then the crude product purified by column
chromatography on silica gel, using ethyl acetate:methanol (80:20)
as eluant, to provide the title compound (500 mg, 37%) as a
colouriess glass. .delta.(CDCl.sub.3): 0.81 (3H,t), 1.04 (3H,t),
1.27 (3H,t), 1.46 (2H,m), 2.00 (2H,m), 2.40 (2H,q), 2.53 (4H,m),
2.86 (2H,t), 3.09 (4H,m), 4.66 (2H,t), 5.27 (1H,s), 5.47 (2H,s),
6.68 (1H,s), 6.93 (1H,d), 7.21 (1H,m), 7.66 (1H,m), 8.59 (1H,d),
8.64 (1H,s), 8.80 (1H,s), 10.47 (1H,s). LRMS: m/z 599
(M+1).sup.+.
PREPARATION 81
2-(2-Benzyloxyethoxy)-3-bromo-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine
[0477] A mixture of a 2M solution of sodium
bis(trimethylsilyl)amide in tetrahydrofuran (4.1 ml, 8.2 mmol),
2-benzyloxyethanol (1.16 ml, 8.2 mmol) and tetrahydrofuran (5 ml)
was stirred at about 0.degree. C. for 1 hour. The title compound of
Preparation 13 (2.0 g, 5.43 mmol) was added and the reaction
mixture stirred at room temperature for 5 hours, then evaporated
under reduced pressure. The residue was suspended in ethyl acetate
(10 ml) and the suspension extracted with 2M hydrochloric acid
(3.times.10 ml). The combined extracts were basified with aqueous
sodium bicarbonate solution and extracted with ethyl acetate
(3.times.15 ml). These combined extracts were dried (MgSO.sub.4)
and evaporated under reduced pressure, then the crude product
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 95:5), to furnish
the title compound (1.95 g, 74%) as an oil. .delta.(CDCl.sub.3):
1.02 (3H,t), 2.40 (2H,q), 2.52 (4H,m), 3.07 (4H,m), 3.88 (2H,t),
4.62 (4H,m), 7.26 (1H,m), 7.34 (4H,m), 8.09 (1H,s), 8.42 (1H,s).
LRMS: m/z 486 (M+2).sup.+.
PREPARATION 82
2-(2-Benzyloxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxy-
lic acid ethyl ester
[0478] Obtained as an oil (42%) from the title compound of
Preparation 81, using the procedure of Preparation 21.
.delta.(CDCl.sub.3): 1.04 (3H,t), 1.38 (3H,t), 2.42 (2H,q), 2.54
(4H,m), 3.08 (4H,m), 3.90 (2H,t), 4.38 (2H,q), 4.67 (4H,m), 7.28
(1H,m), 7.35 (4H,m), 8.41 (1H,s), 8.62 (1H,s). LRMS: m/z 478
(M+1).sup.+.
PREPARATION 83
2-(2-Benzyloxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxy-
lic acid hydrochloride
[0479] Obtained as a pale yellow solid (88%) from the title
compound of Preparation 82, using the procedure of Preparation 26.
.delta.(CDCl.sub.3): 1.45 (3H,t), 2.82 (2H,m), 3.09 (2H,q), 3.26
(2H,m), 3.64 (2H,m), 3.90 (4H,m), 4.64 (2H,s), 4.78 (2H,t), 7.33
(1H,m), 7.37 (4H,m), 8.58 (1H,s), 8.64 (1H,s), 12.17 (1H,s). LRMS:
m/z 450 (M+1).sup.+.
PREPARATION 84
4-[2-(2-Benzyloxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcar-
boxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0480] Obtained as an orange solid (80%) from the title compounds
of Preparation 83 and Preparation 41, using the procedure of
Preparation 52. .delta.(CDCl.sub.3): 0.80 (3H,t), 1.02 (3H,t), 1.42
(2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.81 (2H,t), 3.10 (4H,m), 4.06
(2H,t), 4.57 (2H,s), 4.86 (2H,t), 5.26 (1H,s), 5.45 (2H,s), 6.68
(1H,s), 6.90 (1H,d), 7.17-7.27 (5H,m), 7.34 (1H,m), 7.63 (1H,m),
8.59 (1H,d), 8.62 (1H,s), 8.82 (1H,s), 10.50 (1H,s). LRMS: m/z 692
(M+2).sup.+.
PREPARATION 85
2-Benzyl-3-ethyl-4-nitropyrazole-5-carboxamide
[0481] Caesium carbonate (2.9 g, 9.0 mmol) was added to a stirred,
ice-cooled solution of the title compound of Preparation 35 (1.7 g,
8.8 mmol) in dimethylformamide (20 ml) and the suspension stirred
for 30 minutes. Benzyl bromide (10.6 ml, 9.0 mmol) was added and
the reaction mixture stirred at room temperature for 18 hours, then
evaporated under reduced pressure. The residue was partitioned
between ethyl acetate (125 ml) and brine (100 ml), the phases
separated and the organic phase dried (MgSO.sub.4) and evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel, using ethyl acetate as eluant, to
afford the title compound (1.13 g, 47%) as a white solid.
.delta.(DMSOd.sub.6): 0.97 (3H,t), 2.96 (2H,q), 5.44 (2H,s), 7.24
(2H,m), 7.33 (3H,m), 7.68 (1H,s), 7.95 (1H,s). LRMS: m/z 274
(M+1).sup.+.
PREPARATION 86
4-Amino-2-benzyl-3-ethylpyrazole-5-carboxamide
[0482] Obtained as a pale pink solid (90%) from the title compound
of Preparation 85, using the procedure of Preparation 40.
.delta.(DMSOd.sub.6): 0.87 (3H,t), 2.49 (2H,q), 4.46 (2H,s), 5.22
(2H,s), 6.85 (1H,s), 7.09 (3H,m), 7.25 (1H,m), 7.31 (2H,m). LRMS:
m/z 245 (M+1).sup.+.
PREPARATION 87
2-Benzyl-4-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxa-
mido]-3-ethylpyrazole-5-carboxamide
[0483] Obtained as a white crystalline foam (46%) from the title
compounds of Preparation 18 and Preparation 86, using the procedure
of Preparation 56. .delta.(DMSOd.sub.6): 0.92 (6H,m), 1.44 (3H,t),
2.30 (2H,q), 2.41 (4H,m), 2.74 (2H,q), 2.95 (4H,m), 4.62 (2H,q),
5.40 (2H,s), 7.17 (2H,m), 7.31 (4H,m), 7.50 (1H,s), 8.39 (1H,s),
8.65 (1H,s), 10.38 (1H,s). LRMS: m/z 571 (M+2).sup.+.
PREPARATION 88a
3-Ethyl-1-(1-methylimidazol-2-yl)methyl-4-nitropyrazole-5-carboxamide
and
PREPARATION 88b
3-Ethyl-2-(1-methylimidazol-2-yl)methyl-4-nitropyrazole-5-carboxamide
[0484] A mixture of the title compound of Preparation 35 (2.2 g,
11.95 mmol), 2-chloromethyl-1-methylimidazole hydrochloride (J.
Chem. Soc., 1957, 3305; 2.0 g, 11.95 mmol), caesium carbonate (8.5
g, 26.3 mmol) and dimethylformamide (100 ml) was stirred at room
temperature for 6 hours, then evaporated under reduced pressure.
The residue was partitioned between water (150 ml) and
dichloromethane (150 ml), the phases separated and the aqueous
phase extracted with dichloromethane (2.times.150 ml). The combined
extracts were dried (MgSO.sub.4) and evaporated under reduced
pressure, then the residue triturated with dichloromethane:
methanol (90:10) and the resulting solid collected and dried under
suction to give the first title compound (1-isomer; 305 mg, 9%) as
a cream solid. .delta.(DMSOd.sub.6): 1.16 (3H,t), 2.82 (2H,q), 3.69
(3H,s), 5.40 (2H,s), 6.81 (1H,s), 7.13 (1H,s), 8.20 (1H,s), 8.50
(1H,s). LRMS: m/z 279 (M+1).sup.+.
[0485] The filtrate was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using
dichloromethane:methanol:0.88 aqueous ammonia (90:10:1) as eluant,
to yield the second title compound (2-isomer; 480 mg, 14%) as a
solid. .delta.(CDCl.sub.3): 1.16 (3H,t), 3.20 (2H,q), 3.77 (3H,s),
5.48 (2H,s), 6.22 (1H,s), 6.68 (1H,s), 7.00 (1H,s), 7.25 (1H,s).
LRMS: m/z 279 (M+1).sup.+.
PREPARATION 89
4-Amino-3-ethyl-2-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide
[0486] Obtained as a pink solid (92%) from the title compound of
Preparation 88b, using the procedure of Preparation 40.
.delta.(CDCl.sub.3): 1.00 (3H,t), 2.68 (2H,q), 3.60 (3H,s), 5.34
(2H,s), 5.40 (1H,s), 6.55 (1H,s), 6.82 (1H,s), 6.98 (1H,s). LRMS:
m/z 249 (M+1).sup.+.
PREPARATION 90
3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
-ylcarboxamido]-2-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide
[0487] Obtained as a solid (48%) from the title compounds of
Preparation 29 and Preparation 89, using the procedure of
Preparation 45A. .delta.(CDCl.sub.3): 1.01 (3H,t), 1.10 (3H,t),
2.40 (2H,q), 2.52 (4H,m), 2.98 (2H,q), 3.08 (4H,m), 3.36 (3H,s),
3.66 (3H,s), 3.92 (2H,t), 4.82 (2H,t), 5.35 (1H,s), 5.42 (2H,s),
6.61 (1H,s), 6.86 (1H,s), 7.00 (1H,s), 8.64 (1H,s), 8.81 (1H,s),
10.33 (1H,s). LRMS: m/z 604 (M+1).sup.+.
PREPARATION 91a
1-(1-Methylimidazol-2-yl)methyl-4-nitro-3-n-propylpyrazole-5-carboxamide
and
PREPARATION 91b
2-(1-Methylimidazol-2-yl)methyl-4-nitro-3-n-propylpyrazole-5-carboxamide
[0488] A stirred mixture of the title compound of Preparation 34
(5.0 g, 25.3 mmol), 2-chloromethyl-1-methylimidazole hydrochloride
(J. Chem. Soc., 1957, 3305; 4.6 g, 27.7 mmol), caesium carbonate
(18.1 g, 55.6 mmol) and acetonitrile (100 ml) was heated at
50.degree. C. for 5 hours, then allowed to cool. Ethyl acetate (300
ml) was added and the mixture washed with water (2.times.400 ml),
dried (MgSO.sub.4) and concentrated under reduced pressure to a
volume of about 200 ml. The resulting precipitate was collected and
combined with the material produced by crystallisation from ethyl
acetate of the residue obtained by evaporation under reduced
pressure of the filtrate, to provide, after drying, the first title
compound (1-isomer; 1.0 g, 13%) as white crystals.
.delta.(DMSOd.sub.6): 0.89 (3H,t), 1.60 (2H,m), 2.76 (2H,t), 3.66
(3H,s), 5.39 (2H,s), 6.80 (1H,s), 7.12 (1H,s), 8.20 (1H,s), 8.48
(1H,s). LRMS: m/z 293 (M+1).sup.+.
[0489] The crystallisation mother liquor was evaporated under
reduced pressure and the residue recrystallised from ethyl acetate
to furnish the second title compound (2-isomer; 700 mg, 9%) as a
solid. .delta.(DMSOd.sub.6): 0.92 (3H,t), 1.52 (2H,m), 3.04 (2H,t),
3.68 (3H,s), 5.49 (2H,s), 6.82 (1H,s), 7.14 (1H,s), 7.66 (1H,s),
7.93 (1H,s). LRMS: m/z 293 (M+1).sup.+.
PREPARATION 92
4-Amino-2-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide
[0490] A stirred mixture of the title compound of Preparation 91b
(500 mg, 1.71 mmol), 10% palladium on charcoal (150 mg) and ethanol
(20 ml) was hydrogenated for 4 hours at 345 kPa (50 psi), then
filtered. The filtrate was combined with a dichloromethane:
methanol (80:20) wash (50 ml) of the filter pad, evaporated under
reduced pressure and the residue crystallised from ethyl acetate to
afford the title compound (320 mg, 71%) as a pale pink solid.
.delta.(CDCl.sub.3): 0.90 (3H,t), 1.40 (2H,m), 2.60 (2H,t), 3.58
(3H,s), 3.94 (2H,s), 5.32 (3H,m), 6.54 (1H,s), 6.82 (1H,s), 6.98
(1H,s).
PREPARATION 93
3-(2-Phenylethenyl)pyridazine
[0491] Zinc chloride (820 mg, 6 mmol) was added to a stirred
mixture of benzaldehyde (6.11 ml, 60 mmol) and 3-methylpyridazine
(2.83 g, 30 mmol) and the resulting mixture heated for 20 hours at
150.degree. C. The cool reaction mixture was partitioned between
dichloromethane (40 ml) and 2M aqueous sodium hydroxide solution
(20 ml), then the organic phase separated, combined with a
dichloromethane extract (80 ml) of the aqueous phase, dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel, using
dichloromethane: methanol (99:1) as eluant, to give the title
compound (59%) as a solid. .delta.(CDCL.sub.3): 7.12 (1H,d), 7.34
(3H,m), 7.56 (2H,d), 7.72 (1H,d), 8.37 (1H,s), 8.50 (1H,s), 8.60
(1H,s). LRMS: m/z 183 (M+1).sup.-.
PREPARATION 94
3-Hydroxymethylpyridazine
[0492] Ozone was bubbled through a stirred solution of the title
compound of Preparation 93 (3.60 g, 0.02 mol) in methanol (150 ml)
at -10.degree. C. After 30 minutes the mixture was purged with
nitrogen, sodium borohydride (750 mg, 0.02 mol) added portionwise
and the resulting solution stirred for 2 hours at room temperature.
The reaction mixture was acidified with 2M hydrochloric acid, then
basified with 0.880 aqueous ammonia solution and evaporated under
reduced pressure. Purification of the residue by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (98:2 to 96:4). provided the title
compound (76%) as a solid. .delta.(CDCl.sub.3): 3.66 (1H,s), 4.92
(2H,s), 7.48 (2H,m), 9.06 (1H,d).
PREPARATION 95
3-Chloromethylpyridazine hydrochloride
[0493] Thionyl chloride (3.05 ml, 42 mmol) was added to an
ice-cooled flask containing the title compound of Preparation 94
(920 mg, 8 mmol) and the reaction mixture stirred for 45 minutes at
room temperature, then evaporated under reduced pressure. The
residue was azeotroped with toluene (40 ml) to furnish the crude
title compound (1.4 g) as a brown solid. .delta.(DMSOd.sub.6): 4.98
(2H,s), 7.80 (1H,m), 7.90 (1H,d), 8.19 (1H,s), 9.22 (1H,d).
PREPARATION 96
4-Nitro-3-n-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide
[0494] A mixture of the title compounds of Preparation 95 (700 mg,
4.24 mmol) and Preparation 34 (840 mg, 4.24 mmol), caesium
carbonate (3.45 g, 10.6 mmol) and acetonitrile (30 ml) was stirred
at 80.degree. C. for 2 hours, then allowed to cool. Brine (30 ml)
was added, the mixture extracted with dichloromethane (2.times.80
ml) and the combined extracts dried (Na.sub.2SO.sub.4) and
evaporated under reduced pressure. The residual brown oil was
purified by column chromatography on silica gel, using an elution
gradient of dichloromethane: methanol (100:0 to 90:10) to afford
the title compound (480 mg, 39%) as a yellow solid.
.delta.(CDCl.sub.3): 1.02 (3H,t), 1.60 (2H,m), 3.06 (2H,t), 5.72
(2H,s), 5.87 (1H,s), 7.25 (1H,s), 7.54 (2H,m), 9.20 (1H,s).
PREPARATION 97
4-Amino-3-n-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide
[0495] Obtained as a pink gum (97%) from the title compound of
Preparation 96, using the procedure of Preparation 40.
.delta.(CDCl.sub.3): 0.90 (3H,t), 1.47 (2H,m), 2.51 (2H,t), 5.25
(1H,s), 5.58 (2H,s), 6.58 (1H,s), 7.09 (1H,d), 7.43 (1H,m), 9.14
(1H,d). LRMS: m/z 261 (M+1).sup.+.
PREPARATION 98
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-
-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide
[0496] Obtained as an orange gum (42%) from the title compounds of
Preparation 28 and Preparation 97, using the procedure of
Preparation 45A. .delta.(CDCl.sub.3): 0.81 (3H,t), 1.01 (3H,t),
1.47 (2H,m), 1.55 (3H,t), 2.39 (2H,q), 2.50 (4H,m), 2.87 (2H,t),
3.07 (4H,m), 4.77 (2H,q), 5.58 (1H,s), 5.69 (2H,s), 6.71 (1H,s),
7.18 (1H,d), 7.45 (1H,m), 8.63 (1H,s), 8.79 (1H,s), 9.15 (1H,s),
10.52 (1H,s). LRMS: m/z 586 (M+1).sup.+.
PREPARATION 99
2-Methylpyrimidine-1-oxide
[0497] A freshly prepared solution of sodium metal (11.5 g, 0.50
mol) in ethanol (170 ml) was added dropwise over 1 hour to a
stirred suspension of hydroxylamine hydrochloride (34.75 g, 0.50
mol) and phenolphthalein (50 mg) in ethanol (200 ml) so as to
maintain a colourless solution and the mixture stirred at room
temperature for 3 hours. Acetonitrile (26 ml, 0.50 mol) was added
and this mixture stirred for a further 2 hours at room temperature,
then at 45.degree. C. for 48 hours. The resulting mixture was
filtered and the filtrate concentrated under reduced pressure to a
volume of ca. 100 ml, then cooled to 0.degree. C. The resulting
precipitate was collected and dried under suction to give the
intermediate acetamidoxime (9.9 g, 27%) as white crystals.
[0498] Boron trifluoride diethyl ether complex (9.5 ml, 75 mmol),
followed by 1,1,3,3-tetramethoxypropane (11.5 ml, 70 mmol), were
added to a stirred mixture of dimethylformamide (100 ml) and
toluene (100 ml). The acetamidoxime (5.0 g, 67.5 mmol) was then
added and the reaction mixture heated under reflux for 45 minutes,
then allowed to cool. The resulting mixture was evaporated under
reduced pressure and the residual brown oil partitioned between
dichloromethane: methanol (80:20) (100 ml) and aqueous sodium
carbonate solution (100 ml). The phases were separated, the aqueous
phase extracted with dichloromethane: methanol (80:20) (10.times.50
ml) and the combined organic solutions dried (MgSO.sub.4) and
evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel, using dichloromethane:
methanol (98:2) as eluant, to yield the title compound (2.5 g, 34%)
as an orange solid. .delta.(CDCl.sub.3): 2.74 (3H,s), 7.19 (1H,m),
8.16 (1H,d), 8.39 (1H,d).
PREPARATION 100
2-Chloromethylpyrimidine
[0499] A stirred mixture of the title compound of Preparation 99
(2.5 g, 22.7 mmol) and phosphorous oxychloride (18 ml, 193 mmol)
was heated under reflux for 2 hours, then allowed to cool. The
resulting mixture was poured onto stirred ice and neutralised using
solid sodium carbonate over 3 hours. The aqueous solution thus
obtained was extracted with dichloromethane (3.times.100 ml), then
the combined extracts dried (MgSO.sub.4) and evaporated under
reduced pressure. The residual brown oil was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 97:3), to provide the title
compound (510 mg, 17%). .delta.(CDCl.sub.3): 4.72 (2H,s), 7.22
(1H,m), 8.75 (2H,d). LRMS: m/z 129 (M+1).sup.+.
PREPARATION 101a
4-Amino-3-n-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
and
PREPARATION 101b
4-Amino-3-n-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
[0500] Potassium hydroxide (393 mg, 7 mmol) was added to a stirred,
ice-cooled solution of the title compound of Preparation 36 (1.2 g,
6 mmol) in dimethylformamide (10 ml) and the mixture stirred for 1
hour at room temperature. The title compound of Preparation 100
(900 mg, 7 mmol) was then added and the reaction mixture stirred at
room temperature for 18 hours, then evaporated under reduced
pressure. The residue was partitioned between water (10 ml) and
dichloromethane (15 ml), the phases separated and the aqueous phase
extracted with dichloromethane (2.times.15 ml). The combined
organic solutions were dried (MgSO.sub.4) and evaporated under
reduced pressure, then the residue purified by column
chromatography on silica gel, using dichloromethane: methanol
(95:5) as eluant, to furnish a mixture of the title compounds (not
separated) (1.06 g, 67%) as a pale pink solid. Analysis of the
.sup.1H nmr spectrum indicated a N1:N2 ratio (i.e.
1-isomer:2-isomer) of 22:78. .delta.(DMSOd.sub.6): 0.81 (3H,t),
0.88 (3H,t), 1.38 (2H,m), 1.52 (2H,m), 2.48 (2H,t), 4.10 (2H,s),
4.44 (2H, s), 5.41 (2H,s), 5.73 (2H,s), 6.90 (1H,s), 7.06 (1H,s),
7.35 (1H,m), 7.42 (1H,m), 7.50 (2H,s), 8.68 (2H,d), 8.77 (2H,d).
LRMS: m/z 261 (M+1).sup.+.
PREPARATION 102a
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarbo-
xamido]-3-n-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
and
PREPARATION 102b
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarbo-
xamido]-3-n-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
[0501] Triethylamine (1.12 ml, 8.0 mmol) was added to a stirred,
ice-cooled suspension of the title compounds of Preparation 29 (680
mg, 1.6 mmol) and Preparations 101a/101b (417 mg, 1.6 mmol) in
dichloromethane (20 ml), then the reaction mixture stirred at room
temperature for 18 hours, washed with water (10 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The residual
brown foam was purified by column chromatography on silica gel,
using an elution gradient of dichloromethane: methanol (98:2 to
95:5), to afford the first title compound (1-isomer; 56 mg, 6%) as
an orange gum. .delta.(CDCl.sub.3): 0.96 (3H,t), 1.04 (3H,t), 1.76
(2H,m), 2.42 (2H,q), 2.54 (4H,m), 3.38 (3H,s), 3.86 (2H,t), 4.76
(2H,t), 6.13 (2H,s), 7.11 (1H,m), 8.44 (1H,s), 8.62 (2H,d), 8.78
(1H,s), 10.17 (1H,s). LRMS: m/z 616 (M+1).sup.+; followed by the
second title compound (2-isomer; 460 mg, 47%) as an orange foam.
.delta.(CDCl.sub.3): 0.84 (3H,t), 1.03 (3H,t), 1.50 (2H,m), 2.40
(2H,q), 2.53 (4H,m), 2.88 (2H,t), 3.11 (4H,m), 3.39 (3H,s), 3.96
(2H,t), 4.85 (2H,q), 5.23 (1H,s), 5.58 (2H,s), 6.70 (1H,s), 7.25
(1H,m), 8.63 (1H,s), 8.74 (2H,d), 8.84 (1H,s), 10.52 (1H,s). LRMS:
m/z 616 (M+1).sup.+.
PREPARATION 103a
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-
-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
and
PREPARATION 103b
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-
-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide
[0502] Obtained as a mixture of isomers (88%) from the title
compounds of Preparation 28 and Preparations 101a/101b using the
procedure of Preparation 45A. LRMS: m/z 586 (M+1).sup.+.
PREPARATION 104
4-Amino-3-n-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0503] Obtained as a solid (92%) from the title compound of
Preparation 39a, using the procedure of Preparation 41.
.delta.(DMSOd.sub.6): 0.88 (3H,t), 1.55 (2H,m), 2.43 (2H,t), 4.18
(2H,s), 5.59 (2H,s), 6.73 (1H,d), 7.22 (1H,m), 7.57 (2H,s), 7.69
(1H,m), 8.47 (1H,d). LRMS: m/z 260 (M+1).sup.+.
PREPARATION 105
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-
-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0504] Obtained as a brown foam (74%) from the title compounds of
Preparation 28 and Preparation 104, using the procedure of
Preparation 45A. .delta.(CDCl.sub.3): 0.94 (3H,t), 1.02 (3H,t),
1.62 (5H,m), 2.40 (2H,q), 2.52 (4H,m), 2.64 (2H,t), 3.09 (4H,m),
4.77 (2H,q), 5.58 (2H,s), 5.71 (1H,s), 7.26 (1H,m), 7.40 (1H,d),
7.74 (1H,m), 8.52 (1H,d), 8.67 (1H,s), 8.82 (1H,s), 9.60 (1H,s),
9.96 (1H,s). LRMS: m/z 585 (M+1).sup.+.
PREPARATION 106
4-Amino-3-ethyl-1-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide
[0505] Obtained as a pink foam (95%) from the title compound of
Preparation 88a, using the procedure of Preparation 40.
.delta.(DMSOd.sub.6): 1.09 (3H,t), 2.43 (2H,q), 3.72 (3H,s), 4.37
(2H,s), 5.44 (2H,s), 6.79 (1H,s), 7.08 (1H,s). LRMS: m/z 249
(M+1).sup.-.
PREPARATION 107
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-1-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide
[0506] Obtained as a solid (78%) from the title compounds of
Preparation 28 and Preparation 106, using the procedure of
Preparation 45A. .delta.(CDCl.sub.3): 1.01 (3H,t), 1.21 (3H,t),
1.60 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 2.72 (2H,q), 3.08 (4H,m),
3.94 (3H,s), 4.76 (2H,q), 5.54 (2H,s), 5.93 (1H,s), 6.83 (1H,s),
6.92 (1H,s), 8.65 (1H,s), 8.82 (1H,s), 9.95 (1H,s), 10.27 (1H,s).
LRMS: m/z 575 (M+2).sup.+.
PREPARATION 108
4-Amino-1-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide
[0507] Obtained as a cream solid (78%) from the title compound of
Preparation 91a, using the procedure of Preparation 40.
.delta.(DMSOd.sub.6): 0.87 (3H,t), 1.52 (2H,m), 2.38 (2H,t), 3.70
(3H.s), 4.35 (2H,s), 5.44 (2H,s), 6.78 (1H,s), 7.08 (1H,s). LRMS:
m/z 263 (M+1).sup.+.
PREPARATION 109
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarbo-
xamido]-1-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide
[0508] Obtained (67%) from the title compounds of Preparation 25
and Preparation 108, using the procedure of Preparation 52.
.delta.(CDCl.sub.3): 0.95 (3H,t), 1.02 (3H,t), 1.66 (2H,m), 2.40
(2H,q), 2.51 (4H,m), 2.63 (2H,t), 3.09 (4H,m), 3.39 (3H,s), 3.88
(3H,s), 3.93 (2H.t), 4.80 (2H,t), 5.56 (2H,s), 5.81 (1H,s), 6.83
(1H,s). 6.92 (1H,s), 8.65 (1H,s), 8.82 (1H,s), 9.60 (1H,s), 10.08
(1H,s).
PREPARATION 110
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)py-
ridine
[0509] A mixture of 4-hydroxy-1-methylpiperidine (560 mg, 4.89
mmol), 60% sodium hydride dispersion in mineral oil (200 mg, 4.89
mmol) and tetrahydrofuran (30 ml) was stirred at about 0.degree. C.
for 30 minutes. The title compound of Preparation 13 (600 mg, 1.63
mmol) was added and the reaction mixture heated under reflux for 90
minutes, then allowed to cool. The resulting mixture was evaporated
under reduced pressure, the residue suspended in ethyl acetate (50
ml) and the suspension washed consecutively with 2M aqueous sodium
hydroxide solution (2.times.20 ml), water (20 ml) and brine (20
ml). The resulting solution was dried (MgSO.sub.4) and evaporated
under reduced pressure to give the title compound (660 mg, 70%) as
a yellow oil. .delta.(CDCl.sub.3): 1.05 (3H,t), 1.92 (2H,m), 2.04
(2H,m), 2.33 (3H,s), 2.42 (4H,m), 2.55 (4H,m), 2.66 (2H,m), 3.08
(4H,m), 5.24 (1H,m), 8.09 (1H,s), 8.42 (1H,s). LRMS: m/z 447
(M).sup.+.
PREPARATION 111
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridine-3-
-carboxylic acid ethyl ester
[0510] Triethylamine (2 ml, 1.43 mmol) and
tetrakis(triphenylphosphine)-pa- lladium(0) (200 mg, 0.173 mmol)
were added to a stirred solution of the title compound of
Preparation 110 (640 mg, 1.43 mmol) in ethanol (20 ml) and the
reaction mixture heated under carbon monoxide at 100.degree. C. and
1034 kPa (150 psi) in a sealed vessel for 18 hours, then allowed to
cool. The resulting mixture was evaporated under reduced pressure
and the residue purified by column chromatography on silica gel,
using dichloromethane: methanol (96.5:3.5) as eluant, to yield the
title compound (550 mg, 87%) as an orange solid.
.delta.(CDCl.sub.3): 1.02 (3H,t), 1.40 (3H,t), 2.16 (2H,m), 2.41
(2H,q), 2.56 (6H,m), 2.72 (3H,s), 3.08 (4H,m), 3.19 (4H,m), 4.38
(2H,q), 5.60 (1H,m), 8.42 (1H,s), 8.62 (1H,s). LRMS: m/z 441
(M+1).sup.+.
PREPARATION 112
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridine-3-
-carboxylic acid sodium salt
[0511] A mixture of the title compound of Preparation 111 (550 mg,
1.25 mmol), 1M aqueous sodium hydroxide solution (2.4 ml, 2.40
mmol) and ethanol (5 ml) was stirred at room temperature for 18
hours, then evaporated under reduced pressure. The residue was
partitioned between water (15 ml) and ethyl acetate (15 ml), the
phases separated and the aqueous phase evaporated under reduced
pressure to provide the title compound (510 mg, 94%) as a white
solid. .delta.(DMSOd.sub.6): 0.93 (3H,t), 1.94 (2H,m), 2.10 (2H,m),
2.16 (3H,s), 2.29 (2H,q), 2.40 (4H,m), 2.68 (4H,m), 2.88 (4H,m),
5.08 (1H,m), 7.75 (1H,s), 8.28 (1H,s).
PREPARATION 113a
4-Amino-1-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide
and
PREPARATION 113b
4-Amino-2-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide
[0512] 4-(2-Chloroethyl)morpholine (obtained by basification of the
hydrochloride salt (2.67 g, 14.35 mmol)) was added to a stirred
solution of the title compound of Preparation 36 (2.0 g, 11.96
mmol) and potassium hydroxide (800 mg, 14.35 mmol) in
dimethylformamide (20 ml) and the reaction mixture heated under
reflux for 18 hours, then allowed to cool. The resulting mixture
was evaporated under reduced pressure and the residue purified by
column chromatography on silica gel, using dichloromethane:
methanol: glacial acetic acid (95:5:1) as eluant, to furnish the
second title compound (2-isomer; 480 mg, 14%). .delta.(CDCl.sub.3):
0.98 (3H,t), 1.60 (2H,m), 2.48 (4H,m), 2.55 (2H,t), 2.76 (2H,t),
3.69 (4H,m), 3.94 (2H,s), 4.08 (2H,t), 5.19 (1H,s), 6.55 (1H,s).
LRMS: m/z 282 (M+1).sup.+; followed by the first title compound
(1-isomer;350 mg, 10%). .delta.(CDCl.sub.3): 0.97 (3H,t), 1.64
(2H,m), 2.50 (6H,m), 2.81 (2H,t), 3.48 (2H,s), 3.64 (4H,m), 4.50
(2H,t).
PREPARATION 114
3-t-Butyl-1H-pyrazole-5-carboxylic acid hydrochloride
[0513] Hydrazine hydrate (1.7 ml, 35 mmol) was added dropwise to a
stirred solution of 5,5-dimethyl-2,4-dioxohexanoic acid ethylester
(J. Org. Chem., 1997, 62, 5908; 6.1 g, 30.5 mmol) in ethanol (20
ml) and the reaction mixture stirred at room temperature for 4
hours, then evaporated under reduced pressure. The residue was
partitioned between dichloromethane (20 ml) and water (20 ml), the
phases separated and the aqueous phase extracted with
dichloromethane (2.times.20 ml). The combined organic solutions
were dried (MgSO.sub.4) and evaporated under reduced pressure to
give the crude ester as a yellow solid.
[0514] A mixture of this product, 1,4-dioxan (100 ml) and 2M
aqueous sodium hydroxide solution (25.5 ml, 51 mmol) was stirred at
room temperature for 72 hours, then the pH of the reaction mixture
adjusted to 2 with hydrochloric acid. The resulting mixture was
evaporated under reduced pressure and the residue triturated with
hot ethanol. This mixture was filtered and the filtrate evaporated
under reduced pressure to afford the title compound (5.06 g, 81%)
as an orange solid. .delta.(DMSOd.sub.6): 1.26 (9H,s), 6.46
(1H,s).
PREPARATION 115
3-t-Butyl-4-nitro-1H-pyrazole-5-carboxylic acid
[0515] The title compound of Preparation 114 (1.5 g, 7.3 mmol) was
added portionwise to stirred, ice-cooled concentrated sulphuric
acid (7.5 ml), the mixture warmed to 40.degree. C. and fuming
nitric acid (1.13 ml) then added dropwise, so as to maintain the
internal temperature below 50.degree. C. The reaction mixture was
stirred at 50.degree. C. for 7 hours, allowed to cool and poured
carefully onto ice/water (100 g). The resulting suspension was
stirred for 2 hours and filtered, then the collected solid washed
with water and dried under suction to give the title compound (975
mg, 63%) as a white solid. .delta.(DMSOd.sub.6): 1.33 (9H,s). LRMS:
m/z 231 (M+18).sup.+.
PREPARATION 116
3-t-Butyl-4-nitro-1H-pyrazole-5-carboxamide
[0516] Oxalyl chloride (1.59 ml, 18.2 mmol) was added dropwise to a
stirred, ice-cooled solution of the title compound of Preparation
115 (970 mg, 4.55 mmol) and dimethylformamide (1 drop) in
dichloromethane (20 ml) and the reaction mixture stirred at room
temperature for 3 hours, then evaporated under reduced pressure.
The residue was azeotroped firstly with dichloromethane and then
with 0.88 aqueous ammonia solution. The resulting material was
triturated with hot ethanol, then acetonitrile, the mixture
filtered and the filtrate evaporated under reduced pressure to
yield the title compound (955 mg, 99%) as a white solid.
.delta.(DMSOd.sub.6): 1.36 (9H,s), 7.60 (1H,s), 7.88 (1H,s). LRMS:
m/z 230 (M+18).sup.+.
PREPARATION 117
3-t-Butyl-4-nitro-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0517] A mixture of the title compound of Preparation 116 (960 mg,
4.55 mmol), caesium carbonate (3.7 g, 11.36 mmol) and
2-(chloromethyl)pyridine hydrochloride (821 mg, 5.00 mmol) in
acetonitrile (20 ml) was stirred at 70.degree. C. for 20 hours,
then allowed to cool and filtered. The filtrate was evaporated
under reduced pressure, then the residue purified by column
chromatography on silica gel, using an elution gradient of ethyl
acetate: methanol (100:0 to 95:5), to provide the title compound
(300 mg, 22%) as a yellow solid. .delta.(DMSOd.sub.6): 1.35 (9H,s),
5.40 (2H,s), 7.18 (1H,d), 7.32 (1H,m), 7.80 (1H,m), 8.10 (1H,s),
8.46 (1H,s), 8.51 (1H,d). LRMS: m/z 304 (M+1).sup.+.
PREPARATION 118
4-Amino-3-t-butyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0518] A stirred mixture of the title compound of Preparation 117
(290 mg, 0.96 mmol) and 10% palladium on charcoal (29 mg) in
ethanol (20 ml) was hydrogenated at 345 kPa (50 psi) and room
temperature for 7 hours, then filtered. The filter pad was washed
with ethanol and the combined washings and filtrate evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel, using an elution gradient of ethyl
acetate: methanol (100:0 to 95:5), to furnish the title compound
(220 mg, 84%) as an orange solid. .delta.(CDCl.sub.3): 1.36 (9H,s),
4.00 (2H,s), 5.50 (2H,s), 7.23 (1H,m), 7.38 (1H,d), 7.71 (1H,m),
8.50 (1H,d). LRMS: m/z 274 (M+1).sup.+.
PREPARATION 119
4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridin-
-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0519] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(350 mg, 1.8 mmol) was added to a stirred solution of
1-hydroxybenzotriazole hydrate (250 mg, 1.8 mmol), triethylamine
(350 .mu.l, 2.5 mmol) and the title compounds of Preparation 112
(510 mg, 1.18 mmol) and Preparation 41 (330 mg, 1.25 mmol) in
tetrahydrofuran (20 ml) and the reaction mixture stirred at room
temperature for 72 hours, then evaporated under reduced pressure.
The residue was triturated several times with ethyl acetate to
afford the title compound (175 mg, 21%) as a white solid.
.delta.(CDCl.sub.3): 0.81 (3H,t), 1.04 (3H,t), 1.47 (2H,m), 2.17
(4H,m), 2.32 (5H,m), 2.40 (2H,q), 2.53 (4H,m), 2.76 (2H,m), 2.84
(2H,t), 3.10 (4H,m), 5.49 (3H,m), 5.64 (1H,s), 6.90 (2H,M), 7.22
(1H,m), 7.68 (1H,m), 8.60 (1H,d), 8.64 (1H,s), 8.82 (1H,s), 10.35
(1H,s). LRMS: m/z 654 (M+1).sup.+.
PREPARATION 120
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2-(-
2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide
[0520] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(280 mg, 1.5 mmol) was added to a stirred solution of
1-hydroxybenzotriazole hydrate (200 mg, 1.5 mmol), triethylamine
(278 .mu.l, 2.0 mmol) and the title compounds of Preparation 23
(371 mg, 1.0 mmol) and Preparation 113b (250 mg, 0.9 mmol) in
dichloromethane (20 ml) and the reaction mixture stirred at room
temperature for 18 hours. The resulting mixture was washed with
water (10 ml), dried (MgSO.sub.4) and evaporated under reduced
pressure, then the residue purified by column chromatography on
silica gel, using an elution gradient of dichloromethane: methanol
(97:3 to 95:5), to give the title compound (430 mg, 68%) as a white
solid. .delta.(CDCl.sub.3): 0.93 (3H,t), 1.02 (3H,t), 1.58 (5H,m),
2.40 (2H,q), 2.52 (8H,m), 2.82 (2H,t), 2.90 (2H,t), 3.12 (4H,m),
3.72 (4H,m), 4.20 (2H,t), 4.79 (2H,q), 5.28 (1H,s), 6.63 (1H,s),
8.64 (1H,s), 8.82 (1H,s), 10.50 (1H,s).
PREPARATION 121
3-t-Butyl-4-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarbox-
amido]-1-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0521] The title compound of Preparation 28 (384 mg, 0.967 mmol)
was added dropwise to a stirred, ice-cooled solution of the title
compound of Preparation 118 220 mg, 0.805 mmol) and triethylamine
(330 .mu.l, 2.42 mmol) in dichloromethane (10 ml) and the reaction
mixture stirred at room temperature for 14 hours. The resulting
mixture was washed with aqueous sodium bicarbonate solution (5 ml)
and brine (5 ml), dried (Na.sub.2SO.sub.4) and evaporated under
reduced pressure. The residue was purified by two column
chromatography operations on silica gel, using an elution gradient
of ethyl acetate: methanol (100:0 to 90:10) and then of
dichloromethane: methanol (100:0 to 95:5), to yield the title
compound (156 mg, 32%) as a white solid. .delta.(CDCl.sub.3): 1.02
(3H,t), 1.36 (9H,s), 1.55 (3H,t), 2.42 (2H,q), 2.55 (4H,m), 3.10
(4H,m). 4.77 (2H,q), 5.68 (3H,m), 7.02 (1H,d), 7.19 (1H,m), 7.65
(1H,m), 7.98 (1H,s), 8.56 (1H,d), 8.70 (1H,s), 8.87 (1H,s), 9.35
(1H,s). LRMS: m/z 599 (M+1).sup.+.
PREPARATION 122
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-1-(-
2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide
[0522] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(1.34 g, 7.0 mmol) was added to a stirred solution of
1-hydroxybenzotriazole hydrate (945 mg. 7.0 mmol),
N-ethyldiisopropylamine (1.22 ml, 7.0 mmol) and the title compounds
of Preparation 113a (1.82 g, 6.5 mmol) and Preparation 23 (428 mg,
1.25 mmol) in tetrahydrofuran (120 ml) and the reaction mixture
stirred at room temperature for 72 hours. The resulting mixture was
evaporated under reduced pressure and the residue partitioned
between aqueous sodium carbonate solution (50 ml) and
dichloromethane (100 ml). The phases were separated, the aqueous
phase extracted with dichloromethane (2.times.100 ml) and the
combined organic solutions washed with brine (3.times.50 ml), dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was triturated with ether, then crystallised from ethyl
acetate-methanol, to provide the title compound (310 mg, 42%) as a
white solid. .delta.(CDCl.sub.3): 0.92 (3H,t), 1.01 (3H,t), 1.54
(3H,t), 1.62 (2H,m). 2.36-2.60 (12H,m), 2.80 (2H,t), 3.08 (4H,m),
3.64 (4H,m), 4.49 (2H,t), 4.72 (2H,q), 5.78 (1H,s), 8.30 (1H,s),
8.66 (1H,s), 8.80 (1H,s), 9.49 (1H,s). LRMS: m/z 607
(M+1).sup.+.
PREPARATION 123
3-Ethyl-1-methyl-4-nitropyrazole-5-carboxamide
and
PREPARATION 124
3-Ethyl-2-methyl-4-nitropyrazole-5-carboxamide
[0523] 94
[0524] A mixture of the title compound of Preparation 35 (100 g,
0.54 mol), and caesium carbonate (194 g, 0.60 mol) in
N,N-dimethylformamide (1000 ml) was stirred at room temperature for
45 minutes, then cooled in an ice-bath. Methyl iodide (37.2 ml,
0.60 mol) was added dropwise and once the addition was complete,
the reaction was stirred at room temperature for 18 hours. The
mixture was concentrated under reduced pressure and the residue
partitioned between ethyl acetate (500 ml) and water (300 ml). The
layers were separated, the aqueous phase extracted with ethyl
acetate (4.times.500 ml) and the combined organic solutions dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was recrystallised from dichloromethane/ethyl acetate to
give some of the N1 isomer (17.0 g, 16%).
[0525] The filtrate was evaporated under reduced pressure and the
residue was purified by column chromatography on silica gel, using
ethyl acetate: pentane (80:20) as eluant to afford the title
compound of Preparation 123 (25.0 g, 23%) as a white solid.
[0526] .delta.(CDCl.sub.3): 1.27 (3H, t), 2.94 (2H, q), 4.06 (3H,
s), 6.00 (1H, br s), 7.56 (1H, br s).
[0527] LRMS: m/z 216 (M+18).sup.+and the title compound of
Preparation 124 (28.4 g, 27%) as a white solid.
[0528] .delta.(CDCl.sub.3): 1.29 (3H, t), 3.00 (2H, q), 3.92 (3H,
s), 5.98 (1H, s), 7.32 (1H, s).
PREPARATION 125
2-Methyl-3-n-propyl-pyrazole-5-carboxylic acid ethyl ester
[0529] 95
[0530] A solution of diethyloxalate (27.2 ml, 0.2 mol) in
2-pentanone (21.2 ml, 0.2 mol) was added dropwise to a solution of
sodium (4.83 g, 0.21 mol) in ethanol (200 ml), and the reaction
stirred at 60.degree. C. for 5 hours, then cooled in an ice-bath.
The solution was neutralised using acetic acid (11.5 ml, 0.2 mol)
and N-methyl hydrazine (10.6 ml, 0.2 mol) then added dropwise. The
mixture was stirred for a further 4 hours at room temperature and
concentrated under reduced pressure. The residue was partitioned
between dichloromethane (300 ml) and water (200 ml), and the phases
separated. The aqueous layer was extracted with dichloromethane
(3.times.100 ml), the combined organic solutions were dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel, using
ethyl acetate: hexane (25:75) as eluant to give ethyl
1-methyl-3-n-propyl-pyraz- ole-5-carboxylate (6.1 g) and the title
compound (22.1 g, 56%).
[0531] 67 (CDCl.sub.3): 1.00 (3H, t), 1.40 (3H, t), 1.70 (2H, m),
2.60 (2H, t), 3.87 (3H, s), 4.40 (2H, q), 6.60 (1H, s).
PREPARATION 126
2-Methyl-3-n-propylpyrazole-5-carboxylic acid
[0532] 96
[0533] A mixture of the title compound of Preparation 125 (21.5 g,
0.11 mol) in aqueous sodium hydroxide solution (50 ml, 6N, 0.3 mol)
was heated under reflux for 3 hours. The cooled mixture was diluted
with water (50 ml) and acidified using concentrated hydrochloric
acid (25 ml) and the resulting precipitate was filtered and dried
to give the title compound (17.3 g, 94%) as a pale yellow solid. A
portion (1 g) of this solid, was recrystallised from
water/ethanol.
[0534] m.p. 120-122.degree. C. .delta.(DMSOd.sub.6): 0.95 (3H, t),
1.59 (2H, m), 2.60 (2H, t), 3.78 (3H, s), 6.48 (1H, s), 12.45 (1H,
s).
PREPARATION 127
2-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid
[0535] 97
[0536] Obtained as a solid (89%) from the title compound of
Preparation 126, using a similar procedure to that described in
Preparation 32. .delta.(DMSOd.sub.6): 0.95 (3H, t), 1.60 (2H, m),
2.96 (2H, t), 3.88 (3H, s), 13.75 (1H, s).
PREPARATION 128
2-Methyl-4-nitro-3-n-propylpyrazole-5-carboxamide
[0537] 98
[0538] A mixture of the title compound of Preparation 127 (18.6 g,
87.3 mmol) in thionyl chloride (75 ml), was heated under reflux for
2 hours. The cooled reaction mixture was concentrated under reduced
pressure and the residue poured into an ice/ammonium hydroxide
mixture. This was extracted with dichloromethane (4.times.100 ml)
and the combined organic extracts dried (MgSO.sub.4) and evaporated
under reduced pressure. The crude product was purified by column
chromatography on silica gel, using dichloromethane:methanol:0.88
ammonia (95:5:1) as eluant to afford the title compound (6.8 g,
37%) as a solid.
[0539] .delta.(CDCl.sub.3): 1.07 (3H, t), 1.72 (2H, m), 3.00 (2H,
t), 3.97 (3H, s), 6.14 (1H, s), 7.40 (1H, s).
PREPARATION 129
2,3-Diethyl-4-nitro-pyrazole-5-carboxamide
[0540] 99
[0541] Ethyl iodide (7.2 ml, 90.0 mmol) was added to a suspension
of the title compound of Preparation 35 (15.0 g, 81.0 mmol), and
cesium carbonate (29.3 g, 90.0 mmol) in N,N-dimethylformamide (100
ml) and the reaction stirred at room temperature for 18 hours. The
mixture was concentrated under reduced pressure and the residue
triturated with water (100 ml), and the resulting solid filtered
and dried. A suspension of this solid in ether (250 ml) was heated
at 35.degree. C. for an hour, and the precipitate filtered and
dried. This was recrystallised from ethyl acetate to afford the
title compound as a crystalline solid (5.8 g, 34%).
[0542] .delta.(CDCl.sub.3) 1.30 (3H, t), 1.54 (3H, t), 3.00 (2H,
q), 4.20 (2H, q), 5.92 (1H, s), 7.27 (1H, s).
[0543] LRMS: m/z 212 (M).sup.+
PREPARATION 130
3-Ethyl-4-nitro-2-(pyridazin-3-yl)methyl-pyrazole-5-carboxamide
[0544] 100
[0545] A mixture of the title compounds of Preparation 35 (2.66 g,
14.5 mmol), and 95 (2.65 g, 16.1 mmol) and caesium carbonate (13.1
g, 40.2 mmol) in acetonitrile (100 ml) was stirred under reflux for
18 hours. The cooled reaction was concentrated under reduced
pressure, the residue suspended in water and extracted with
dichloromethane (5.times.100 ml). The combined organic extracts
were dried (Na.sub.2SO.sub.4), adsorbed onto silica gel and the
product isolated by column chromatography on silica gel, using an
elution gradient of methanol: dichloromethane (5:95 to 10:90) to
give 3-ethyl-4-nitro-1-(pyridazin-3-yl)methyl-pyrazole-5-car-
boxamide (1.31 g) and the title compound (1.81 g, 45%) as a pale
yellow solid.
[0546] .delta.(CDCl.sub.3): 1.20 (3H, t), 3.11 (2H, q), 5.72 (2H,
s), 5.89 (1H, s), 7.29 (1H, s), 7.55 (2H, m), 9.20 (1H, d).
[0547] LRMS: m/z 277 (M+1).sup.+
PREPARATION 131
3-Ethyl-4-nitro-2-[1-(pyridin-2yl)ethyl]-pyrazole-5-carboxamide
[0548] 101
[0549] A mixture of 2-ethylpyridine (20.0 g, 187 mmol),
N-bromosuccinimide (38.0 g, 213 mmol), and benzoyl peroxide (1.09,
75% in water) in 1,1,1-trichloroethane (200 ml), was heated under
reflux for 3 hours. The cooled mixture was filtered, and the
filtrate washed with water (2.times.100 ml), aqueous sodium
thiosulphate solution (100 ml), and brine (100 ml). The solution
was dried (MgSO.sub.4), filtered through charcoal, and then
hydrobromic acid (25 ml, 62%) added. This solution was concentrated
under reduced pressure and azeotroped with toluene to give
2-(1-bromoethyl)pyridine hydrochloride as a dark oil (66.0 g).
[0550] A mixture of the title compound of Preparation 35 (8.0 g,
43.4 mmol), caesium carbonate (35.0 g, 107.4 mmol) and the crude
2-(1-bromoethyl)pyridine hydrochloride (13.6 g, 52.0 mmol) in
N,N-dimethylformamide (80 ml) was stirred at room temperature for
20 hours. The mixture was concentrated under reduced pressure and
the residue partitioned between ethyl acetate (150 ml) and water
(50 ml). The layers were separated and the organic phase washed
with more water (3.times.50 ml), brine (50 ml), then dried
(MgSO.sub.4) and evaporated under reduced pressure. The residual
oil was purified by column chromatography on silica gel, using an
elution gradient of pentane: ethyl acetate: methanol (90:10:0 to
0:100:0 to 0:90:10) to afford the N1 isomer (4.3 g), and the title
compound (5.7 g, 45%).
[0551] .delta.(CDCl.sub.3): 1.14 (3H, t), 2.01 (3H, d), 3.00 (2H,
q), 5.66 (2H, q), 5.88 (1H, s), 6.98 (1H, s), 7.18 (1H, d), 7.25
(1H, m), 7.68 (1H, m), 8.56 (1H, d).
[0552] LRMS: m/z 290 (M+1).sup.+
PREPARATION 132
3-Ethyl-2-(6-methylpyridin-2-yl)methyl-4-nitropyrazole-5-carboxamide
[0553] 102
[0554] A mixture of the title compound of Preparation 35 (4.32 g,
23.5 mmol) and 6-methyl-2-picolyl chloride hydrochloride (5.0 g,
23.4 mmol) in N,N-dimethylformamide (50 ml) was stirred at room
temperature for 20 hours. The reaction mixture was concentrated
under reduced pressure and the residue partitioned between water
(50 ml) and dichloromethane (50 ml). The layers were separated and
the aqueous phase extracted with dichloromethane (3.times.50 ml),
the combined organic solutions washed with brine (50 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel, twice, using
dichloromethane: methanol (95:5) as eluant and repeated using an
elution gradient of pentane: ethyl acetate (50:50 to 0:100) to give
the N1 isomer (1.0 g) and the title compound (2.47 g, 36%) as a
white solid.
[0555] .delta.(CDCl.sub.3): 1.18 (3H, t), 2.53 (3H, s), 3.06 (2H,
q), 5.42 (2H, s), 5.97 (1H, s), 6.90 (1H, d), 7.12 (1H, d), 7.22
(1H, s), 7.58 (1H, m).
[0556] LRMS: m/z 312 (M+23).sup.+
PREPARATION 133
2-Methoxy-6-methylpyridine
[0557] 103
[0558] Trimethyloxonium tetrafluoroborate (10.0 g, 67.6 mmol) was
added portionwise to a suspension of 6-methylpyridin-2-one (7.3 g,
67.0 mmol) in dichloromethane (100 ml), and once addition was
complete, the reaction was stirred at room temperature for 24
hours. Dichloromethane (50 ml) and aqueous sodium hydroxide
solution (50 ml, 2N) were added and the layers separated. The
aqueous phase was extracted with dichloromethane (2.times.50 ml),
the combined organic solutions washed with brine (50 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The crude
product was purified by column chromatography on silica gel, using
an elution gradient of pentane: dichloromethane (66:34 to 0:100) to
afford the title compound (2.25 g, 27%) as a colourless oil.
[0559] .delta.(CDCl.sub.3): 2.49 (3H, s), 3.90 (3H, s), 6.38-6.73
(2H, m), 7.23-7.40 (1H, br d).
PREPARATION 134
6-Bromomethyl-2-methoxypyridine
[0560] 104
[0561] A mixture of the title compound of Preparation 133 (2.5 g,
20.3 mmol), N-bromosuccinamide (3.7 g, 20.8 mmol) and benzoyl
peroxide (100 mg, 0.41 mmol) in 1,1,1-trichloroethane (50 ml) was
stirred under reflux for 3 hours, and a further 16 hours at room
temperature. The reaction was washed with water (2.times.25 ml),
aqueous sodium thiosulphate solution (25 ml), brine (25 ml) and
dried (MgSO.sub.4) and evaporated under reduced pressure. The
residue was shaken well with hydrobromic acid (62%, 2.4 ml), and
the suspension concentrated under reduced pressure, and azeotroped
twice with toluene, to give the title compound as a yellow solid.
.delta.(CDCl.sub.3): 3.95 (3H, s), 4.46 (2H, s), 6.63 (1H, d), 6.98
(1H, d), 7.53 (1H, m). LRMS: m/z 202/204 (M+1).sup.+
PREPARATION 135
3-Ethyl-2-(6-methoxypyridin-2-yl)methyl-4-nitro-pyrazole-5-carboxamide
[0562] 105
[0563] A mixture of the title compound of Preparation 134 (5.2 g,
18.4 mmol), caesium carbonate (6.58 g, 32.5 mmol) and the title
compound of Preparation 35 (3.4 g, 18.4 mmol) in
N,N-dimethylformamide (30 ml) was stirred at room temperature for
18 hours. The reaction was concentrated under reduced pressure, the
residue partitioned between ether (100 ml) and water (50 ml), and
the phases separated. The organic layer was washed with brine (20
ml), dried (MgSO.sub.4) and evaporated under reduced pressure. The
residual gum was triturated with ether, to give the title compound
(640 mg, 11%) as a white solid.
[0564] The filtrate was evaporated under reduced pressure and the
residue purified by column chromatography on silica gel, using
pentane: ethyl acetate (66:34) as eluant to give a further (280 mg,
5%) of the title compound.
[0565] .delta.(DMSOd.sub.6) 1.18 (3H, t), 2.84 (2H, q), 3.68 (3H,
s), 5.34 (2H, s), 6.73 (2H, m), 7.66 (1H, m), 8.17 (1H, s), 8.39
(1H, s).
[0566] LRMS: m/z 306 (M+1).sup.+
PREPARATION 136
4-Amino-2-methyl-3-n-propylpyrazole-5-carboxamide
[0567] 106
[0568] A mixture of the title compound of Preparation 128 (6.17 g,
29.0 mmol) and tin (II) chloride dihydrate (32.8 g, 145 mmol) in
industrial methylated spirits (IMS) (100 ml) was heated under
reflux for 2 hours. The cooled mixture was ccncentrated under
reduced pressure to approximately half it's volume, basified to pH
9 using aqueous 2N sodium hydroxide solution, and extracted with
dichloromethane (3.times.300 ml). The combined organic extracts
were dried (MgSO.sub.4) and evaporated under reduced pressure and
the crude product recrystallised from ethyl acetate/methanol to
afford the title compound (4.86 g, 92%).
[0569] m.p.170-174.degree. C.
[0570] .delta.(DMSOd.sub.6): 0.90 (3H, t), 1.47 (2H, m), 2.50 (2H,
t), 3.68 (3H, s), 4.43 (2H, s), 6.92 (1H, s), 7.04 (1H, s).
PREPARATION 137
4-Amino-2,3-diethyl-pyrazole-5-carboxamide
[0571] 107
[0572] A mixture of the title compound of Preparation 129 (5.7 g,
26.9 mmol) and tin (II) chloride dihydrate (29.0 g, 128 mmol) in
ethanol (200 ml) was heated under reflux for 45 minutes. The cooled
reaction mixture was evaporated under reduced pressure and
re-dissolved in ethyl acetate (200 ml). This solution was poured
into a 10% aqueous solution of sodium carbonate (400 ml), and the
mixture stirred vigorously for an hour. The layers were separated
and the aqueous phase was extracted with ethyl acetate (2.times.100
ml). The combined organic solutions were dried (Na.sub.2SO.sub.4)
and concentrated under reduced pressure to a volume of 50 ml, and
the resulting crystals filtered off and dried, to afford the title
compound (3.3 g, 67%).
[0573] .delta.(CDCl.sub.3): 1.19 (3H, t), 1.40 (3H, t), 2.59 (2H,
q), 3.94 (2H, s), 4.02 (2H, q), 5.20 (1H, s), 6.57 (1H, s).
[0574] LRMS: m/z 183 (M+1).sup.+
PREPARATION 138
4-Amino-3-ethyl-2-methylpyrazole-5-carboxamide
[0575] 108
[0576] A mixture of the title compound of Preparation 124 (5.8 g,
29.3 mmol) and 10% palladium on charcoal (650 mg) in ethanol (100
ml) was hydrogenated at 60 psi and room temperature for 20 hours.
The reaction was filtered through Arbocel.RTM. and the filter pad
washed well with hot ethanol (200 ml). The combined filtrate was
evaporated under reduced pressure to afford the title compound as a
solid (4.7 g, 95%).
[0577] .delta.(CDCl.sub.3): 1.20 (3H, t), 2.59 (2H, q), 3.77 (3H,
s), 3.95 (2H, s), 5.21 (1H, s), 6.54 (1H, s).
PREPARATIONS 139 TO 142
[0578] The compounds of the following tabulated Preparations of
general formula: 109
[0579] were prepared from the corresponding nitropyrazoles, using a
similar procedure to that described in Preparation 138.
6 LRMS: Preparation R m/z .sup.1H nmr 139 110 .delta. (CDCl.sub.3):
0.98 (3H, t), 1.93 (3H, d), 2.50 (2H, q), 3.98 (2H, s), 5.23 (1H,
s), 5.50 (1H, q), 6.68 (1H, s), 6.80 (1H, d), 7.17 (1H, m), 7.59
(1H, m), 8.54 (1H, d). 140 111 282 (M + 23).sup.+ .delta.
(CDCl.sub.3): 1.04 (3H, t), 2.55 (5H, m), 4.00 (2H, s), 5.19 (1H,
s), 5.30 (2H, s), 6.52 (1H, d), 6.60 (1H, s), 7.03 (1H, d), 7.48
(1H, m). 141.sup.1 112 298 (M + 23).sup.+ .delta. (CDCl.sub.3):
1.22 (3H, t), 2.57 (2H, q), 3.78 (2H, s), 3.84 (3H, s), 5.45 (2H,
s), 6.68 (1H, d), 6.90 (1H, d), 7.58 (1H, m). 142 113 247 (M +
1).sup.+ .delta. (CDCl.sub.3): 1.05 (3H, t), 2.58 (2H, q), 4.01
(2H, s), 5.28 (1H, br s), 5.59 (2H, s), 6.60 (1H, br s), 7.11 (1H,
d), 7.42 (1H, m), 9.15 (1H, d). .sup.1= purified by column
chromatography using ethyl acetate as eluant
PREPARATION 143
4-Amino-3-ethyl-1-methylpyrazole-5-carboxamide
[0580] 114
[0581] A mixture of the title compound of Preparation 123 (940 mg,
4.75 mmol), and 10% palladium on charcoal (200 mg) in ethanol (100
ml) was hydrogenated at 50.degree. C. and 50 psi for 18 hours. The
cooled mixture was filtered through Arbocel.RTM., and the filtrate
evaporated under reduced pressure to afford the title compound (786
mg, 98%) as a clear oil.
[0582] .delta.(CDCl.sub.3): 1.23 (3H, t), 2.59 (2H, q), 2.82 (2H,
s), 4.12 (3H, s).
[0583] LRMS: m/z 169 (M+1).sup.+
PREPARATION 144
3-Bromo-2-chloro-5-(4-methylpiperazin-1-ylsulphonyl)pyridine
[0584] 115
[0585] N-Methylpiperazine (7.65 ml, 69.0 mmol) was added dropwise
to a solution of the title compound of Preparation 12 (10.0 g, 34.5
mmol) in ethanol (200 ml), and the reaction stirred at room
temperature for 3 hours. The mixture was concentrated under reduced
pressure and the residue partitioned between dichloromethane (200
ml) and water (100 ml) and the layers separated. The organic phase
was dried (Na.sub.2SO.sub.4), and evaporated under reduced pressure
to afford the title compound (10.53 g, 87%) as a yellow solid.
[0586] .delta.(CDCl.sub.3): 2.28 (3H, s), 2.51 (4H, m), 3.14 (4H,
m), 8.24 (1H, s), 8.67 (1H, s).
PREPARATION 145
3-Bromo-2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine
[0587] 116
[0588] A mixture of the title compound of Preparation 144 (10.0 g,
39.1 mmol), potassium bis(trimethylsilyl)amide (5.92 g, 29.7 mmol)
and ethanol (3.5 ml) in tetrahydrofuran (150 ml) was stirred at
room temperature for 24 hours. The reaction mixture was
concentrated under reduced pressure and the residue partitioned
between ethyl acetate (150 ml) and brine (50 ml). The layers were
separated, and the organic phase dried (Na.sub.2SO.sub.4), filtered
and evaporated under reduced pressure, to afford the title
compound, (9.1 g, 88%).
[0589] .delta.(CDCl.sub.3): 1.44 (3H, t), 2.29 (3H, s), 2.51 (4H,
m), 3.08 (4H, m), 4.54 (2H, q). 8.10 (1H, s), 8.44 (1H, s).
[0590] LRMS: m/z 365 (M+1).sup.+
PREPARATION 146
3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine
[0591] 117
[0592] A mixture of the title compound of Preparation 13 (1.11 g,
3.0 mmol) and n-propylamine (590 mg, 10.0 mmol) in toluene (20 ml)
was stirred under reflux for 90 minutes. The cooled mixture was
partitioned between ethyl acetate (50 ml) and water (20 ml), and
the layers separated. The organic phase was washed with brine (20
ml), dried (Na.sub.2SO.sub.4) and evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel, using an elution gradient of dichloromethane: methanol
(100:0 to 96:4) to afford the title compound (1.15 g, 98%) as a
yellow crystalline solid.
[0593] .delta.(CDCl.sub.3): 1.02 (6H, m), 1.68 (2H, m), 2.41 (2H,
q), 2.54 (4H, m), 3.06 (4H, m). 3.47 (2H. q), 5.57 (1H, m), 7.86
(1H, s), 8.40 (1H, s).
[0594] LRMS: m/z 393 (M+2).sup.+
PREPARATION 147
2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid ethyl ester
[0595] 118
[0596] Obtained (85%) as an orange solid, from the title compound
of Preparation 145 using a similar procedure to that described in
Preparation 21.
[0597] .delta.(CDCl.sub.3): 1.40 (3H, t), 1.46 (3H. t), 2.28 (3H,
s), 2.50 (4H, m), 3.09 (4H, m), 4.40 (2H, q), 4.57 (2H, q), 8.40
(1H, s), 8.63 (1H, s). LRMS: m/z 358 (M+1).sup.+
PREPARATION 148
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine-3-carboxylic
acid ethyl ester
[0598] 119
[0599] A mixture of the title compound of Preparation 146 (1.10 g,
2.81 mmol), triethylamine (5 ml), and
tetrakis(triphenylphosphine)palladium (0) (250 mg, 0.216 mmol) in
ethanol (25 ml) was stirred under an atmosphere of carbon monoxide
at 100.degree. C. and 100 psi for 16 hours. The cooled solution was
evaporated under reduced pressure and the residue purified by
column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 96:4) to afford the title
compound (1.07 g, 99%) as a yellow oil.
[0600] .delta.(CDCl.sub.3): 1.02 (6H, t), 1.40 (3H, t), 1.69 (2H,
m), 2.40 (2H, q), 2.55 (4H, m), 3.05 (4H, m), 3.54 (2H, q), 4.37
(2H, q), 8.37 (1H, s), 8.57 (2H, m).
[0601] LRMS: m/z 385 (M+1).sup.+
PREPARATION 149
2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic
acid hydrochloride
[0602] 120
[0603] Sodium hydroxide solution (21 ml, 2M, 42.0 mmol) was added
to a solution of the title compound of Preparation 147 (7.57 g,
21.0 mmol) in dioxan (150 ml) and the reaction stirred at room
temperature for 18 hours. The mixture was neutralised using
hydrochloric acid, the dioxan removed under reduced pressure and
the remaining aqueous solution acidified to pH 2, using
hydrochloric acid. The solution was evaporated under reduced
pressure, the residue re-suspended in hot ethanol, filtered, and
the filtrate re-evaporated to afford the title compound (5.46 g,
71%).
[0604] .delta.(DMSOd.sub.6): 1.37 (3H, t), 2.50 (4H, m), 2.72 (3H,
s), 3.13-3.39 (4H, m), 4.53 (2H, q), 8.30 (1H, s), 8.75 (1H,
s).
[0605] LRMS: m/z 330 (M+1).sup.+
PREPARATION 150
5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine-3-carboxyiic
acid sodium salt
[0606] 121
[0607] A mixture of the title compound of Preparation 148 (1.06 g,
2.76 mmol) in sodium hydroxide solution (1.5 ml, 2N, 3.0 mmol) and
ethanol (10 ml) was stirred at room temperature for 4 hours. The
reaction was evaporated under reduced pressure, the solid
triturated with ether, and the suspension filtered and dried to
afford the title compound (950 mg).
[0608] .delta.(DMSOd.sub.6): 0.87 (6H, t), 1.50 (2H, m), 2.43 (2H,
q), 2.56 (4H, m), 2.78 (4H, m), 3.34 (2H, t), 8.08 (1H, s), 8.16
(1H, s).
PREPARATION 151
4-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2--
methyl-3-n-propylpyrazole-5-carboxamide
[0609] 122
[0610] The title compound of Preparation 136 (525 mg, 2.88 mmol)
was added to a mixture of the title compound of Preparation 149
(1.04 g, 3.2 mmol), 1-hydroxybenzotriazole hydrate (470 mg, 3.5
mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(670 mg, 3.5 mmol) and N-ethyldiisopropylamine (2.4 ml, 14.0 mmol)
in tetrahydrofuran (50 ml), and the reaction stirred at room
temperature for 36 hours. The reaction mixture was concentrated
under reduced pressure and the residue suspended in sodium
carbonate solution (20 ml) and extracted with dichloromethane
(3.times.20 ml). The combined organic extracts were washed with
brine (3.times.20 ml), dried (Na.sub.2SO.sub.4) and evaporated
under reduced pressure. The crude product was triturated with ether
to give a yellow solid which was then purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 96:4) to give the title
compound (720 mg, 51%) as a white solid.
[0611] A sample (50 mg) of this product was recrystallised from
ethyl acetate to give colourless crystals (32 mg) of the title
compound.
[0612] m.p. 242-244.degree. C.
[0613] .delta.(CDCl.sub.3): 0.95 (3H, t), 1.59 (5H, m), 2.27 (3H,
s), 2.48 (4H, m), 2.89 (2H, t), 3.10 (4H, m), 3.86 (3H, s), 4.79
(2H, q), 5.27 (1H, s), 6.63 (1H, s), 8.65 (1H, s), 8.84 (1H, s),
10.53 (1H, s).
[0614] LRMS: m/z 494 (M+1).sup.+
PREPARATION 152
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-2-methylpyrazole-5-carboxamide
[0615] 123
[0616] Obtained as a solid (65%) from the title compounds of
Preparations 23 and 138, following the procedure described in
Preparation 151.
[0617] .delta.(CDCl.sub.3): 1.02 (3H, t), 1.21 (3H, t), 1.58 (3H,
t), 2.39 (2H, q), 2.54 (4H, m), 2.90 (2H, q), 3.10 (4H, m), 3.84
(3H, s), 4.78 (2H, q), 5.30 (1H, s), 6.63 (1H, s), 8.64 (1H, s),
8.83 (1H, s), 10.54 (1H, s).
[0618] LRMS: m/z 494 (M+1).sup.+
PREPARATION 153
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2-m-
ethyl-3-n-propylpyrazole-5-carboxamide
[0619] 124
[0620] Obtained as a solid (64%) from the title compounds of
Preparations 23 and 136, following a similar procedure to that
described in Preparation 151, except an elution gradient of
methanol: ethyl acetate (7:93 to 10:90) was used as the
chromatographic eluant.
[0621] .delta.(CDCl.sub.3): 0.94 (3H, t), 1.02 (3H, t), 1.60 (5H,
m), 2.40 (2H, q), 2.54 (4H, m), 2.89 (2H, t), 3.10 (4H, m), 3.84
(3H, s), 4.78 (2H, q), 5.25 (1H, s), 6.63 (1H, s), 8.65 (1H, s),
8.83 (1H, s), 10.52 (1H, s).
[0622] LRMS: m/z 508 (M+1).sup.+
PREPARATION 154
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2,3-
-diethylpyrazole-5-carboxamide
[0623] 125
[0624] The title compound of Preparation 137 (3.3 g, 16.8 mmol) and
triethylamine (7.5 ml, 54.0 mmol) were added to an ice-cooled
solution of the title compound of Preparation 28 (6.51 g, 18.0
mmol) in dichloromethane (100 ml), and the reaction was stirred at
room temperature for 18 hours. The mixture was washed consecutively
with brine (50 ml), aqueous sodium bicarbonate solution (2.times.50
ml), then dried (Na.sub.2SO.sub.4) and evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel, using an elution gradient of dichloromethane: methanol
(100:0 to 90:10) to afford the title compound as a solid.
[0625] .delta.(CDCl.sub.3): 1.04 (3H, t), 1.22 (3H, t), 1.50 (3H,
t), 1.59 (3H, t), 2.40 (2H, q), 2.54 (4H, m), 2.91 (2H, q), 3.10
(4H, m), 4.16 (2H, q), 4.78 (2H, q), 5.30 (1H, s), 6.68 (1H, s),
8.65 (1H, s), 8.84 (1H, s), 10.55 (1H, s).
[0626] LRMS: m/z 508 (M+1).sup.+
PREPARATIONS 155 TO 157
[0627] The compounds of the following tabulated Preparations of the
general formula: 126
[0628] were prepared, from the title compound of Preparation 28 and
the appropriate amines, following similar procedures to that
described in Preparation 154.
7 Prep. R1 Data 155.sup.1 127 .delta. (CDCl.sub.3): 1.02 (6H, m),
1.59 (3H, t), 1.98 (3H, d), 2.40 (2H, q), 2.54 (4H, m), 2.86 (2H,
q), 3.09 (4H, m), 4.79 (2H, q), 5.32 (1H, s), 5.67 (1H, q), 6.77
(1H, s), 6.94 (1H, d), 7.20 (1H, m), 7.63 (1H, m), 8.58 (1H, d),
8.65 (1H, s), 8.82 (1H, s), 10.55 (1H, s). LRMS: m/z 585 (M +
1).sup.+ 156.sup.2 128 .delta. (CDCl.sub.3): 1.04 (6H, m), 1.59
(3H, t), 2.40 (2H, q), 2.52 (4H, m), 2.59 (3H, s), 2.89 (2H, q),
3.09 (4H, m), 4.80 (2H, q), 5.30 (1H, s), 5.42 (2H, s), 6.62 (1H,
d), 6.70 (1H, s), 7.08 (1H, d), 7.54 (1H, m), 8.64 (1H, s), 8.82
(1H, s), 10.61 (1H, s). 157.sup.2 129 .delta. (CDCl.sub.3): 1.04
(3H, t), 1.23 (3H, t), 1.59 (3H, t), 2.41 (2H, q), 2.54 (4H, m),
2.70 (2H, q), 3.10 (4H, m), 3.86 (3H, s), 4.78 (2H, q), 5.52 (2H,
s), 5.66 (1H, s), 6.70 (1H, d), 6.93 (1H, d), 7.59 (1H, m), 8.68
(1H, s), 8.83 (1H, s), 9.02 (1H, s), 9.90 (1H, s). LRMS: m/z 601 (M
+ 1).sup.+ .sup.1= the title compound was isolated by trituration
with ether. .sup.2= ethyl acetate: methanol (94:6) was used as the
chromatographic eluant.
PREPARATION 158
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-1-methylpyrazole-5-carboxamide
[0629] 130
[0630] Obtained (51%) as a white solid from the title compounds of
Preparations 23 and 143, using a similar procedure to that
described in Preparation 151.
[0631] .delta.(CDCl.sub.3): 1.03 (3H, t), 1.25 (3H, t), 1.57 (3H,
t), 2.42 (2H, q), 2.58 (6H, m), 3.10 (4H, m), 4.06 (3H, s), 4.76
(2H, q), 5.57 (1H, br s), 7.55 (1H, br s), 8.70 (1H, s), 8.83 (1H,
s). 9.24 (1H, s).
[0632] LRMS: m/z 494 (M+1).sup.+
PREPARATION 159
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-1-m-
ethyl-3-n-propylpyrazole-5-carboxamide
[0633] 131
[0634] A mixture of the title compounds of Preparation 24 (2.0 g,
5.48 mmol), the hydrochloride salt of
4-amino-1-methyl-3-n-propylpyrazole-5-ca- rboxamide, EP-A-0463756;
(1.08 g, 4.94 mmol), 1-hydroxybenzotriazole hydrate (920 mg, 6.87
mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimid- e
hydrochloride (1.15 g, 6.0 mmol) and N-ethyldiisopropylamine (2.86
ml, 16.5 mmol) in tetrahydrofuran (20 ml) was stirred at room
temperature for 18 hours. The reaction mixture was concentrated
under reduced pressure and the residue partitioned between ethyl
acetate (100 ml) and water (50 ml). The layers were separated and
the organic phase was dried (MgSO.sub.4) and evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel, using dichloromethane: methanol (95:5) as eluant to
afford the title compound (940 mg, 38%), as a white solid.
[0635] .delta.(CDCl.sub.3): 0.95 (3H, t), 1.02 (3H, t), 1.52 (3H.
t), 1.63 (2H, m), 2.40 (2H, q), 2.54 (6H, m), 3.09 (4H, m), 4.05
(3H, s), 4.75 (2H, q), 5.81 (1H, s), 7.58 (1H, s), 8.67 (1H, s),
8.80 (1H, s), 9.25 (1H, s).
[0636] LRMS: m/z 509 (M+2).sup.+
PREPARATION 160
3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridin-3-ylc-
arboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide
[0637] 132
[0638] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(250 mg, 1.3 mmol) was added to a solution of the title compounds
of Preparations 40 (245 mg, 1.0 mmol) and 150 (456 mg, 1.2 mmol),
N-ethyldiisopropylamine (194 mg, 1.5 mmol) and
1-hydroxybenzotriazole hydrate (203 mg, 1.5 mmol) in
dichloromethane (10 ml), and the reaction stirred at room
temperature for 16 hours. The reaction was poured into ethyl
acetate (30 ml), washed with water (10 ml) and brine (10 ml), dried
(MgSO.sub.4) and evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel using an elution
gradient of dichloromethane: methanol (100:0 to 94:6), and
triturated with ether, to afford the title compound (242 mg, 41%)
as a white solid.
[0639] .delta.(CDCl.sub.3): 0.95 (3H, t). 1.01 (6H, m), 1.62 (2H,
m), 2.39 (2H, q), 2.52 (4H, m), 2.86 (2H, q), 3.09 (4H. m), 3.46
(2H, q), 5.39 (1H, s), 5.43 (2H, s). 6.64 (1H, s), 6.87 (1H, d),
7.20 (1H. m), 7.63 (1H, m), 8.17 (1H, s), 8.53 (1H, s), 8.58 (1H,
d), 8.64 (1H, m), 9.58 (1H, s).
[0640] LRMS: m/z 584 (M+1).sup.-
PREPARATION 161
4-(2-Ethoxy-5-nitropyridin-3-ylcarboxamido)-3-ethyl-2-methylpyrazole-5-car-
boxamide
[0641] 133
[0642] Oxalyl chloride (2.6 ml, 30.2 mmol) was added dropwise to an
ice-cooled solution of the title compound of Preparation 8 (1.6 g,
7.55 mmol) and N,N-dimethylformamide (1 drop) in dichloromethane
(40 ml), and the reaction stirred at room temperature for 3 hours.
The mixture was concentrated under reduced pressure and azeotroped
with dichloromethane several times.
[0643] This intermediate acid chloride was added to an ice-cooled
solution of the title compound of Preparation 138 (960 mg, 5.74
mmol) and triethylamine (2.6 ml, 18.7 mmol) in dichloromethane (40
ml), and the reaction stirred at room temperature for 2 hours. The
mixture was washed with water (20 ml), brine (20 ml), dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel, using
an elution gradient of dichloromethane: methanol (100:0 to 90:10)
to afford the title compound (2.06 g, 99%).
[0644] .delta.(CDCl.sub.3): 1.24 (3H, t), 1.61 (3H, t), 2.92 (2H,
q), 3.88 (3H, s), 4.84 (2H, q), 5.27 (1H, s), 6.66 (1H, s), 9.17
(1H, s), 9.33 (1H, s), 10.57 (1H, s).
[0645] LRMS: m/z 363 (M+1).sup.-
PREPARATION 162
4-(5-Amino-2-ethoxypyridin-3-ylcarboxamido)-3-ethyl-2-methylpyrazole-5-car-
boxamide
[0646] 134
[0647] A mixture of the title compound of Preparation 161 (2.06 g,
5.7 mmol) and 10% palladium on charcoal (200 mg) in ethanol (70 ml)
was hydrogenated at room temperature and 50 psi, for 6 hours. The
reaction mixture was filtered through Arbocel.RTM., the filter pad
washed with further ethanol, and the combined filtrates evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 95:5) to afford the title
compound (760 mg, 40%) as a solid.
[0648] .delta.(CDCl.sub.3): 1.23 (3H, t), 1.54 (3H, t), 2.87 (2H,
q), 3.50 (2H, s), 3.87 (3H, s), 4.60 (2H, q), 5.24 (1H, s), 6.62
(1H, s), 7.78 (1H, s), 7.96 (1H, s), 10.54 (1H, s).
[0649] LRMS: m/z 333 (M+1).sup.+
PREPARATION 163
5-(5-Amino-2-ethoxypyridin-3-yl)-3-ethyl-2-methylpyrazole-2,6-dihydro-7H-p-
yrazolo[4,3-d]pyrimidin-7-one
[0650] 135
[0651] A mixture of the title compound of Preparation 162 (760 mg,
2.29 mmol) and potassium bis(trimethylsilyl)amide (685 mg, 3.43
mmol) in ethanol (50 ml) was heated at 100.degree. C. in a sealed
vessel for 20 hours. The cooled mixture was evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel, using an elution gradient of dichloromethane:
methanol (100:0 to 95:5) to afford the title compound (550 mg, 76%)
as a solid.
[0652] .delta.(CDCl.sub.3): 1.41 (3H, t), 1.53 (3H, t), 3.03 (2H,
q), 3.58 (2H, s), 4.09 (3H, s), 4.58 (2H, q), 4.78 (1H, s), 8.20
(1H, s), 11.17 (1H, s).
[0653] LRMS: m/z 315 (M+1).sup.+
PREPARATION 164
5-(5-Chlorosulphonyl-2-ethoxypyridin-3-yl)-3-ethyl-2-methylpyrazole-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0654] 136
[0655] Obtained (72%) from the title compound of Preparation 163
following a similar procedure to that described in Preparation
63.
[0656] .delta.(CDCl.sub.3): 1.42 (3H, t), 1.60 (3H, t), 3.07 (2H,
q), 4.14 (3H, s), 4.82 (2H, q), 8.92 (1H, s), 9.36 (1H, s), 10.58
(1H, s).
PREPARATION 165
(R)-1-Methoxy-2-propanol
[0657] 137
[0658] Sodium methoxide (54 g, 1.0 mol) was added portionwise to
ice-cooled methanol (1000 ml), and the resulting solution stirred
for 20 minutes in an ice-bath. (R)-Propylene oxide (58 g, 1 mol)
was added dropwise over 30 minutes, and once addition was complete,
the reaction was stirred at room temperature for 18 hours. The
mixture was concentrated under reduced pressure, and acidified,
with ice-cooling, using (1M) ethereal hydrochloric acid, and the
resulting mixture stirred for an hour, then filtered. The filtrate
was dried (K.sub.2CO.sub.3), filtered and evaporated under reduced
pressure. The residue was heated to 70.degree. C. over dried
calcium oxide for 30 minutes, then distilled at atmospheric
pressure to afford the title compound (25.4 g, 28%) as an oil.
[0659] b.p. 118-120.degree. C.
[0660] .delta.(CDCl.sub.3): 1.16 (3H, d), 2.28 (1H, d), 3.20 (1H,
m), 3.36 (1H, m), 3.40 (3H, s), 3.97 (1H, m).
[0661] [.alpha.].sub.D-20.83.degree. (c=1.02, dichloromethane)
PREPARATION 166
4-Methoxy-2-butanol
[0662] 138
[0663] Lithium aluminium hydride (220 ml 1.0M solution in
tetrahydrofuran, 220 mmol) was added dropwise over 15 minutes, to
an ice-cooled solution of 4-methoxybut-3-en-2-one (20.0 g, 200
mmol) in tetrahydrofuran (200 ml), and the reaction stirred at room
temperature for 16 hours. The solution was re-cooled in an
ice-bath, water (8 ml) was added dropwise, followed by 15% aqueous
sodium hydroxide solution (8 ml), and after a further 10 minutes,
additional water (24 ml). The mixture was stirred for 20 minutes,
filtered, and the filtrate concentrated under reduced pressure to a
volume of 100 ml. 10% Palladium on charcoal (500 mg) was added and
the mixture hydrogenated at 60 psi for 16 hours. The reaction was
filtered through Arbocel.RTM., and the filtrate evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel using an elution gradient of dichloromethane: ether
(99:1 to 50:50) to afford the title compound (4.0 g, 19%).
[0664] .delta.(CDCl.sub.3): 1.20 (3H, d), 1.67-1.78 (2H, m), 2.80
(1H, s), 3.38 (3H, s), 3.55-3.65 (2H, m), 4.00 (1H, m).
PREPARATION 167
N-Methylcyclopropylcarboxamide
[0665] 139
[0666] Cyclopropane carboxylic acid (15.83 ml, 200 mmol) was added
dropwise to a warm (40.degree. C.) solution of thionyl chloride
(16.71 ml, 213 mmol) in toluene (80 ml), and once addition was
complete, the reaction was stirred at 80.degree. C. for 2 hours.
The mixture was cooled in an ice-bath, a solution of methylamine in
tetrahydrofuran (300 ml, 2M, 600 mmol) was added, the mixture
allowed to warm to room temperature and concentrated under reduced
pressure. The residue was suspended in dichloromethane (200 ml),
washed with saturated aqueous sodium bicarbonate solution (200 ml),
brine (200 ml). dried (MgSO.sub.4) and evaporated under reduced
pressure. The residual white solid was recrystallised from
hexane/ether, to afford the title compound (11.3 g, 57%) as a white
crystalline solid.
[0667] Found: C, 58.73; H, 9.30; N, 13.70.
C.sub.5H.sub.9NO:0.2H.sub.2O requires C, 58.46: H, 9.22; N,
13.63%
[0668] .delta.(CDCl.sub.3): 0.70 (2H. m), 0.95 (2H, m). 1.32 (1H.
m), 2.81 (3H, d), 5.73 (1H. s).
[0669] LRMS: m/z 199 (M+1).sup.+
PREPARATION 168
N-Cyclopropylmethyl-N-methylamine hydrochloride
[0670] 140
[0671] A solution of the title compound of Preparation 167 (7.90 g,
79.7 mmol) in ether (75 ml) was added dropwise over 5 minutes to a
suspension of lithium aluminium hydride (3.03 g, 96.0 mmol) in
ether (100 ml), and the reaction stirred under reflux for 4 hours.
The cooled mixture was quenched by the consecutive addition of
water (3 ml), 10% aqueous sodium hydroxide solution (9 ml) and
water (3 ml). The resulting suspension was stirred for 5 minutes,
filtered and the solids washed well with ether (100 ml). The
combined filtrate was dried (MgSO.sub.4), cooled in an ice-bath,
and saturated with hydrochloric acid. This solution was evaporated
under reduiced pressure to afford the title compound (8.7 g, 90%)
as a gum.
[0672] .delta.(CDCl.sub.3): 0.45 (2H, m), 0.72 (2H, m), 1.24 (1H,
m), 2.70 (3H, t). 2.88 (3H, t), 2.88 (2H, m), 9.48 (2H, br s).
Preparation 169
4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-e-
thyl-2-(1-methylimidazol-2-yl) methylpyrazole-5-carboxamide
[0673] 141
[0674] 1-3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(1.2 g. 6.25 mmol) was added to a solution of the preparations of
23 (1.6 g. 4.66 mmol) and 89 (1.2 g, 4.84 mmol),
hydroxybenzotriazole hydrate (960 mg. 6.2 mmol) and
N-ethyidiisopropylamine (2.5 ml, 14.5 mmol) in tetrahydrofuran (15
ml), and N,N-dimethylformamide (3 ml), and the reaction stirred at
room temperature for 18 hours. The mixture was diluted with water
(100 ml). and extracted with dichloromethane (3.times.150 ml). The
combined organic extracts were dried (Na.sub.2SO.sub.4) and
evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel using dichloromethane:methanol
(95:5) as eluant to afford the title compound (1.42 g, 2.55
mmol).
[0675] .delta.(CDCl.sub.3): 0.98-1.16 (6H, m), 1.52-1.70 (6H, m),
2.40 (2H, q), 2.55 (4H, m), 2.99-3.16 (6H, m), 3.72 (3H, s), 4.78
(2H. q), 5.30 (1H, br s), 5.44 (2H, s), 6.60 (1H, br s), 6.86 (1H,
s), 7.00 (1H. s), 8.65 (1H, s), 8.82 (1H, s), 10.48 (1H, s).
[0676] LRMS: m/z 574 (M+18).sup.+
Preparation 170
5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-m-
ethylimidazol-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
[0677] 142
[0678] Obtained as a cream foam (62%) from the title compound of
Preparation 169 following a similar procedure to that described in
Example 78.
[0679] .delta.(CDCl.sub.3): 1.00 (3H. t), 1.30 (3H, t), 1.57 (3H,
t), 2.40 (2H, q), 2.54 (4H, m), 3.06-3.20 (6H, m), 3.78 (3H, s),
4.75 (2H, q), 5.64 (2H, s), 6.84 (1H, s), 6.99 (1H,s), 8.61 (1H,
s), 8.99 (1H, s), 10.66 (1H, s).
[0680] LRMS: m/z 556 (M+1).sup.+
Biological Activity
[0681] The following Table illustrates the in vitro activities for
a range of the compounds of the invention as inhibitors of cGMP
PDE5.
8 TABLE EXAMPLE IC.sub.50 (nm) 10 10.1 11 10.0 18 8.9 43b 3.6 46
8.1 48 6.9 98 7.0 99 5.7 127 7.3 153 7.2
Safety Profile
[0682] Several compounds of the invention have been tested at doses
of up to 3 mg/kg i.v. in mouse and at 0.5 mg/kg p.o. in dog, with
no untoward effects being observed.
* * * * *